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1.	Summary	
 
 The development of lymphocytes is a precise, stepwise process that is subject to 
multiple extrinsic as well as intrinsic molecular mechanisms that guide cell differentiation and 
selection. Two essential regulators of lymphopoiesis are environmental signal mediators in the 
form of cytokines and transcription factors. Both influence proliferation, survival, differentiation 
and cell fate decisions.  
 In the present thesis, we investigated the role of the cytokines Flt3-ligand and IL-7 in 
lymphocyte development by the use of various mutant mouse strains. Our results unraveled 
crucial functions for both cytokines during lymphocyte differentiation. Flt3-ligand drives the 
proliferation of uncommitted progenitor populations such as CLP and EPLM, whereas IL-7 has 
a pro-survival effect on these cells. High levels of Flt3-ligand rescued the B-cell defect in  
IL-7-/- mice due to the tremendous expansion of the CLP and EPLM populations, surpassing 
the need for IL-7 as a survival factor. Thus, these observations clearly demonstrate that both, 
Flt3-ligand as well as IL-7, function in a permissive mode in the commitment process towards 
the B-cell lineage. Flt3 expression is suppressed upon commitment to the B-cell fate, but IL-7 
has furthermore a proliferative function for committed CD19+ progenitor cells. Constitutive 
over-expression of both Flt3-ligand and IL-7 resulted in a lympho- and myelo-proliferative 
disease. The two cytokines had a synergistic effect on the development of B cells, resulting in 
the accumulation of progenitors also in peripheral lymphoid organs. Interestingly, even MPPs 
could be detected in lymph nodes of these mice and transplantation experiments confirmed 
the functionality of these progenitors, since they were capable of long-term multilineage 
reconstitution. Thus, Flt3-ligand and IL-7 act in concert during lymphocyte development. We 
further provided evidence that peripheral lymphoid organs have the capability to support 
extramedullary hematopoiesis in pathological situations.  
 In a second study we focused on the molecular and transcriptional regulation of the first 
essential checkpoint of the antigen-receptor rearrangement in T-cell development, called β-
selection. Even though almost half of the cells are eliminated at this checkpoint, only little is 
known about the underlying molecular mechanisms. Improvement of the current staging of 
thymocyte development by the addition of CD27 downregulation as a marker for cells that 
failed productive β-chain rearrangement at the DN3 stage allowed us to investigate this 
process in more detail than previously possible. Transcriptional analysis revealed a specific 
expression of the transcription factor Duxbl in cells prior to β-selection. Transgenic expression 
of Duxbl blocked the development of pre-T cells in vitro and in vivo due to increased apoptosis 
and cell cycle arrest. Further studies revealed the involvement of the Oas/RNaseL apoptosis 
   1. Summary 
 
  6 
pathway in this Duxbl-mediated developmental arrest. Additional expression of the pro-survival 
factor Bcl2 partially rescued the block and in vitro knockdown experiments of Duxbl reduced 
apoptosis induction within the DN3 compartment. Thus, the specific expression of Duxbl in 
conjunction with the gain- and loss-of-function phenotypes of increased and reduced 
apoptosis, respectively, provide clear evidence for a key role of Duxbl in the elimination of DN3 
cells that are not able to recombine a functional β-chain.  
Overall, the results presented in this thesis, provide important new insights on the cell-
extrinsic and -intrinsic regulation of differentiation and selection events in the development of 
lymphocytes. Furthermore, they highlight the validity of in vivo models for the investigation of 
immune cell development and function. 
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2.	Introduction	
 
2.1.		 The	hematopoietic	system	
All organs involved in blood cell production and function belong to the hematopoietic 
system, including primarily bone marrow, spleen, thymus, and lymph nodes. The composition 
of blood cells can be roughly divided into erythrocytes, leukocytes, and thrombocytes. The 
function of thrombocytes, or platelets, is to prevent massive blood loss in the case of injuries 
by the formation of a blood clot.  The largest portion of the blood is built by erythrocytes, or red 
blood cells, that are responsible for the oxygen transport throughout the body’s tissues via 
binding of oxygen to hemoglobin that gives the cells their red color. By contrast, leukocytes 
are named white blood cells. They are classified into two separate lineages: lymphoid, 
composing mainly the adaptive immune system, and myeloid cells, composing mainly the 
innate immune system, that together defend our body against invading pathogens and 
transformed cells. 
 
  
2.2.		 The	hematopoietic	stem	cell	
Due to the short lifespan of most mature blood cells, around 1011 to 1012 cells have to 
be newly generated every day in humans, a process that is termed hematopoiesis (Vaziri et 
al., 1994). During ontogeny the site of ongoing hematopoiesis changes. The first wave of 
hematopoietic cell production originates from the yolk sac at embryonic day (E) 7.5 and 
subsequently moves to the aorta-gonad-mesonephros from where the fetal liver and the bone 
marrow are seeded (Johnson and Moore, 1975; Medvinsky and Dzierzak, 1996; Orkin and 
Zon, 2008). Fetal liver is the major place of hematopoiesis during embryogenesis whereas the 
bone marrow is taking over after birth where it continues during adulthood. The only other 
primary lymphoid organ, that is responsible for the production of T leukocytes, is the thymus, 
which starts to be seeded already from E12 onwards (Boehm, 2008; Ramond et al., 2014). 
The hematopoietic stem cell (HSC) is responsible for this continuous production due to 
its two defining properties: self-renewal capacity and multipotentiality to differentiate into all 
blood cell subsets. The first evidence for stem cell function in the hematopoietic system was 
described in the beginning of the 1960 by James Till and Ernest McCulloch, and was based 
on rescue of lethally irradiated mice by bone marrow transplantation (Becker et al., 1963; 
McCulloch and Till, 1960; Till and Mc, 1961).  
Technical improvements in the field of fluorescence-activated cell sorting (FACS) 
resulted in the first characterization and purification of mouse HSCs in 1988 (Spangrude et al., 
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1988). Based on these experiments it is known that a ThylowSca1+ population that lacks the 
expression of lineage-specific markers (Lin-) within the bone marrow contained the stem cell 
activity resulting in long-term reconstitution of erythroid, myeloid, and lymphoid cell types after 
transplantations. Since only about 25% of clonal reconstitutions by these cells were shown to 
be long term (Morrison and Weissman, 1994; Spangrude et al., 1995) the phenotype of HSCs 
was continuously refined and improved over the years. One important addition was c-kit 
(CD117) surface expression as a positive marker for self-renewal and stem cell activity 
resulting in the term LSK cells (L=Lin-, S=Sca1+, K=c-kit+) (Okada et al., 1992; Osawa et al., 
1996b). Moreover, stem cell purity was further improved with exclusion of CD34 and Flt3 
(CD135) expression on these cells (Adolfsson et al., 2001; Christensen and Weissman, 2001; 
Kondo et al., 1997b; Osawa et al., 1996a). Based on ability to long-term reconstitute lethally 
irradiated mice, HSCs were subdivided into Flt3-CD34- long-term HSCs and Flt3-CD34+ short-
term HSCs (Brown et al., 2018; Yang et al., 2005). Additionally, also molecules belonging to 
the SLAM family receptors were used to enrich for HSCs, marking them as CD150+ and  
CD48-, resulting in almost 50% long-term multilineage reconstitution of single Lin-Sca1+ 
c-kit+CD150+CD48- cells (Kiel et al., 2005). Combining all described markers, the true HSCs 
must reside within the Lin-Sca1+c-kit+Flt3-CD34-CD150+CD48- compartment. Another 
approach to identify HSCs was developed by analyzing the exclusion of a fluorescent dye from 
cells. One example for this strategy was described in 1996 using the fluorescent dye Hoechst 
33342 (Goodell et al., 1996). Cells that excluded the Hoechst dye were shown in 
transplantation experiments to be highly enriched for HSCs without the use of any other 
marker.  
  The isolation of pure HSCs raised the possibility to investigate their cellular and 
metabolic properties and differences to other cell types in detail. The work of several groups 
revealed that HSCs are slowly dividing, mostly quiescent cells (Cabezas-Wallscheid et al., 
2017; Cheshier et al., 1999; Foudi et al., 2009; Wilson et al., 2008), with high glycolytic (Simsek 
et al., 2010) but low mitochondrial activity (Vannini et al., 2016), that are dependent on 
autophagy (Ho et al., 2017) and have a low protein synthesis rate (Laurenti and Gottgens, 
2018; Signer et al., 2014).  
 
 
2.3.		 Early	hematopoiesis	
 The first population downstream of the HSC compartment has lost its self-renewal 
capacity, but has retained the multipotentiality. These cells are therefore termed multipotent 
progenitors (MPPs) and are still able to differentiate into all blood lineages. The description of 
the common lymphoid progenitor (CLP), Lin-Sca1intc-kitintIL-7Ra+,  (Kondo et al., 1997b) and 
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the common myeloid progenitor (CMP), Lin-Sca1-c-kit+IL-7Ra-FcgRlowCD34- (Akashi et al., 
2000) by the group of Irving Weissman established the classical model of the hematopoietic 
tree proposing a stepwise differentiation of the cells toward different lineages and the 
simultaneous loss of other lineage potentials. In this view hematopoiesis is a unidirectional 
program of a sequence of defined differentiation events with the HSC at the apex, developing 
via restricted routes into all committed mature blood cell types (Figure 1). 
 
 
Figure 1 | Classical hematopoietic tree. Schematic representation of the classical hematopoietic tree with the 
HSC at the apex and the mature populations at the end of the differentiation process. Arrows indicate developmental 
progress and potential of the different progenitor populations. Colors indicate the affiliation of the populations to the 
erythroid/megakaryocyte (red), myeloid (green), or lymphoid (blue) lineage. Multipotent progenitors are colored 
grey. Progenitor populations with mixed lineage populations have the corresponding mixed colors 
(erythroid/myeloid = yellow; lymphoid/myeloid = turquoise). HSC: hematopoietic stem cell, MPP: multipotent 
progenitor, LMPP: lymphoid-primed multipotent progenitor, CMP: common myeloid progenitor, CLP: common 
lymphoid progenitor, MEP: megakaryocytic-erythroid progenitor, GMP: granulocyte/macrophage progenitor, MkP: 
megakaryocyte committed progenitor, ErP: erythrocyte progenitor, EPLM: early progenitor with lymphoid and 
myeloid potential, EILP: early innate lymphoid progenitor, CDP: common dendritic cell progenitor, ILC: innate 
lymphoid cell, ETP: early thymic progenitor. 
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Based on these initial studies the first lineage decision subsequent of the MPP stage 
would result in the bifurcation to either the lymphoid lineage via the CLP or to the 
myeloid/erythroid lineage via the CMP. Thus, B, T, and innate lymphoid cells (ILCs), like 
natural killer cells (NK cells), are the progeny of the CLPs.  Although the origin of dendritic cells 
(DCs) was controversial, a recent paper provided clear evidence for a lymphoid pathway for 
the generation of plasmacytoid DCs (pDCs) via an interleukin-7 receptor (IL-7R) positive 
progenitor (Rodrigues et al., 2018; Shortman and Naik, 2007). The CMP, on the other hand, 
gives rise to megakaryocytes and erythrocytes via the megakaryocytic-erythroid progenitor 
(MEP) and to monocytes/macrophages, granulocytes, and conventional DCs (cDCs) via the 
granulocytic-monocytic progenitor (GMP). The master transcription factors for the 
megakaryocytic-erythroid and granulocyte/monocyte lineages are Gata1 (Fujiwara et al., 1996; 
Pevny et al., 1991; Shivdasani et al., 1997) and Pu.1 (DeKoter et al., 1998), respectively. Over-
expression of either one of these two factors was shown to result in a reprogramming of cells 
towards their corresponding lineage (Kulessa et al., 1995; Nerlov and Graf, 1998). Thus, 
hematopoietic development is not necessarily a unidirectional process, but contains the 
plasticity to overcome lineage restriction under certain circumstances. Whether this happens 
under normal undisturbed hematopoietic development is still unresolved. 
The initial model of hematopoiesis was further challenged by the identification of 
several progenitor populations containing mixed lymphoid and myeloid potential. Adolfsson et 
al described the lymphoid-primed multipotent progenitor (LMPP), which is composed of the 
cells with highest Flt3 expression within the LSK compartment, that were capable to generate 
myeloid cells, like macrophages and granulocytes, but also lymphoid cells, like B and T cells 
(Adolfsson et al., 2005). However, these cells had lost the potential to differentiate to 
erythrocytes or megakaryocytes in vitro as well as in vivo. Based on these findings a revised 
road for the earliest hematopoietic developmental steps was proposed, in which the 
erythrocyte/megakaryocyte lineage restriction occurs before the lymphoid versus myeloid 
decision. Therefore, the LMPP was placed upstream of the CLP and GMP populations. 
Transcriptional analysis further confirmed the loss of an erythroid/megakaryocyte gene 
expression profile with concomitant myeloid signatures and upregulation of genes associated 
with lymphoid cells like Rag1, Rag2, Dntt, or Il7ra (Mansson et al., 2007). Another population 
described to have mixed lineage potentials was the early progenitor with lymphoid and myeloid 
potential (EPLM) (Balciunaite et al., 2005b). As the name implicates these cells contain B, T, 
and myeloid potential and are defined as B220+CD117+CD19-NK1.1-. 
Due to the identification of progenitors with diverse cell fates and mixed lymphoid and 
myeloid potentials, already in 2009 a new model for hematopoiesis was proposed. This 
“pairwise model” for hematopoiesis argues against the strict predefined pathways and 
branches of the classical hematopoietic tree and suggests instead that a specific cell fate can 
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be reached by more than one route and more than one intermediate progenitor (Figure 2) 
(Brown et al., 2018; Ceredig et al., 2009). 
 
 
Figure 2 | Pairwise model of hematopoiesis. In this model hematopoiesis is depicted as a continuum of lineage 
relationships between HSCs and different cell fates. Partial arcs represent known progenitor populations having 
specific differentiation potentials and options. Overlapping arcs indicate that cell types can be reached by more 
than one route during hematopoiesis. HSC: hematopoietic stem cell, NK cell: natural killer cell, DC: dendritic cell, 
EPLM: early progenitor with lymphoid and myeloid potential, LMPP: lymphoid-primed multipotent progenitor. Taken 
from (Brown et al., 2018). 
 
2.3.1.		Heterogeneity	within	early	progenitors	
The identification of progenitor populations described in the previous section were all 
based on the expression of several surface markers.  The mixed lineage potential that was 
observed for some of these progenitors could therefore result from heterogeneity within these 
defined populations. Technical progress in the field of single-cell analysis technologies and the 
usage of reporter and fate-mapping mice stimulated an important progression in the 
understanding of hematopoietic development and the composition of the progenitor 
populations. For instance, single-cell RNA sequencing of the EPLM population separated the 
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lymphoid-biased cells based on the overall gene expression profile, revealing that the Ly6D+ 
fraction contains only lymphoid-biased cells, whereas the Ly6D- fraction was a mixture of 
different lineages (Alberti-Servera et al., 2017). A similar refinement was also implemented on 
the CLP, identifying Flt3 as an additional marker to define lymphoid multipotentiality (Karsunky 
et al., 2008). Furthermore, Ly6D was shown to mark the cells that were already biased to the 
B-cell lineage within the CLPs, whereas the Ly6D- fraction contained also T- and NK-cell 
potential (Inlay et al., 2009). Therefore, Ly6D+ CLP were termed B-cell biased lymphoid 
progenitors (BLP) and the Ly6D- fraction was termed all lymphoid progenitors (ALP). Single-
cell RNA sequencing of myeloid progenitors also revealed multiple progenitor subgroups, 
which could be separated into 18 different subpopulations based on their transcriptional profile 
(Paul et al., 2015). In particular the CMP was shown to be highly heterogeneous. Based on 
CD105 and CD150 expression the CMP could be sub-fractionated into four subpopulations 
with already defined lineage restrictions (Pronk et al., 2007). Using a Pu.1eYFP Gata1mCherry 
double reporter mouse Tim Schroeder’s group was able to split the CMP population into cells 
expressing high Pu.1 levels and cells expressing Gata1 with low or no Pu.1 expression. These 
populations were shown to be already committed to the granulocyte/macrophage or 
megakaryocyte/erythrocyte lineage, respectively, concluding that the CMP is a mixture of 
GMPs and MEPs (Hoppe et al., 2016).  
Even within the LSK compartment heterogeneity was described in several studies 
revealing differing relative outputs to the different lineages (Copley et al., 2012). For instance, 
labeling of LMPPs with lentiviral barcodes followed by subsequent transplantations into mice 
separated the LMPP population into three main groups containing lymphoid-biased, myeloid-
biased, and  DC-biased cells suggesting that the DC-fate should be considered as a distinct 
lineage based on their separate ancestry (Naik et al., 2013). Likewise, MPPs could be 
separated into three subpopulations based on the SLAM markers that were used to define 
HSCs and Flt3 expression. Therewith, megakaryocytic/erythroid-biased MPP2 (Flt3-
CD150+CD48+), myeloid-biased MPP3 (Flt3-CD150-CD48+), and lymphoid-biased MPP4 
(Flt3+CD150-CD48+) were identified (Pietras et al., 2015). In line with these results CD150 
downregulation within the CD34- LSK compartment was already previously linked with reduced 
megakaryocyte/erythrocyte differentiation potential (Morita et al., 2010). Despite the detailed 
analysis and phenotypical definition of HSCs several studies also revealed that the HSC 
compartment itself contains some lineage bias already (Copley et al., 2012). The Müller-
Sieburg and Eaves groups showed a diverse relative output to the myeloid and lymphoid 
lineages in limiting dilution analysis and single-cell transplantation experiments (Dykstra et al., 
2007; Muller-Sieburg et al., 2004). The expression of CD41 and CD86 likewise revealed 
myeloid and lymphoid biased HSCs (Gekas and Graf, 2013; Shimazu et al., 2012). 
Furthermore, by using a mouse model reporting the expression of von Willebrand factor (vWF) 
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the HSC compartment was separated into vWF- and vWF+ cells (Sanjuan-Pla et al., 2013). 
The results of this study identified vWF+ platelet-primed HSCs to reside at the top of 
hematopoiesis, further confirming that heterogeneity exists already at the stem cell level during 
development.  
Collectively, these data argue in favor of a revised model of hematopoiesis in which 
imprinting to a specific lineage is initiated already at the HSC level resulting in a progressive 
or graded commitment to the various differentiated cell types during hematopoiesis. 
 
2.3.2.		Steady-state	hematopoiesis	
 The architecture of the hematopoietic tree is mainly built up by results derived from cell 
potential measurements in colony or transplantation assays. However, this can be significantly 
different in the unperturbed bone marrow environment. This issue was addressed by several 
groups using barcoding and inducible labeling of HSCs. For instance, unique integration of the 
“sleeping beauty” transposon in a doxycycline inducible system in stem and progenitor cells 
was used to generate barcodes, which could be stably incorporated into the genome and 
detectable by subsequent sequencing (Sun et al., 2014). Surprisingly, this system indicated 
that HSCs contribute only partly to steady-state hematopoiesis in an unperturbed setting, 
which is instead mainly driven by the MPP compartment. This result was further supported by 
experiments using inducible fluorescent labeling of the HSC compartment (Busch et al., 2015). 
Contrary to that, another group reported that HSCs indeed contribute more during steady state 
hematopoiesis than proposed by the ones described above and that HSC contribution is 
multilineage (Sawai et al., 2016). 
Most recently two groups investigated lineage fates of stem cells and progenitors in 
unperturbed hematopoiesis. The group of Hans-Reimer Rodewald generated a mouse model 
enabling barcoding based on the Cre-loxP recombination system (Pei et al., 2017). Tagging of 
single-cells was induced specifically in HSCs and analysis of different progenitor and mature 
populations for their barcode overlap revealed that HSCs mostly gave rise to multiple lineages. 
Furthermore, a major myelo-erythroid and a common lymphoid pathway was detected, 
supporting the classical tree-like model of hematopoiesis. However, they lacked analysis of 
megakaryocytic fate, which was addressed in detail by the group of Fernando D. Camargo. 
They made use again of the doxycycline inducible transposon system revealing that 
megakaryocyte lineage fate descends directly from long-term HSCs independently of other 
hematopoietic fates (Rodriguez-Fraticelli et al., 2018). Furthermore, they were able to show 
that progenitor subsets like CMP, GMP, and MEP consist largely of cells with unilineage 
outcome, suggesting that these populations are composed of a mix of already lineage-
restricted cells. Multilineage outcome was only detected in the MPP populations with biases to 
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different lineages, as described before. Therefore, their model is still in line with a progressive 
developmental restriction to the different lineages, but it indicates that this is happening much 
earlier during native hematopoiesis and is more clonally heterogeneous than previously 
believed. 
 
 Taken together, the exact early developmental pathways from HSCs to the different 
mature blood lineages have been studied extensively, but are still under debate and need 
further analysis in the future in order to unravel the exact mechanisms and pathways 
underlying hematopoiesis.  
	
 
2.4.		 B-cell	development	
The development of B lymphocytes is an absolute requirement for the generation of a 
fully functional adaptive immune system, as they are responsible for the production of 
antibodies, that protect our body against all kind of harmful invading objects like pathogens 
and venoms. During embryogenesis B-cell development takes place in the fetal liver and 
postnatally in the bone marrow. The process involves several highly controlled successive 
stages and checkpoints ensuring the generation of the B-cell receptor (BCR) consisting of a 
heavy and light immunoglobulin chain, lacking self-reactivity. The capability of the BCR to 
recognize the tremendous amounts of different antigens is achieved by random recombination 
of gene segments facilitated by the recombination activated genes, Rag1 and Rag2 
(Mombaerts et al., 1992; Shinkai et al., 1992). The initial diversity is encoded by the presence 
of multiple V-, D- (only heavy chain), and J-gene segments, which gets further increased by 
the introduction of deletions and insertions during the recombination process at the V-D and 
D-J junctions, resulting in a theoretical diversity of >1013 (Elhanati et al., 2015; Glanville et al., 
2009; Nadel and Feeney, 1997). Surface and intracellular markers, cell cycle status, as well 
as the progress of rearrangement of the immunoglobulin heavy and light chain genes can be 
used in order to divide the developmental pathway of B cells into separate stages (Ehlich et 
al., 1994; Hardy and Hayakawa, 2001; Osmond et al., 1998; ten Boekel et al., 1995). Once B 
cells have accomplished to successfully produce a functional BCR they undergo final 
maturation processes in the spleen. During the course of an immune response, antigens are 
detected via the BCR, which results in the final differentiation of B cells to either memory B 
cells, which ensure a long-lasting protection against the pathogen, or plasma cells, which start 
to secrete antibodies, the soluble form of the BCR, to fight against the infection. 
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2.4.1.		Lymphoid	specification	
Initial priming to the B-cell lineage takes place already within the LSK compartment. 
Several important transcriptional regulators are involved in the initiation of the B-cell program.  
At the MPP stage Ikaros (encoded by Ikfz1), Pu.1 (encoded by Spi1), E2A (encoded 
by Tcf3), and Foxo1 have been associated with lymphoid priming of chromatin and enhancers 
(Nutt and Kee, 2007). Thus, Pu.1 acts in a dose dependent manner in the decision between 
the granulocyte/macrophage and the lymphoid fates.  On the one hand, high Pu.1 levels will 
drive the cells into the myeloid direction whereas lower Pu.1 concentrations favor a lymphoid 
choice (DeKoter and Singh, 2000). Ikaros is regulating this process by direct repression of 
Spi1 via binding to its promoter (Zarnegar and Rothenberg, 2012). Mice deficient for either 
Pu.1 or Ikaros displayed a severe defect in the formation of LMPPs and CLPs resulting in 
arrested lymphopoiesis (Nichogiannopoulou et al., 1999; Scott et al., 1994; Yoshida et al., 
2006).  Therefore, both factors are absolutely required for the first developmental stages of 
lymphoid specification. Later on, they were shown to regulate Flt3 and IL-7R expression as 
well as the earliest expression of lymphoid specific genes like Rag1, Rag2 and Dntt (Carotta 
et al., 2010; DeKoter et al., 2002; Heizmann et al., 2013; Ng et al., 2009; Reynaud et al., 2008). 
Since Pu.1 and Ikaros regulate the expression of Flt3 and IL-7R, which are markers that are 
used to define LMPPs and CLPs, it was difficult to resolve the precise function and the exact 
developmental stage at which these factors are absolutely required. However, recently the 
group of Stephen Nutt reported, by the use of a Rag2 reporter mouse, that Pu.1 is indeed 
essential for the developmental progression of MPPs towards LMPPs as well as the 
subsequent formation of CLPs (Pang et al., 2018).  
Moreover, the basic helix-loop-helix transcription factor E2A is involved at this early 
timepoints of B lymphopoiesis. Mice deficient for E2A display a developmental block in the 
development of B cells after the CLP stage (Bain et al., 1994; Zhuang et al., 1994). However, 
E2A plays also a role in the formation of LMPPs from HSCs as shown by reduced LMPP 
numbers in these mice and reduced transcription of lymphoid lineage genes (Dias et al., 2008). 
E2A is likewise involved in the induction of lymphoid-associated genes including Il7ra, Rag1, 
and Dntt and interestingly, many of these genes share potential binding sites for Pu.1 and 
Ikaros indicating that these factors act in concert in the regulation of early lymphoid priming 
(Boller and Grosschedl, 2014). Furthermore, E2A promotes the expression of Foxo1, a factor 
that was shown to be important at different stages during B-cell development including the 
activation of Rag1 and IL-7R expression (Amin and Schlissel, 2008; Dengler et al., 2008). 
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2.4.2.		Commitment	to	the	B-cell	fate	
Final commitment to the B-cell lineage is achieved by the upregulation of the 
transcription factors Ebf1 (early B-cell factor 1) and Pax5 (paired box 5). These two factors are 
exclusively expressed in B-cells in the hematopoietic system and mice deficient for either of 
the two show a complete block of B lymphopoiesis, slightly earlier in development for Ebf1 
than for Pax5 (Lin and Grosschedl, 1995; Urbanek et al., 1994).  
Ebf1 was shown to become directly activated by E2A and since ectopic Ebf1 
expression in E2A deficient mice is able to partially restore B-cell development, induction of 
Ebf1 expression seems to be one of the key functions of E2A (Seet et al., 2004; Smith et al., 
2002). Ebf1 starts to be expressed at the BLP stage and its expression is mediated by two 
distinct promoters. The distal a-promoter has potential bindings sites for E2A, Ikaros, Ebf1 and 
shows responsiveness to Stat5 signaling, whereas the proximal b-promoter is driven by Ets1, 
Pu.1, Runx1, and Pax5 (Roessler et al., 2007; Smith et al., 2002). Ebf1 in turn activates several 
B-cell specific genes including Cd79a, Cd79b, Blk, Igll1, Vpreb1 as well as Foxo1 and Pax5 
(Akerblad et al., 1999; Akerblad and Sigvardsson, 1999; Hagman et al., 1991; Zandi et al., 
2008). Ebf1 bound regions in the genome were shown to be highly enriched in binding sites 
for several other transcriptional regulators including E2A and Pax5, furthermore underpinning 
the complex cross-regulatory feedback loops that stabilize specification and commitment to 
the B-cell lineage (Gyory et al., 2012; Lin et al., 2010). In addition to its activating role Ebf1 is 
also repressing several genes important for other lineages, thereby directly antagonizing 
alternative cell fates. In particular, Tcf7 and Gata3, which are essential for early T-cell 
development, are regulated by Ebf1 and were increased upon loss of Ebf1 (Banerjee et al., 
2013; Nechanitzky et al., 2013). Moreover, Id2, which is a key player for the development of 
ILCs, and Id3 are directly repressed by Ebf1 (Thal et al., 2009). This in turn leads to an increase 
of E2A activity, since Id proteins antagonize the DNA-binding ability of E proteins, thereby 
further strengthening B-cell specification. Likewise, Ebf1 inhibits myeloid differentiation, 
because of its repression of Cebpa (Pongubala et al., 2008). In summary, Ebf1 is repressing 
important key regulators of the T cell, ILC, and myeloid fates. This is further confirmed by the 
fact that inactivation of Ebf1 in already committed pro-B cells can result in a lineage conversion 
to T cells and ILCs (Nechanitzky et al., 2013). In addition to its role in the regulation of gene 
expression, Ebf1 acts furthermore on the epigenetic landscape, changing the chromatin 
accessibility, thereby paving the way for B-cell programming (Boller et al., 2016; Li et al., 2018). 
Upregulation of Pax5 is required to fully establish B-cell commitment. Mice deficient for 
Pax5 exhibit an arrested B-cell development at the pro-B stage, which is characterized by the 
expression of many B-cell specific genes and DH to JH rearrangements of the heavy  
chain. (Nutt et al., 1999; Nutt et al., 1997). Normally pro-B cells are defined as 
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B220+CD19+CD117+CD127+, but since Pax5 is controlling the expression of CD19, these cells 
are negative for this marker in Pax5 deficient mice (Nutt et al., 1998). Analysis for a 
corresponding CD19- population in WT mice led to the discovery of the EPLM population 
(Balciunaite et al., 2005b). Similar to the EPLM population, Pax5 deficient pro-B cells were 
shown to retain the capability for in vitro and in vivo differentiation into myeloid and T-lymphoid 
cells (Rolink et al., 1999b; Rolink et al., 2002). However, the clear-cut difference between these 
cells is the high efficiency of EPLM to generate B-cells, which is completely missing in Pax5 
deficient pro-B cells. Upon conditional inactivation of Pax5 already committed pro-B and even 
mature B cells regained the possibility to differentiate into other lineages, further strengthening 
the importance of this factor for the B-cell fate (Cobaleda et al., 2007; Mikkola et al., 2002). 
Therefore, Pax5 is not only important for the commitment to the B-cell fate, but is also an 
absolute requirement for all subsequent stages during the life of a B-cell. This is because it not 
only establishes, but also maintains the global-lineage-specific architecture of B cells until its 
downregulation upon plasma-cell differentiation (Horcher et al., 2001; Johanson et al., 2018; 
Nutt et al., 2001). Similarly to Ebf1, components of the pre-BCR and BCR including CD19, 
Blnk, CD79a, and Igll1 are target genes of Pax5 (Cobaleda et al., 2007). Furthermore, Pax5 
binds to the distal a-promoter of Ebf1 and therefore a main function of Pax5 is also to maintain 
and enhance Ebf1 levels resulting in a positive feedback loop between these two factors 
ensuring B-cell specification (Roessler et al., 2007). The importance of this feedback 
mechanism is further illustrated by the fact that cells with heterozygous loss of both Ebf1 and 
Pax5 displayed an increased T-cell potential in vivo and in vitro, demonstrating the 
collaborative activity of these two factors in preserving B-cell identity (Ungerback et al., 2015). 
However, Pax5 is not only acting as an activator but also as a repressor, promoting B-cell 
commitment by inactivation of non-B-cell genes. This includes the genes encoding the surface 
receptors Mcsf-R and Notch1, which are key players in myeloid and T-cell development, 
respectively (Souabni et al., 2002; Tagoh et al., 2006). This also explains the fact that pro-B 
cells deficient for Pax5 gain the capability to differentiate into myeloid and T-lymphoid cells. 
Therefore, Pax5 represses surface receptors and Ebf1 antagonizes transcription factor genes 
of alternative cell fates, resulting in a double-lock mechanism to establish B-cell specification. 
 
2.4.3.		Early	developmental	stages	
After the BLP stage surface expression of B220 is one of the first markers associated 
with B-cell progenitors. Therefore, the Ly6D+ EPLM population might developmentally arise 
from the BLP, which is also implied by the overlapping surface expression of c-kit (CD117), IL-
7R (CD127), and Flt3 (CD135) between these two populations. A large fraction of the Ly6D+ 
EPLM already expresses Ebf1, but is not yet fully committed to the B-cell lineage, since the 
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cells still retain T-cell potential in limiting dilution assays (Alberti-Servera et al., 2017).  Thus, 
these Ebf1 positive cells most likely resemble the last stage before commitment to the B-cell 
fate. Recently, the group of Mikael Sigvardsson revealed another way to dissect successive 
developmental stages from the CLP until final commitment (Jensen et al., 2018). By the use 
of the surface markers Gfra2 and Bst1 they were able to split BLPs into the three distinct 
subpopulations BLP1, BLP2, and BLP3. Gfra2 upregulation in BLP2 cells coincided with Ebf1 
induction and subsequently with the expression of B-cell specific genes. Thus, these cells most 
likely overlap with the Ebf1+Ly6D+ fraction of the EPLM population described above. At the 
BLP3 stage, identified by additional Bst1 expression, cells are committed to the B-cell lineage 
and Pax5 expression is initiated. All successive populations after commitment are marked by 
the expression of CD19, which is induced by Pax5.  
 
 
Figure 3 | Early B-cell development. Schematic representation of early B-cell development stages in the bone 
marrow. Sequential stages are connected by arrows indicating the developmental progression from Ly6D+ EPLM 
up to mature B cells. Recombination process is indicated in boxes above the different populations. Table below the 
populations shows surface marker expression of the different populations (blue) as well as intracellular expression 
of transcription factors and genes involved in the recombination process (green). EPLM: early progenitor with 
lymphoid and myeloid potential 
 
The different early developmental stages in the bone marrow can be further separated 
by the use of the surface markers c-kit, CD25, IL-7R, CD93, by the status of the 
rearrangements of the heavy and light chain loci, and by their cell cycle status (Figure 3) 
(Ceredig and Rolink, 2002; Rolink et al., 1994; ten Boekel et al., 1995).  
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The first committed cell, the pro-B cell, is marked by the expression of CD19 and c-kit 
and is characterized genotypically by DH-JH rearrangements of the heavy chain loci (ten Boekel 
et al., 1995). After completion of the VH-DHJH recombination cells are tested for an effective 
rearrangement. Only if the recombination process resulted in the expression of a functional 
heavy chain cells are allowed to proceed in development. This selection is achieved by the 
formation of the pre-BCR, which is composed of the heavy chain and the surrogate light chain 
proteins VpreB and l5, together with the signaling molecules Iga and b (Karasuyama et al., 
1990; Kitamura et al., 1992; Kudo and Melchers, 1987; Sakaguchi and Melchers, 1986). Cells 
that reach this status are termed large pre-B cells, defined as c-kit-CD25+CD127+ (Rolink et al., 
1994). Signaling of the pre-BCR on the surface of these cells initiates a proliferative expansion 
and induces survival signals, thereby enriching for cells with a successful heavy chain 
rearrangement (Ohnishi and Melchers, 2003; Rolink et al., 2000; ten Boekel et al., 1995). 
Signaling via the pre-BCR furthermore ensures allelic exclusion by inducing a transient 
downmodulation of the recombination machinery (Grawunder et al., 1995; Mostoslavsky et al., 
2004). The proliferation and survival signals during that step are further mediated by IL-7R 
signaling, which acts in concert with the pre-BCR for an effective expansion. Cells undergo 
five to six divisions in total after activation of the pre-BCR (Decker et al., 1991; Rolink et al., 
2000). At the same time, the pre-BCR initiates a transcriptional program including the 
activation of E2A, Irf4, Irf8 and Aiolos, which will eventually induce cell-cycle arrest as well as 
opening of the light chain locus (Lazorchak et al., 2006; Lu et al., 2003; Ma et al., 2006; Mandal 
et al., 2009; Stadhouders et al., 2014). Aiolos in particular, through repression of the Igll1 gene, 
is responsible for the termination of the pre-BCR complex (Thompson et al., 2007). Induction 
of cell-cycle arrest at that stage is essential for further differentiation, as demonstrated by an 
impaired development if growth supporting genes are not efficiently silenced (Lindner et al., 
2017). 
The transition from proliferation to quiescence marks the entrance to the small pre-B 
stage (Parker et al., 2005). These cells are defined by a downregulation of the IL-7R and their 
reduced size compared to the proliferating large pre-B cells. Furthermore, the recombination 
machinery becomes re-expressed initiating recombination at the k or l immunoglobulin light 
chain loci (ten Boekel et al., 1995). For the light chain, besides allelic exclusion, also isotype 
exclusion is applied, resulting in the expression of only one light chain that is either k or l 
(Mostoslavsky et al., 1998; Neuberger et al., 1989).  
Once a light chain is generated the BCR is formed successfully, provided that pairing 
of the light chain with the heavy chain is possible. Surface IgM expression defines the cells as 
immature B cells, which can be distinguished from mature recirculating B cells by the 
expression of CD93 (Rolink et al., 1998). If pairing of the light chain with the heavy chain is not 
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successful or the resulting BCR has specificity against self-antigens, secondary 
rearrangements of the light chain can be initiated, a process known as receptor editing (Gay 
et al., 1993; Rolink et al., 1993; Tiegs et al., 1993). It is believed that the BCR signal strength 
of newly formed immature B cells determines whether cells continue in development or have 
to undergo receptor editing. In that scenario anti-nonself BCRs with effective pairing of the 
heavy and light chains induce the right amount of BCR signaling (tonic BCR signaling) resulting 
in developmental progression of these cells. An autoreactive BCR, on the other hand, induces 
a much stronger signal, whereas inefficient pairing results in a signal that is too weak 
(Tussiwand et al., 2009). The importance of an appropriate BCR signal is further highlighted 
by the developmental perturbation in mice with deficiencies in regulators of the BCR signal 
strength (Khan et al., 1995; Liu et al., 1998; Sato et al., 1996). For their final maturation steps 
immature B cells leave the bone marrow and migrate to the spleen. 
 
2.4.4.		Late	developmental	stages	
 Around 2x106 immature B cells per day reach the periphery in a mouse (Rolink et al., 
1998; Rolink et al., 1999a). Approximately 25% of these have undergone receptor editing 
(Casellas et al., 2001; Retter and Nemazee, 1998). Immature B cells that have migrated to the 
spleen from the bone marrow are called transitional B cells. They can be distinguished from 
their mature counterparts by surface receptor expression, their short half-life time and their 
susceptibility to anti-IgM induced apoptosis (Allman et al., 2001; Loder et al., 1999; Rolink et 
al., 1998). Based on the expression of several markers transitional B cells can be subdivided 
into CD93+CD21-CD23-IgMhighIgDlow T1, and CD93+CD21+CD23+IgMhighIgDint T2 populations 
(Rolink et al., 2004). A third transitional B-cell population called T3 is nowadays believed to 
contain mainly anergic B cells (Merrell et al., 2006). In contrast to mature B-cell populations 
transitional B cells still undergo apoptosis upon BCR triggering, indicating that they are still 
subject to selection against autoreactive B cells (Carsetti et al., 1995). Transitional B cells 
become also sensitive to the action of the pro-survival factor Baff as demonstrated by the block 
at the T1 stage occurring in Baff-/- or Baff-R-/- mice (Gross et al., 2001; Schiemann et al., 2001; 
Thompson et al., 2000; Yan et al., 2001). This dependency on Baff for survival persists also in 
mature marginal zone and follicular B-cell (MZB and FoB) populations, whereas B1 B cells are 
Baff-independent (Rauch et al., 2009). 
The conventional B2 B cells, consisting of MZB and FoB, together with B1 B cells 
represent the different mature B cell populations (Figure 4). B1 cells were first described in 
1983 as a unique B-cell population (Hayakawa et al., 1983). They are defined as 
CD19highCD11b+CD23-IgMhighIgDlow and can be further subdivided into CD5+ and CD5- B1a and 
B1b cells, respectively. Their predominant locations are the peritoneum and pleural cavities. 
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Whether B1 B cells share a common progenitor with B2 B cells or represent a completely 
separate lineage has been under debate for a long time. Due to the absence of N-nucleotide 
additions in the VDJ junctions of the majority of B1 B cells they are thought to be mainly fetally 
derived, since the Tdt enzyme, which is responsible for these additions during recombination, 
is only expressed during adulthood (Desiderio et al., 1984; Feeney, 1992). The group of 
Kenneth Dorshkind identified a distinct B1 progenitor in the fetal bone marrow of mice, 
proposing a distinct developmental pathway for B1 B cells (Montecino-Rodriguez et al., 2006). 
However, others proposed that BCR signal strength as well as responsiveness to T-cell 
independent antigens determines B1 fate from a common progenitor with B2 cells (Lam and 
Rajewsky, 1999). Since the two models are not mutually exclusive both pathways might 
actually contribute. B1 B cells are responsible for the production of so called natural antibodies, 
which can bind to different conserved pathogen-associated antigens (Panda and Ding, 2015). 
Thus, the B1 BCRs exhibit a more restricted repertoire with the preferential usage of certain 
germline V(D)J gene segments, representing a rather innate response to pathogens (Kantor 
et al., 1997; Tornberg and Holmberg, 1995). 
 
 
Figure 4 | Late stages of B-cell development. Schematic representation for the generation of mature B-cell 
subsets. MZB and FoB cells are derived from transitional B cells, which undergo their final maturation steps in the 
spleen. BCR signal strength and the induction of Notch2 signaling are responsible for the bifurcation to either the 
MZB or FoB fate. Origin of B1 B cells remains still controversial as some experiments indicate a separate origin 
from a distinct fetal B1 progenitor, whereas other data argue for a common origin with B2 cells, in which case BCR 
signal strength and BCR specificity direct differentiation to the B1 fate. B2 development is dependent on Baff 
survival signaling, whereas B1 cells are independent of that. T1: transitional 1; T2: transitional 2; MZB: marginal 
zone B cell; FoB: follicular B cell; FP: fetal progenitor. Adapted from (Pillai and Cariappa, 2009). 
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The B2 B-cell populations are the progeny of transitional B cells. The decision between 
the MZB and FoB-cell fate was proposed to rely on BCR-signaling strength (Pillai and 
Cariappa, 2009). Weak signaling promotes MZB, whereas stronger signals promote FoB-cell 
differentiation (Casola et al., 2004). An apparent difference between FoB and MZB cells is the 
dependency of the latter on Notch2 signaling, manifested by the strong reduction of this 
population in conditional Notch2-deficient mice (Saito et al., 2003). A recent study indeed 
postulated that BCR signals influence the MZB-lineage choice by regulating the surface 
expression of Adam10 (Hammad et al., 2017), which is important for the activation of Notch2 
(Gibb et al., 2010). Furthermore, they showed that an Adam10 positive fraction within the T1 
population is most likely the direct progenitor of MZB cells whereas T2 cells only marginally 
contribute to the MZB-cell pool. As suggested by their name MZB are located between the 
marginal sinus and the red pulp of the spleen and build a first line of defense against 
encapsulated blood-borne bacterial pathogens (Pillai et al., 2005). They are defined as 
CD19+CD93-CD21highCD23lowIgMhighIgDlow. The large majority of mature B cells belong to the 
FoB population characterized as CD19+CD93-CD21+CD23+IgMlowIgDhigh. They are located in 
the follicles of the spleen and lymph nodes adjacent to the T-cell zone, thereby mediating 
mainly T-cell dependent immune responses. 
 
 
2.5.		 T-cell	development	
 The second arm of the adaptive immune system is built by T lymphocytes. 
Development of T cells is restricted to the thymus. As it is for B cells, the development of T 
cells follows a highly controlled pathway including several important checkpoints, ultimately 
leading to the production of a functional T-cell receptor (TCR) that lacks reactivity to self-
antigens. The successive stages can be distinguished by the use of surface markers as well 
as by the status of the rearrangement of the TCR b- and a-chain (Ceredig and Rolink, 2002). 
In many instances this process shows similarities to the generation of B cells; however, it also 
involves many factors and regulations that are unique to T-cell development. Cells that have 
passed all stages and selection checkpoints mature either towards a CD4-positive or CD8-
positive cell. T cells expressing CD4 are classified as helper cells, since their main function is 
to support other cells by the production of cytokines or by direct cell-cell interactions to fight 
against different kinds of infections. Moreover, a specific subset of CD4 T cells, termed 
regulatory T cells, was shown to have an important function in controlling immune responses 
and to specifically prevent reactions to self-antigens.  CD8 T cells, or cytotoxic T cells, on the 
other hand, directly recognize and eliminate transformed cells that were either infected or 
display an abnormal phenotype like in the case of cancer cells. In addition to the conventional 
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ab-T cells several other T-cell subsets mature in the thymus, such as gd-T cells, MAIT (mucosal 
associated invariant T) cells, and NK-T cells. 
	
2.5.1.		Seeding	of	the	thymus	
The production of T lymphocytes takes place exclusively in the thymus. Continuous 
production therefore requires migration of hematopoietic progenitors from the bone marrow via 
the blood to the thymus. In order to do so progenitors have to be mobilized from the bone 
marrow into circulation. HSCs can be found in the peripheral blood, where downstream 
progenitor populations like MPPs, LMPPs, and CLPs can also be detected at very low 
frequencies (Goodman and Hodgson, 1962; Lai and Kondo, 2007; Perry et al., 2006; Schwarz 
and Bhandoola, 2004; Wright et al., 2001). However, the physiological mechanism underlying 
the mobilization of bone marrow progenitors into the blood is still not completely resolved. 
Migration of cells is mainly driven by chemokines and their corresponding receptors. Homing 
and retention of cells to the bone marrow environment was shown to be regulated by the 
chemokine receptor Cxcr4, whose expression forces the cells to migrate towards its ligand 
Cxcl12, which is highly expressed by bone marrow endothelial cells (Ceradini et al., 2004; 
Pitchford et al., 2009). Sphingosine-1 phosphate receptor 1 (S1PR1) plays a role in the 
mobilization of immature B cells from the bone marrow and might therefore be also relevant 
for the egress of earlier progenitors (Allende et al., 2010).  
The next step after mobilization from the bone marrow into circulation is the efficient 
homing to the thymus. Several groups independently postulated that settling of the thymus is 
a very rare event with around 10 cells entering per day (Kadish and Basch, 1976; Spangrude 
and Scollay, 1990; Wallis et al., 1975). Efficient homing requires the concerted action of 
several chemokine receptors, integrins and selectin ligands (Scimone et al., 2006). For 
instance, efficient thymic settling relies on the expression of Psgl-1 on the entering cells and 
the presence of P-selection on the thymic endothelium (Gossens et al., 2009). Progenitors 
lacking Psgl-1 were defective in the generation of thymocytes in competition with wild-type 
controls (Rossi et al., 2005). Moreover, the chemokine receptors Ccr7 and Ccr9 were 
demonstrated to function in thymus seeding. The ligands for these two receptors, Ccl21/Ccl19 
and Ccl25 respectively, are produced by the stromal epithelial cells of the thymus (Misslitz et 
al., 2004; Tenno et al., 2018; Uehara et al., 2002). Both Ccr7- as well as Ccr9-deficient cells 
were defective in generating thymocytes after intravenous but not intrathymic injections 
(Krueger et al., 2010; Schwarz et al., 2007; Zlotoff et al., 2010).  
The exact bone marrow progenitor population to settle the thymus has been a matter 
of debate for a long time, since many different progenitors harbor T-cell potential. The 
necessity of Ccr7, Ccr9, and Psgl-1 for efficient trafficking and entrance into the thymus 
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implicates that these receptors must be expressed by potential candidates, unless they get 
upregulated during their migration in the blood. HSCs are negative for both Ccr7 and Ccr9, 
and indeed HSCs were shown to rapidly generate T-cells only after intrathymic but not 
intravenous injections (Schwarz et al., 2007). Several independent approaches localized the 
major thymus seeding capacity to be within the Flt3 positive pool of progenitor cells, including 
the LMPP and CLP populations (Saran et al., 2010; Serwold et al., 2009). A part of LMMPs 
and most CLPs express Ccr7, whereas Ccr9 expression is more limited to only subsets of 
these Ccr7+ LMPPs and CLPs (Krueger et al., 2010; Zlotoff and Bhandoola, 2011). 
Additionally, Psgl-1 expression is highest on Ccr9+ LMPPs and Ly6D- CLPs (Sultana et al., 
2012). Therefore, it is reasonable to predict that the most competent thymus settling 
progenitors reside within these subsets of LMPPs and CLPs. 
 
2.5.2.		Initiation	of	the	T-cell	program	
 The most immature populations in the thymus are generally characterized by the 
absence of expression of CD4 and CD8 and are therefore termed double negative (DN). By 
the use of several additional surface markers DN thymocytes can be further subdivided into 
consecutive stages as summarized in Figure 5. The earliest progenitors are defined by high 
expression of CD44 and c-kit and the absence of CD25 (DN1) (Godfrey et al., 1993; Godfrey 
et al., 1992; Massa et al., 2006). Cells that have just entered the thymus, named early thymic 
progenitors (ETPs), furthermore express Flt3 and are negative for IL-7R. These cells are not 
yet committed to the T-cell lineage, but instead contain the potential to differentiate into B cells, 
NK cells, as well as a variety of myeloid cells (Balciunaite et al., 2005c; Bell and Bhandoola, 
2008; Ceredig et al., 2007; Luc et al., 2012; Luis et al., 2016; Wada et al., 2008).  
The T-lineage program in ETPs is initiated by the activation of Notch1 signaling. This 
is specifically induced in the thymic environment due to the dense presentation of the Notch1 
ligand Delta-like 4 (Dll4) on thymic epithelial cells, which triggers the release of intracellular 
Notch1 domain (Love and Bhandoola, 2011). Association with the DNA-bound recombining 
binding protein suppressor of hairless (Rbpj) results in the recruitment of a transcriptional co-
activator complex to activate the expression of Notch1 target genes (Radtke et al., 2013). The 
absolute requirement of Notch1 for T-cell development is manifested by the complete absence 
of mature T cells and also T-cell precursors in the thymus in its absence (Radtke et al., 1999). 
Moreover, expression of constitutively active Notch1 in hematopoietic progenitors resulted in 
a severely altered lymphoid development in the bone marrow, namely a block in B-cell 
development and instead the ectopic generation of T cells (Pui et al., 1999). Due to the 
importance of Notch1 during these early stages, this first part of the development of T cells in 
the thymus is termed “Notch-dependent”. Notch1 signaling drives proliferation of the cells and 
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becomes increasingly important also for their viability as they progress through early 
development.  
 
 
Figure 5 | T-cell development. Schematic representation of early T-cell development stages in the thymus. 
Sequential stages are connected by arrows indicating the developmental progression from ETPs up to mature SP 
T cells. Recombination processes are indicated in boxes above the different populations. Table below the 
populations shows surface marker expression of the different populations (yellow) as well as intracellular expression 
of transcription factors and genes involved in the recombination process (red). DN: double negative, DP: double 
positive, SP: single positive. 
 
Transcriptionally, Notch1 signaling in ETPs is responsible for the initiation of the 
expression of several important regulators of early T-cell development, including the induction 
of the genes Hes1, Gata3 and Tcf7. Hes1 is a transcriptional repressor that is turned on in 
ETPs and stays highly expressed until final commitment to the T-cell lineage (Wendorff et al., 
2010). It was shown to play a role in antagonizing myeloid differentiation and supporting 
proliferative expansion of ETPs (De Obaldia et al., 2013; Tomita et al., 1999). Tcf7 and Gata3 
are two absolutely crucial genes for T-cell fate initiation and are activated in parallel by Notch1. 
Deficiency of either of the two was shown to impair survival and differentiation of ETPs as well 
as their progeny (Germar et al., 2011; Hosoya et al., 2009). Tcf7 was proven to be activated 
by Notch1 directly, but its expression becomes independent of Notch1 in the later stages of T-
cell development (Germar et al., 2011; Weber et al., 2011). Primarily it collaborates with 
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Notch1 in the positive regulation of T-cell specification. Over-expression of Tcf1 resulted in the 
activation of T-cell specific genes in multipotent progenitors including Gata3, Bcl11b, Il2ra, 
CD3g, Lat, Lck, and endogenous Tcf7 even in the absence of Notch1 signaling (Weber et al., 
2011). Most recently, the mechanism of this activation by Tcf1 was shown to rely on its ability 
to target silent chromatin and increases its accessibility, thereby controlling the epigenetic 
identity of T cells (Johnson et al., 2018). Similarly, Gata3 has important dose-dependent 
functions for survival, growth, specification and commitment during early T cell specification, 
and remains crucial also at later differentiation stages after TCR expression (Hosoya et al., 
2010; Yui and Rothenberg, 2014). In addition, Gata3 expression in ETPs is responsible for the 
exclusion of the B-cell fate (Garcia-Ojeda et al., 2013). However, the expression level of Gata3 
has to be tightly controlled, since enforced expression resulted in an impaired T-cell 
development as severe as in the absence of Gata3 (Xu et al., 2013). 
Transition to the DN2 stage is marked by the up-regulation of the surface receptor 
CD25 (IL2 receptor a, Il2ra), which is also directly induced by Notch1. At this stage the 
expression of several key transcriptional regulators like Runx1, Gfi1, Ets1, Tcf12, as well as 
Gata3 and Tcf7 is further increased. As a consequence, initial expression of the T cell specific 
genes Thy1, Cd3g, Cd3d, and Cd3e can be detected. Furthermore, Rag1/2 gene expression 
is activated, initiating the process of rearrangement of the TCRb, TCRg, and TCRd chains 
(Rothenberg, 2014). Upregulation of the IL-7R on these cells becomes important for their 
expansion as well as for the decision between the ab and gd T-cell fate (Huang et al., 2001; 
Ye et al., 2001). Nevertheless, DN2 cells are still not fully committed to the T-cell lineage as 
they were shown to retain the capability to differentiate into NK cells, DCs, mast cells, a subset 
of ILCs, macrophages, and granulocytes (Rothenberg, 2011; Taghon et al., 2007; Wong et al., 
2012).  
Committed cells were initially discovered with the use of a Lck-GFP transgene reporter 
mouse (Masuda et al., 2007). Based on reporter expression the DN2 population could be 
subdivided into GFP-, which retained dendritic cell potential, and GFP+ cells, which were fully 
committed to the T-cell lineage. Functionally this step is dependent on the up-regulation of the 
transcription factor Bcl11b, whose activation is absolutely required for T-lineage commitment 
(Ikawa et al., 2010; Li et al., 2010a; Li et al., 2010b). The enhancer and promoter regions that 
participate in Bcl11b activation contain binding sites for Rbpj, Tcf1, Gata3, and Runx1, which 
were all shown to positively regulate Bcl11b expression (Garcia-Ojeda et al., 2013; Li et al., 
2013; Weber et al., 2011). Thus, it can be envisaged that a certain threshold expression of 
these regulators has to be reached for proper Bcl11b activation, since they are expressed 
already at earlier stages of T-cell development. Concurrent with Bcl11b activation, E-protein- 
and Notch1-dependent gene expression increases, resulting in the upregulation of genes 
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belonging to the VDJ recombination machinery including Rag1, Rag2, Dntt, CD3e and the first 
expression of the Ptcra gene, encoding the surrogate chain for a rearranged TCRb gene 
product (Georgescu et al., 2008; Takeuchi et al., 2001; Xu et al., 2013). At the same time many 
genes important in the early stages become silenced. Phenotypically this is determined by a 
reduction of c-kit expression on the surface of the cells, potentially directly regulated by Bcl11b. 
Furthermore, Spi1 expression is terminated at this point, which is another contributor to lineage 
exclusion, since its termination antagonizes the myeloid and DC fate (Anderson et al., 2002). 
Additionally, genes involved in the progenitor-like phenotype before commitment get repressed 
such as Tal1, Gfi1b, Hhex, Bcl11a, Lmo2, Mf2c, and Lyl1 (Mingueneau et al., 2013). Overall, 
proliferation of the cells slows down, while recombination activity intensifies by the time that 
the first crucial checkpoint of T-cell development is reached. 
 
2.5.3.		b-selection		
 At the DN3a stage cells are characterized by lower c-kit and CD44 expression, but 
sustained high levels of CD25. Morphologically these cells are very small in size since they 
undergo TCRb rearrangements, which requires exit from cell cycle (Hathcock et al., 2011; Lin 
and Desiderio, 1994). Accordingly, highest expression of the recombination machinery is 
detected in these cells. Moreover, CD3 components, Notch1, Tcf1, Gata3, and E proteins 
reach their expression maxima.  
 VDJ-recombination itself is a random and imprecise process, failing in two-thirds of the 
attempts to maintain the translational reading frame, thereby generating non-functional b-
chains. On account of this, almost half of the cells are not able to productively rearrange their 
TCRb loci on any allele (Mallick et al., 1993). Removal of cells with a non-functional 
rearrangement consists the first important checkpoint in T-cell development, termed β-
selection. During this process it is ensured that only those cells with a productive b-chain will 
undergo further differentiation, whereas the others will die by apoptosis. This selection is 
achieved by assembling of the pre-TCR, which is composed of a productively rearranged b-
chain, the CD3 signaling components, and the invariant pre-T cell receptor a (pTa) chain 
(Saint-Ruf et al., 1994) (Figure 6). Expression of the Ptcra gene, that encodes the pTa-chain, 
is jointly regulated by Notch1 and E proteins and reaches its highest expression in DN3a cells 
(Ikawa et al., 2006; Reizis and Leder, 2002). Subsequent signaling by the pre-TCR is 
dependent both on its extracellular domains, which are important for oligomerization, and its 
intracellular cytoplasmic tail, which facilitates signal transduction. This signaling results in 
survival and proliferative expansion of DN3 cells (Aifantis et al., 2002; Irving et al., 1998; 
Jacobs et al., 1996; Yamasaki et al., 2006). Moreover, signaling is constitutive and ligand 
independent, which is believed to lead to a rapid internalization and degradation of the pre-
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TCR complex, since only very low expression can be detected on the surface of pre-T cells 
(Panigada et al., 2002; Yamasaki and Saito, 2007). The requirement of pre-TCR signaling for 
further differentiation is manifested by the arrest of T-cell development in mice deficient for the 
pTa chain, the CD3 signaling components, or the genes of the recombination machinery 
(Fehling et al., 1995; Malissen et al., 1995; Shinkai et al., 1992).   
 Pre-TCR signaling disrupts the state of quiescence and induces a phase of proliferation 
that is strictly required for further differentiation (Kreslavsky et al., 2012). Moreover, it induces 
key survival signals. Thus, increased cell size as well as upregulation of the co-stimulatory 
markers CD27, CD28, and CD71 can be used to define the DN3b stage in development, which 
is composed of cells that have passed the b-selection checkpoint and express a functional pre-
TCR (Brekelmans et al., 1994; Gravestein et al., 1996; Taghon et al., 2006; Williams et al., 
2005). Furthermore, Rag1/2 gene expression is downregulated thereby terminating TCRb 
rearrangements, ensuring allelic exclusion, as well as excluding the gd-T-cell fate (Aifantis et 
al., 1998; Lopez-Rodriguez et al., 2015; Saint-Ruf et al., 2000).   
 
 
Figure 6 | b-selection. Schematic representation of the concept of b-selection. DN3a cells undergoing TCRb 
recombination either produce a functional rearrangement on one allele or fail to rearrange on both. Productive 
rearrangement will lead to the formation of the pre-TCR and subsequent signaling results in survival, proliferation 
as well as differentiation of the cells. Cells with a non-productive rearrangement on the other hand will undergo 
apoptosis. Pre-TCR: pre-T cell receptor. 
 
On a transcriptional level, pre-TCR signaling induces the activity of several important 
programs responsible for expansion and survival of the cells. For instance, NFkB as well as 
NFAT activity are turned on and are indispensable for the transition through b-chain selection 
(Aifantis et al., 2001; Mandal et al., 2005; Voll et al., 2000). Another important factor that 
becomes activated is c-myc. It regulates the cellular proliferation and growth of the cells (Dose 
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et al., 2006; Douglas et al., 2001). In addition, Notch1 signaling was shown to act cooperatively 
with the pre-TCR further promoting the survival, cellular expansion and differentiation of the 
cells (Ciofani et al., 2004; Ciofani and Zuniga-Pflucker, 2005; Tussiwand et al., 2011). 
However, soon after pre-TCR activation Notch1 gets downregulated due to the induction of 
Id3, which antagonizes E proteins that promote and sustain Notch1 expression (Yashiro-
Ohtani et al., 2009). Thus, pre-T cells become independent of Notch1 soon after passage 
through the b-selection checkpoint, hereby switching from the “Notch-dependent” to the “TCR-
dependent” part of T-cell development. Once cells have passed b-selection they also 
downregulate IL-7R and become sensitive to chemokine receptor Cxcr4 signaling as another 
co-stimulus controlling survival and proliferation via PI3K activation (Janas et al., 2010; 
Trampont et al., 2010). 
Since a large fraction of the cells fail to rearrange an in frame b-chain or are incapable 
of paring with the pTα-chain, programmed induction of apoptosis in these cells is a requirement 
to prevent accumulation of non-functional cells. Studies in the late nineties proposed a role of 
the p53 pathway in the regulation of apoptosis at this checkpoint. p53 gets activated during 
VDJ recombination as this process involves the generation of DNA double-strand breaks. In 
the case of a non-functional rearrangement cells lack survival signals from the pre-TCR and 
instead accumulate p53, which in turn induces pro-apoptotic proteins such as Noxa, Puma, 
and Bid (Mandal et al., 2008).  By contrast, successful generation of the b-chain suppresses 
the p53 pathway via the pre-TCR (Costello et al., 2000). This is supported by the fact that pre-
T cells defective in pre-TCR signaling are partially rescued from the differentiation block when 
p53 is deleted (Bogue et al., 1996; Haks et al., 1999; Mombaerts et al., 1995). More recently, 
activity of the transcription factor Miz-1 was associated with p53 regulation during b-selection 
by the induction of ribosomal protein L22 expression (Rpl22), which was previously described 
to be a negative regulator of p53 translation (Anderson et al., 2007; Rashkovan et al., 2014; 
Saba et al., 2011; Stadanlick et al., 2011). In addition to this intrinsic apoptosis pathway the 
extrinsic Fas system was also linked to the pre-TCR checkpoint. Fas is expressed on the 
surface of thymocytes and after binding to Fas-ligand apoptosis can be induced via interaction 
of the cytoplasmic death domain with adapter molecules inducing a downstream caspase 
activation cascade (Ashkenazi and Dixit, 1998). Similarly, to the p53 pathway, deficiency of 
Fas or downstream adapters led to pre-T cell differentiation even in the absence of pre-TCR 
signaling (Newton et al., 2000; Yasutomo et al., 1997).  
However, the involvement of these factors still not fully resolves the underlying 
mechanisms of apoptosis induction in cells with a non-functional rearrangement. Especially 
since the described factors like p53, Miz-1, Rpl22, and Fas are not differentially expressed 
between DN3a and DN3b thymocytes (Immgen Database). Therefore, the exact factors, 
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mechanisms, and regulations responsible for the induction of apoptosis have to be further 
investigated in order to completely understand the b-selection process. 
 
2.5.4.		Final	maturation	steps	
 During the proliferative expansion after pre-TCR triggering, cells lose the expression of 
CD25, thereby entering the DN4 stage defined as CD44-CD117-CD25-. Subsequently, also as 
a result of pre-TCR signaling, CD4 and CD8 expression is induced, assigning the double 
positive (DP) stage. Rag genes become re-expressed and initiate the recombination of the 
TCRα locus (Koch and Radtke, 2011). Once a functional TCR is expressed by DP cells its 
functionality and specificity is tested for binding to peptide-major histocompatibility complex 
(MHC) complexes presented by cortical thymic epithelial cells (cTECs) and DCs (Klein et al., 
2009). Interactions of intermediate affinity for self-peptide-MHC complexes positively select 
the cells and induce survival (Starr et al., 2003). The recombination machinery is again rapidly 
repressed in order to ensure allelic exclusion. Depending on whether the interaction was 
successful with MHCI or MHCII the cells will now develop in either CD8 or CD4 single positive 
(SP) T cells, respectively. At the same time, the chemokine receptor Ccr7 becomes 
upregulated and facilitates the migration into the medulla, where the cells undergo negative 
selection (Ueno et al., 2004). During this process, cells with a high affinity to self-antigens, 
which are presented by medullary thymic epithelial cells (mTECs), are eliminated, thereby 
ensuring tolerance and reducing the risk for the generation of autoreactive T cells (Palmer, 
2003). Upregulation of S1PR1 expression on mature SP thymocytes finally mediates the 
egress from the thymus into the circulation, where the concentration of its chemokine S1P is 
higher (Matloubian et al., 2004). 
  
 
2.6.		 Flt3-ligand	and	IL-7	in	lymphoid	development	
 
2.6.1.		Instructive	versus	permissive	action	of	cytokines	
Cytokines play important roles in the regulation of hematopoiesis as they influence 
survival, proliferation, differentiation, and maturation of cells (Metcalf, 2008). In lineage 
specification cytokines can act either in an instructive or a permissive manner. The induction 
of a specific signaling cascade that results in a genetic programming that determines lineage 
fate specification describes an instructive cytokine (Figure 7, left panel). A permissive cytokine, 
on the other hand, influences the selection of cells with appropriate receptor expression by 
regulating the survival and/or proliferation capacity (Figure 7, right panel). In many cases 
investigations identifying the exact action of a cytokine led to conflicting results, thus, the 
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precise mode of action of many cytokines studied remains unresolved. For instance, deletion 
of either the cytokine or its receptor reduces the lineage output, a result which is compatible 
with both instructive and permissive function of the cytokine. It should be noted however, that 
deficiencies never resulted in a complete absence of a lineage, which could be taken as 
evidence for permissive roles of cytokines, but could also be explained by compensatory 
mechanisms and redundancy in the system (Brown et al., 2018).  
 
 
Figure 7 | Instructive vs permissive action of cytokines. Schematic representation for a permissive versus 
instructive action of a cytokine. If a cytokine has an instructive role it initiates a cell-type specific program in the 
target cell resulting in differentiation and commitment to a certain lineage. A Permissive action on the other hand 
influences the survival or proliferation of the target cells resulting in its expansion compared to other receptor 
negative cell types. Adapted from (Brown et al., 2018). 
 
First experiments providing evidence for instructive roles of cytokines were performed 
in 1982 revealing the impact of macrophage colony-stimulating factor (M-CSF) and 
granulocyte-macrophage colony-stimulating factor (GM-CSF) in the cell fate decision of 
macrophages and granulocytes, respectively (Metcalf and Burgess, 1982). These findings 
were confirmed by technical improvements explicitly proving the instructive mode of action of 
M-CSF and GM-CSF on the GMP progenitor population (Rieger et al., 2009). Moreover, 
induction of the transcriptional regulators Pu.1 and Gata1 by M-CSF and Epo was shown to 
instruct myeloid and erythroid cell fate specification, respectively (Grover et al., 2014; 
Mossadegh-Keller et al., 2013). Nevertheless, most experimental evidence for instructive 
function of cytokines are derived from in vitro studies and might therefore not reflect the 
mechanisms of in vivo steady-state hematopoiesis. 
Two essential cytokines for the development of lymphocytes are Fms-like tyrosine 
kinase 3 (Flt3) ligand and interleukin-7 (IL-7). 
Cytokine
Instructive Permissive
Commitment Survival / Proliferation
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2.6.2.		Flt3-ligand	in	early	hematopoiesis	
 Flt3 (or Flk2/CD135) is so far the only receptor identified for the cytokine Flt3-ligand. 
As Flt3 belongs to the type III receptor tyrosine kinases it has an extracellular part with five 
immunoglobulin-like domains and a cytoplasmic part with two tyrosine kinase domains 
(Matthews et al., 1991; Rosnet et al., 1991). Binding of soluble as well as membrane-bound 
Flt3-ligand initiates receptor homo-dimerization that in turn induces a conformational change 
resulting in phosphorylation of the tyrosine kinase domains (Tsapogas et al., 2017). Stimulation 
of the receptor is followed by rapid internalization and degradation (Turner et al., 1996). The 
signaling cascade downstream of the receptor ultimately leads to Ras/Mek/Erk, PI3K, signal 
transducer and activator of transcription (Stat) 3, and on some occasions Stat5a activation in 
a cell-context dependent manner (Laouar et al., 2003; Marchetto et al., 1999; Zhang and 
Broxmeyer, 2000; Zhang et al., 2000). 
 Flt3 is mostly expressed on early hematopoietic progenitors, whereas more mature 
populations are Flt3 negative, with the exception of the dendritic cell compartment (Hagman 
et al., 1991; Karsunky et al., 2003; Liu et al., 2009; Onai et al., 2013; Rosnet et al., 1991) 
(Figure 8). Upregulation of Flt3 within the LSK population was associated with the loss of self-
renewal capacity, which allowed the definition of true HSCs as Flt3 negative and MPPs as Flt3 
positive (Adolfsson et al., 2001). Moreover, the LMPP population was defined as the 25% of 
cells with the highest Flt3 expression of the LSK population (Adolfsson et al., 2005). These 
studies also linked Flt3 expression with a loss of megakaryocyte and erythrocyte potential by 
MPPs. This is further strengthened by the absence of Flt3 on all megakaryocyte/erythrocyte 
progenitor populations. Surprisingly, lineage tracing of Flt3 expression resulted in labeling of 
all lineages, including megakaryocyte and erythrocyte progenitors and their progeny, 
suggesting that all hematopoietic cells develop through a Flt3 positive stage (Boyer et al., 
2011; Buza-Vidas et al., 2011). Expression of Flt3 on HSCs remains controversial, as one 
group could not find labeled HSCs in the lineage-tracing model, whereas another group did 
find partial labeling. Analysis of Flt3 mRNA expression at the single-cell level revealed that 
indeed small fractions of LT- as well as ST-HSCs express Flt3, in agreement with the rising 
concept of heterogeneity within the HSC compartment (Mead et al., 2017; Mooney et al., 
2017). Even though Flt3+ MPPs have robust myeloid potential, downstream progenitors such 
as the CMP or GMP switch off its expression (Boyer et al., 2011). Lymphoid progenitor 
populations on the other hand, such as the CLP, EPLM, and ETP populations, retain Flt3 
expression until final commitment (Buza-Vidas et al., 2011; Karsunky et al., 2008; Luc et al., 
2012). In the B-cell lineage, for instance, Pax5 downregulates Flt3 expression, resulting in its 
absence on all CD19 positive cells (Holmes et al., 2006). 
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 Functionally, Flt3-ligand was originally identified as a proliferation promoting factor for 
early Flt3+ progenitors. However, in in vitro culture systems Flt3-ligand alone had only a limited 
effect, whereas combination with other cytokines such as stem cell factor (SCF), GM-CSF, IL-
3, IL-6, or IL-11 demonstrated its importance for the generation of myeloid cells (Broxmeyer et 
al., 1995; Jacobsen et al., 1995).  Especially for DC cultures Flt3-ligand turned out to be very 
important (Brasel et al., 2000; Brawand et al., 2002). On the other hand, there was no positive 
effect on erythrocyte or megakaryocyte growth and differentiation (Banu et al., 1999). In 
combination with SCF and/or IL-7 Flt3-ligand also improved in vitro generation of B cells as it 
acts on its progenitor populations (Namikawa et al., 1996; von Muenchow et al., 2017).  
 Deficiency for either Flt3 or Flt3-ligand is causing defects in myeloid and lymphoid 
progenitors (Mackarehtschian et al., 1995; McKenna et al., 2000). Notably, the effect was more 
pronounced in the Flt3-ligand knockout mice, with decreased B-cell progenitors, NK cells, and 
DCs, indicating the possibility of the existence of another not yet identified receptor for Flt3-
ligand. Additional analysis revealed that Flt3-ligand is furthermore important for normal 
production and/or maintenance of CLPs and MPPs, while HSCs seemed to be independent 
(Sitnicka et al., 2002). These knockout models ruled out an absolute requirement of Flt3-ligand 
for hematopoiesis, but clearly demonstrated its importance for the generation of lymphoid and 
myeloid cells, whereas it is dispensable for the megakaryocyte and erythroid lineages. These 
findings raised the question whether the role of the Flt3-Flt3-ligand system is just permissive 
with regards to proliferation and survival, or whether it has also an instructive function for the 
lymphoid/myeloid pathway. This was addressed by the generation of a Flt3-ligand transgenic 
mouse model, in which, additionally to its endogenous expression, Flt3-ligand expression is 
driven by the β-actin promoter, causing sustained high in vivo levels (Tsapogas et al., 2014). 
In these mice a massive expansion of all Flt3+ cells and their progeny was detected including 
MPPs, CLPs, EPLMs, CMPs, GMPs, mature myeloid cells, pDCs, and cDCs. On the contrary, 
these mice suffered from severe anemia caused by the reduction of erythroid and 
megakaryocyte progenitors and consequently also their mature progeny. Detailed analysis 
provided clear evidence for an instructive role of Flt3-ligand in early hematopoiesis, initiating 
lymphoid/myeloid specification in MPPs and suppressing the megakaryocyte/erythrocyte fate 
(Tsapogas et al., 2014). 
 With regards to lymphoid development, Flt3-ligand has a positive effect on B-cell 
precursors as it increases their generation in the transgenic mouse (Tsapogas et al., 2014), 
whereas cell numbers are reduced in the absence of Flt3 signaling (McKenna et al., 2000). 
Whether this effect is based on a permissive or an instructive mode of action needs further 
investigation. Interestingly, Flt3-ligand over-expression resulted in a disturbed development 
from the pro-B cell stage onwards, with reduced numbers of pre-B and immature B cells 
(Tsapogas et al., 2014). Since Flt3 expression is turned off upon Pax5 induction, this must be 
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an indirect effect. One hypothesis is that due to the expansion of IL-7R+ CLP/EPLM progenitors 
and pDCs, which are also IL-7R positive, in Flt3-ligand transgenic mice, IL-7 availability is 
decreased, thus affecting the proliferation of pre-B cells. The production of T lymphocytes is 
not affected in Flt3-ligand or Flt3 deficient mice (Mackarehtschian et al., 1995; McKenna et al., 
2000). However, in combination with IL-7R deletion, the IL-7R mediated block in T-cell 
development is amplified (Sitnicka et al., 2007). This is most likely attributed to the Flt3+ ETPs, 
which were shown to rely on Flt3-ligand production by thymic epithelial cells (Kenins et al., 
2010). Moreover, Flt3-ligand is also involved in the regulation of ILC numbers, since it acts on 
their early progenitors (Baerenwaldt et al., 2016). 
 Due to its function in promoting the proliferation of hematopoietic progenitor cells it is 
not surprising that deregulated Flt3 signaling can cause hematopoietic malignancies. 
Specifically, activating mutations in the human FLT3 gene are frequently found in leukemic 
cells. The most common one, termed FLT3-ITD, results in a constitutive activation of the 
cytoplasmic kinase domains and is found in 25% of the cases of acute myeloid leukemia. 
Moreover, it is associated with a poor clinical prognosis (Gilliland and Griffin, 2002; Nakao et 
al., 1996). This clinical significance further illustrates the importance of further investigations 
to unravel the exact mechanism and regulations involved in Flt3 signaling. 
	
2.6.3.		IL-7	in	lymphopoiesis	
 Three decades ago IL-7 was discovered as a growth factor in in vitro cultures of 
progenitor B cells (Namen et al., 1988). These were soon followed by studies revealing that 
this effect holds true for T cells as well. Further investigations led to the conclusion that the 
receptor for IL-7 is mainly expressed by lymphoid cells (Ceredig and Rolink, 2012). The IL-7R 
is composed of two subunits: the α-chain (IL-7Rα, or CD127) and the common γ-chain (or 
CD132). Only if both chains dimerize on the cell membrane IL-7 can bind and trigger 
intracellular signaling. The common γ-chain is not unique to the IL-7R as it is furthermore part 
of the receptor complexes for the cytokines IL-2, IL-4, IL-9, IL-15, and IL-21 (Jiang et al., 2005). 
Likewise, specificity of the α-chain is not limited to IL-7 alone. In complex with the thymic 
stromal lymphopoietin receptor (TSLPR) chain it additionally can bind the cytokine TSLP 
(Pandey et al., 2000; Park et al., 2000). Signaling via the IL-7R after binding of IL-7 is initiated 
by Janus kinases (Jak) 1 and 3. Jak1 is associated with the intracellular domain of the α-chain, 
while Jak3 associates with the common γ-chain (Suzuki et al., 2000). Ligand binding facilitates 
cross-phosphorylation of Jak1 and Jak3, which allows for Jak mediated phosphorylation of a 
tyrosine residue within the α-chain (Foxwell et al., 1995; Kasai et al., 2018). Recruitment of 
further signaling molecules ultimately results in the activation of Stat5 by phosphorylation-
dependent dimerization and subsequent translocation into the nucleus. Stat5 then initiates 
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gene expression of factors important for survival, proliferation, as well as differentiation 
(Hennighausen and Robinson, 2008). For instance, activation of the anti-apoptotic genes Bcl2 
and Mcl1 is mediated by Stat5, thereby promoting survival (Jiang et al., 2004; Opferman et al., 
2003). Proliferation of cells, on the other hand, is induced by the expression of cyclin D3, a 
positive regulator of the cell cycle (Cooper et al., 2006).  In addition to Stat5, IL-7R signaling 
further activates PI3K/Akt, Mapk/Erc, and Src kinase pathways, which are facilitators of 
survival and proliferation too (Clark et al., 2014; Fleming and Paige, 2001; Page et al., 1995; 
Venkitaraman and Cowling, 1994; Yasuda et al., 2008). The various pathways downstream of 
IL-7R activation indicate a cell-type and context-dependent induction of specific signaling 
events, leading to varying outcomes. 
 While the common γ-chain is expressed by nearly all hematopoietic cells, restricted 
expression of the IL-7R α-chain provides the specificity for IL-7 signaling. Consequently, IL-7R 
expression in the hematopoietic system is almost limited to lymphoid cells such as B- and T-
cell progenitors as well as mature T cells, innate lymphoid cells like ILC2s and ILC3s, but also 
certain DCs, such as migratory DCs and pDCs (Chappaz and Finke, 2010; Hoyler et al., 2012; 
Rodrigues et al., 2018; Vogt et al., 2009) (Figure 8). Initiation of IL-7R expression on early 
progenitors is associated with lymphoid specification, in particular since its surface expression 
is used to define the CLP stage. Transcriptional activation of the Il7ra gene was shown to be 
mediated by Pu.1 and also by Ikaros, resulting in Il7ra mRNA detection already at the LMPP 
stage (DeKoter et al., 2002; Yoshida et al., 2006). Moreover, the expression of the IL-7R is 
under the control of extracellular signals as it is upregulated by factors like Flt3-ligand, type-I 
interferons, and tumor necrosis factor (TNF), whereas IL-2, IL-4, IL-6, and IL-15 suppress its 
expression (Borge et al., 1999; Park et al., 2004; Pleiman et al., 1991; Tian et al., 2005). The 
latter can act as survival factors for different hematopoietic cell types. Therefore, one 
hypothesis is that cells, which do not require IL-7 signaling for their survival anymore 
downregulate IL-7R in order to stop the consumption of IL-7, which is only available at limited 
amounts under steady state conditions. Suppression of IL-7R by other survival factors and 
even by IL-7 signaling itself thus prevents needless consumption of IL-7 (Park et al., 2004). 
 The significance of IL-7R signaling for lymphoid differentiation is demonstrated by the 
dramatic defect for both B- and T-cell generation in mice defective for either the cytokine or its 
receptor (Peschon et al., 1994; von Freeden-Jeffry et al., 1995).  During B-cell specification IL-
7R is expressed by uncommitted progenitors such as the CLP and EPLM as well as on CD19+ 
pro-B and large pre-B cells, but gets downregulated at the small pre-B stage. In Il7-/- or Il7r-/- 
mice B-cell development is perturbed, as indicated by the absence of pro-B cells and their 
progeny (Peschon et al., 1994; von Freeden-Jeffry et al., 1995). Additional over-expression of 
the pro-survival gene Bcl2 in these mice did not rescue the defect in B-cell development 
indicating that the role of IL-7 for B-cell differentiation is not only permissive in the sense of 
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providing survival signals, but acts in an instructive manner in promoting B-cell specification 
(Kondo et al., 1997a; Maraskovsky et al., 1998). Subsequent studies on the effect of IL-7 
absence on CLP strengthened this hypothesis due to a significant decrease of CLP numbers 
and especially a reduction of Ebf1 transcript levels in this compartment (Dias et al., 2005). 
Thus, it was concluded that IL-7R signaling instructs B-cell commitment by the induction of 
Ebf1 in the CLP population. This assumption was further based on the discovery of Stat5 
binding sites within the Ebf1 and Pax5 promoters and by a partial rescue of B-cell potential in 
Il7-/- CLPs by Ebf1 over-expression (Hirokawa et al., 2003; Kikuchi et al., 2005; Roessler et al., 
2007). However, in vivo binding of Stat5 to the Ebf1 and Pax5 promoters could not be 
confirmed. More detailed analysis of the Il7-/- CLP compartment revealed that the reduction 
was specific to the Ly6D+ fraction, in which Ebf1 expression and further specification to the B-
cell fate is initiated (Tsapogas et al., 2011). Thus, the observed reduction of Ebf1 levels in  
Il7-/- CLPs might actually result from the elimination of the Ebf1+Ly6D+ CLP compartment due 
to a potential role of IL-7 in survival. In accordance with that the group of Meinrad Busslinger 
showed that transgenic Bcl2 expression in mice with B-cell specific deletion of Stat5 could 
restore pro-B cell differentiation (Malin et al., 2010). In addition, they also observed a partial 
restoration of committed pro-B cells in Il7r-/- mice by Bcl2 over-expression and neither Stat5 
nor IL7-R signaling was absolutely critical for Ebf1 and Pax5 transcription in their experiments. 
These data support a rather permissive survival-mediated role of IL-7 in B-cell specification. 
 After commitment to the B-cell lineage IL-7 does not only promote survival, but also the 
proliferation of pre-B cells (Cooper et al., 2006; Mandal et al., 2009). After effective expansion 
of pre-B cells IL-7Rα expression is suppressed via pre-BCR signaling (Ochiai et al., 2012). 
This is important for further development, since loss of IL-7R signaling is allowing κ light-chain 
transcription, which is normally silenced due to a repressed chromatin configuration on the k 
locus by Stat5 (Malin et al., 2010; Mandal et al., 2011). In accordance with that, IL-7 removal 
from in vitro pro-B cell cultures initiates light chain rearrangements and further maturation to 
IgM+ B cells (von Muenchow et al., 2017). However, sustained high in vivo levels of IL-7 did 
not block B-cell differentiation, but instead expanded all IL-7R positive precursor and also 
mature B-cell populations (Ceredig et al., 2003; Fisher et al., 1995). Interestingly, pro-B and 
pre-B cells were even detected in the periphery of these mice in large numbers, including the 
spleen and lymph nodes (Mertsching et al., 1996). Whether these resulted from in situ 
generation of B cells or whether this was just a result of emigration of the cells from the bone 
marrow is not clear.  
Altogether, it is apparent that IL-7 is the most crucial cytokine for mouse B-cell 
development. However, not all mature B-cell populations are missing in the absence of IL-7. 
As these unaffected populations mainly present a MZB or B1 phenotype, it is believed that 
fetal B-cell development is not dependent on IL-7. Neonatal mice defective for IL-7 have almost 
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unchanged B-cell numbers (Carvalho et al., 2001). Similarly, also human B cells seem to be 
unaffected in the absence of IL-7 (Noguchi et al., 1993; Puel et al., 1998). However, it has to 
be considered that patients with IL-7 deficiency are always infants, as without treatment they 
don’t reach adulthood. Therefore, the difference in IL-7 dependency between humans and 
mice might just reflect the difference in this dependency between fetal and adult B cells. This 
idea is supported by the observation that ex vivo cultured human pre-B cells exhibited an 
increased IL-7 dependency compared to cord blood derived pre-B cells (Parrish et al., 2009). 
Il7-/- and Il7r-/- mice display a severe block in the generation of T lymphocytes, similar 
to B cells (Peschon et al., 1994; von Freeden-Jeffry et al., 1995). Even though expression of 
IL-7R on ETPs is not detectable by FACS, they were shown to be responsive to IL-7, 
suggesting that IL-7R expression might be just below the detection limit. IL-7R becomes 
strongly upregulated on DN2 cells and is crucial for their survival and proliferation. However, 
IL-7R signaling is not involved in the commitment to the α/β T-cell lineage, since Bcl2 over-
expression as well as deficiency for the pro-apoptotic genes Bax and Bim rescued α/β T-cell 
development in Il7r-/- mice (Akashi et al., 1997; Khaled et al., 2002; Kondo et al., 1997a; 
Maraskovsky et al., 1997; Pellegrini et al., 2004). Thymocyte numbers are not fully restored in 
these mouse models, since IL-7 has not only a major function for the survival of DN2/3 cells, 
but is also responsible for their expansion. Thus, IL-7 is also essential for the in vitro 
propagation of pre-T cells (Balciunaite et al., 2005a; Gehre et al., 2015). In contrast to α/β T 
cells, the development of γ/δ T cells is not rescued by additional Bcl2 expression, indicating 
that IL-7 is more than just a survival and proliferation factor for these cells. Indeed, IL-7R 
signaling was proposed to influence the α/β versus γ/δ T-cell decision at the DN2 stage by 
regulating the chromatin accessibility of the TCRγ locus (Huang et al., 2001; Ye et al., 2001).   
At the β-selection checkpoint IL-7 acts cooperatively with pre-TCR and Notch1 
signaling in the proliferation and differentiation of the cells and prevents TCRa rearrangements 
similarly to the light chains in pre-B cells (Boudil et al., 2015). Therefore, in analogy to B-cell 
development, IL-7R has to be suppressed at the DN3-DP transition for further maturation and 
initiation of TCRa recombination. This is reflected in vitro by the fact, that pre-T cells do not 
properly differentiate to the DP stage unless IL-7 is removed from the cultures (Balciunaite et 
al., 2005a; Tussiwand et al., 2011). Downregulation of IL-7R on DP cells might also be 
important for the regulation of IL-7 availability in the thymus. Since the DP stage is by far for 
the major population of thymocytes, consumption of IL-7 by this population might negatively 
influence other IL-7 dependent populations. This hypothesis is supported by reduced Bcl2 
expression and increased apoptosis of DN cells when IL-7Rα expression was induced on all 
thymocytes (Munitic et al., 2004).  
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Figure 8 | Flt3 and IL-7R expression in the hematopoietic system. Schematic representation of the classical 
hematopoietic tree indicating expression of Flt3 and IL-7R in different colors of the cells. Blue marks expression of 
Flt3, red IL-7R expression, and violet cells that express both receptors. Arrows indicate developmental progress 
and potential of the different progenitor populations. HSC: hematopoietic stem cell, MPP: multipotent progenitor, 
LMPP: lymphoid-primed multipotent progenitor, CMP: common myeloid progenitor, CLP: common lymphoid 
progenitor, MEP: megakaryocytic-erythroid progenitor, GMP: granulocyte/macrophage progenitor, MkP: 
megakaryocyte committed progenitor, ErP: erythrocyte progenitor, EPLM: early progenitor with lymphoid and 
myeloid potential, EILP: early innate lymphoid progenitor, CDP: common dendritic cell progenitor, ILC: innate 
lymphoid cell, ETP: early thymic progenitor. 
 
Unlike B cells, IL-7 signaling remains crucial for both survival and proliferation of mature 
naïve as well as memory T cells in the periphery (Chetoui et al., 2010; Lali et al., 2004; Li et 
al., 2010c; Swainson et al., 2007). Thus, induced deletion of Il7ra caused a rapid decrease of 
peripheral T cells before thymic output was affected (Jacobs et al., 2010).  Moreover, treatment 
of mice with IL-7/anti-IL-7 complexes as well as transgenic expression of IL-7 promoted the 
expansion of peripheral T cells even though development in the thymus was not affected 
(Boyman et al., 2008; Mertsching et al., 1995). Interestingly, the CD4-to-CD8 ratio was altered 
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in IL-7 transgenic mice, indicating that mature CD8 T cells are more responsive to IL-7R 
signaling than CD4 T cells (Tan et al., 2002).  
Mutations in the human IL7RA gene or other components of the IL-7R signaling 
pathway result in severe combined immunodeficiency (SCID), manifested by the absence of 
T-cells. These mutations have to be corrected by bone marrow transplantations or gene 
replacement therapy since the adaptive immune response is absolutely required for sufficient 
protection against pathogens (Buckley, 2004). 
Apart from B and T lymphopoiesis, ILC development is also known to transit through IL-7R+ 
stages, as they are most likely derived from the CLP as well (Gronke et al., 2016). In addition, 
most ILCs, with the exception of NK cells, retain IL-7R expression also upon maturation. While 
ILC1s and ILC2s do not absolutely require IL-7 for their survival, ILC3s and in particular 
lymphoid tissue inducer cells (LTi cell) are clearly dependent on functional IL-7R signaling 
(Daussy et al., 2014; Robinette et al., 2017). Since LTi cells are crucial for the generation of 
lymphoid structures such as lymph nodes and Peyer´s patches, IL-7 or IL-7R deficiency results 
in the absence of Peyer´s patches (Adachi et al., 1998; Yoshida et al., 1999). In addition, IL-7 
mediated survival of ILC3s is important for correct lymph node function as they were shown to 
regulate homing of lymphocytes to adult lymph nodes (Yang et al., 2018).  
 
As evident from the above, both Flt3-ligand as well as IL-7 have essential roles during 
lymphopoiesis. This is highlighted by the complete absence of progenitor and mature B cells 
and the exacerbated defect in T-cell development, when both cytokines are absent (Sitnicka 
et al., 2003; Sitnicka et al., 2007). The effect of the two cytokines is mostly restricted to 
separate stages in development, as Flt3-ligand acts on earlier progenitors, whereas IL-7R 
signaling has also essential roles for already committed B- and T-cell progenitors. However, 
some stages during differentiation, such as CLP, EPLM, and ETP, indeed are positive for both 
receptors, thereby enabling a potential synergistic action of the two cytokines on these 
populations (Figure 8). 
  
   3. Aims of the thesis 
 
  40 
3.	Aims	of	the	thesis	
 
 The regulation of lymphocyte development is of central interest, as the adaptive 
immunity is absolutely required for life. Disturbances in the differentiation process often result 
in immunodeficiency, autoimmunity or leukemia.  
In the past years several conflicting results were obtained regarding the role of IL-7 in 
B-cell commitment. While some reports provided evidence for an instructive function of IL-7, 
others argued for an only permissive mode of action. The CLP and EPLM populations are of 
particular interest in that sense, since they contain the last uncommitted B-cell progenitors and 
are heavily affected by the absence of IL-7. Since the Flt3-ligand transgenic mouse, that was 
previously generated in our lab, leads to a dramatic expansion of the CLP and EPLM 
populations, we aimed to address the exact function of IL-7 in B-cell commitment in vivo by 
making use of these mice and other combinations of mutant mouse strains. We thus aimed at 
unravelling, in an in vivo setting, the functions of IL-7 and Flt3-ligand on commitment to the B-
cell lineage and their potential synergistic role on lymphocyte development. 
Another important aspect of lymphocyte development is the selection of cells with 
functional rearrangements of their antigen-receptor chains. Especially within the thymus the 
majority of cells are eliminated during the differentiation process due to failure of successful 
recombination. However, little is known about the mechanisms that regulate the first essential 
checkpoint, the β-selection, which induces the elimination of almost half of the cells. Therefore, 
investigation of the detailed mechanisms that initiate apoptosis and identification of key 
mediators in this process was one major aim of this work. Moreover, genetic modification of 
mice for detailed analysis of potential candidates was the major tool we planned to implement 
in order to validate the exact molecular pathways involved in the apoptosis induction during β-
selection. 
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Hematopoietic cells are continuously generated throughout life from
hematopoietic stem cells, thus making hematopoiesis a favorable
system to study developmental cell lineage commitment. The main
factors incorporating environmental signals to developing hemato-
poietic cells are cytokines, which regulate commitment of hemato-
poietic progenitors to the different blood lineages by acting either in
an instructive or a permissive manner. Fms-like tyrosine kinase-3
(Flt3) ligand (FL) and Interleukin-7 (IL-7) are cytokines pivotal for B-cell
development, as manifested by the severely compromised B-cell
development in their absence. However, their precise role in regulat-
ing B-cell commitment has been the subject of debate. In the present
study we assessed the rescue of B-cell commitment in mice lacking
IL-7 but simultaneously overexpressing FL. Results obtained demon-
strate that FL overexpression in IL-7–deficient mice rescues B-cell com-
mitment, resulting in significant Ebf1 and Pax5 expression in Ly6D+
CD135+CD127+CD19− precursors and subsequent generation of nor-
mal numbers of CD19+ B-cell progenitors, therefore indicating that IL-7
can be dispensable for commitment to the B-cell lineage. Further anal-
ysis of Ly6D+CD135+CD127+CD19− progenitors in IL-7– or FL-deficient
mice overexpressing Bcl2, as well as in IL-7 transgenic mice suggests
that both FL and IL-7 regulate B-cell commitment in a permissivemanner:
FL by inducing proliferation of Ly6D+CD135+CD127+CD19− progen-
itors and IL-7 by providing survival signals to these progenitors.
hematopoiesis | cytokines | commitment | immunology
Hematopoiesis, the generation of all blood cells from hema-topoietic stem cells (HSCs), takes place continuously in the
adult bone marrow. Accumulating evidence suggests that HSCs
generate the different hematopoietic lineages via oligopotent
progenitors having limited self-renewal capacity and restricted
developmental potentials. Activation of lineage-specific gene
transcription in these progenitors eventually leads to their com-
mitment to a particular lineage. Cytokines are the most prominent
environmental factors regulating hematopoietic lineage commit-
ment, doing so by acting either in an instructive or a permissive
manner (1). In the instructive model, cytokines induce a signaling
cascade in progenitors leading to the initiation of a lineage-specific
gene program, typically through up-regulation and/or activation of
transcription factors, eventually resulting in commitment to a
particular lineage. In contrast, the permissive model advocates that
commitment of progenitors to different lineages occurs in a cell-
autonomous, stochastic manner, with cytokines acting as a selec-
tion rather than a commitment factor, promoting the survival and/
or proliferation of a specific lineage at the expense of other line-
ages originating from the same progenitor. Elucidating the precise
mode of action of cytokines is technically challenging and there-
fore the instructive versus permissive role of cytokines is hotly
debated (2–4). Although the permissive model was favored in the
past, recent data provide solid evidence for the instructive action of
several cytokines including M-CSF, G-CSF, EPO, and fms-like
tyrosine kinase-3 (Flt3) ligand (5–8). However, our understanding
of how cytokines regulate hematopoiesis remains elusive, as dif-
ferent cytokines can act in various ways and their function might be
cell-context dependent (9). Moreover, most studies to date have
addressed cytokine-regulated myeloid differentiation with rela-
tively little information on lymphoid lineage commitment.
That Interleukin-7 (IL-7) is a crucial cytokine for B-cell devel-
opment is demonstrated by the dramatic defect in B-cell genera-
tion in mice lacking either the cytokine (10) or its receptor (11).
Interestingly, whereas human B-cell progenitors are also respon-
sive to IL-7 (12), disruption of IL-7 signaling caused by mutations
does not ablate B-cell development in man (13, 14). IL-7 was
initially identified as a growth factor for B-cell progenitors (15)
and early studies demonstrated that in vivo overexpression of the
prosurvival gene Bcl2 did not rescue B-cell development in the
absence of IL-7 signaling, suggesting that IL-7 acts in an instruc-
tive manner in B-cell commitment (16, 17). The subsequent
findings that uncommitted common lymphoid progenitors (CLPs)
from Il7−/−mice lacked expression of the transcription factor early
B-cell factor 1 (Ebf1) (18) and that Ebf1 overexpression partially
restored B-cell generation from these CLPs (19), led to the hy-
pothesis that IL-7, through Stat5 activation, instructs commitment
to the B-cell lineage by initiating Ebf1 expression in uncommitted
progenitors. Supporting this hypothesis, a putative Stat5 binding
site was later identified in one of the Ebf1 promoters (20). How-
ever, a more recent study has shown that Bcl2 can rescue B-cell
generation in a Stat5 conditional knockout mouse (21). Further-
more, the Ebf1-expressing fraction of CLP (Ly6D+ CLP) is dra-
matically reduced in Il7−/− mice (22), therefore providing an
alternative possibility for the reduced Ebf1 expression observed in
Il7−/− CLPs. Interestingly, B-cell lineage commitment is initiated
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at the molecular level in Ly6D+CD19− progenitors (23). Hence,
whereas the importance of IL-7 as a growth factor for committed
B-cell progenitors has been well established, it remains unclear
whether it instructs oligopotent progenitors to commit to the
B-cell lineage through Ebf1 and Pax5 up-regulation.
Ftl3 ligand (FL), the only known ligand for the Flt3 receptor
(CD135), is a cytokine important for the generation of many he-
matopoietic lineages and its function has gained much attention as
mutations in FL signaling are commonly found in acute myeloid
leukemias (AMLs) (24). Committed B-cell progenitors do not ex-
press CD135, because expression of the B-cell commitment factor
Pax5 (paired box 5) leads to its down-regulation (25). However,
upon transplantation, bone marrow progenitors from Flt3−/− and
Flt3l−/− mice reconstitute the B-cell compartment poorly (26, 27),
and FL was found to be essential for maintaining normal numbers
of uncommitted B-cell progenitors (28).
Recently, we described a FL-transgenic mouse model (hereafter
Flt3ltg) expressing high levels of FL in vivo, which has enabled us
to suggest an instructive role for FL in early stages of hemato-
poiesis (8). By breeding these mice with Il7−/− mice, we herein
show that increased FL levels can rescue B-cell commitment in
CD135+CD127+CD19− progenitors and restore early CD19+ B-cell
progenitor numbers in the absence of IL-7 signaling, suggesting
a permissive role for IL-7 in B-cell commitment. Further anal-
yses of a combination of mouse genotypes overexpressing or
lacking FL and IL-7, as well as the prosurvival gene Bcl2, have
enabled us to identify a permissive role for both IL-7 and FL in
B-cell commitment.
Results
Increased in Vivo Levels of FL Rescue B-Cell Commitment in Il7−/− Ly6D+
CD19 − Progenitors. We have previously characterized an uncom-
mitted B-cell progenitor with combined lymphoid and myeloid
potential [early progenitor with lymphoid and myeloid potential
(EPLM)] (29). EPLM can be further subdivided by SiglecH,
CD11c, CD115, and Ly6D expression enabling us to identify the
Ly6D+SiglecH−CD11c−CD115− fraction of EPLM (hereafter Ly6D+
EPLM) as the population containing most B-cell potential, while
being devoid of myeloid potential (Fig. S1B). This EPLM
subpopulation is identified as Lin−CD19−CD117intB220int
Ly6D+CD135+CD127+ (Fig. 1A), therefore partially overlapping
phenotypically with Ly6D+ CLPs (Fig. S1A) and pre/pro-B cells
(30, 31). Ly6D+ EPLM numbers in Il7−/− and Flt3l−/− mice are
significantly decreased compared with WT: 7-fold for Il7−/− and
13-fold for Flt3l−/−, respectively, and a similar dramatic decrease was
observed in Ly6D+ CLPs from both mutant mice (Fig. 1 B and C).
FL deficiency also affected the numbers of Ly6D− EPLM and CLP,
whereas IL-7 did not (Fig. S1 C and D). Therefore, Ly6D+ EPLM/
CLP represent the earliest developmental stage of the B-cell path-
way affected by the absence of IL-7.
We have recently generated a mouse model expressing high in
vivo levels of FL (8). The progenitor compartment of these mice
showed a dramatic increase in EPLM and CLP numbers, with
their Ly6D+ fractions increased 90-fold and 28-fold, respectively,
relative to WT (Fig. 1 D and E). We crossed Flt3ltg with Il7−/−mice
to assess the extent to which increased FL levels could potentially
rescue the loss of Ly6D+CD19− progenitors in Il7−/− mice. As
shown in Fig. 2 A and B, in vivo overexpression of FL leads to a
Fig. 1. IL-7 and FL are necessary for the generation of a normal Ly6D+CD135+CD127+CD19− compartment. (A) FACS plots showing the gating strategy used for
identification of Ly6D+ EPLM and their percentage of CD135 and CD127 expression. Lineage staining was as follows: SiglecH, CD115, CD11c, NK1.1, Gr-1.
(B) Representative FACS plots of EPLM (Upper row) and CLP (Lower row) from the bone marrow of WT, Il7−/−, and Flt3l−/−mice. (C) Absolute numbers of Ly6D+ EPLM
(Upper graph) and CLP (Lower graph) from the bonemarrow ofWT (n = 13), Il7−/− (n = 5), and Flt3l−/− (n = 10) mice. (D) Representative FACS plots of EPLM and CLP from
WT and Flt3ltg mice. (E) Absolute numbers of total EPLM and CLP (Left graphs) and Ly6D+ EPLM and CLP (Right graphs) from WT and Flt3ltg mice. ***P ≤ 0.001.
2 of 9 | www.pnas.org/cgi/doi/10.1073/pnas.1613316113 von Muenchow et al.
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significant increase in Flt3ltg-Il7−/− EPLM and CLP numbers,
reaching levels of those in Flt3ltg mice. Crucially, a full rescue of
Ly6D+ EPLM and CLP can be seen in these mice, with a striking
470-fold and 31-fold increase in numbers compared with their Il7−/−
counterparts (Fig. 2 A and B). Furthermore, the numbers of the
earliest committed CD19+CD117+ pro-B cells were fully restored
in Flt3ltg-Il7−/− mice, showing a 251-fold increase compared with
Il7−/− (Fig. 2C and Fig. S2). However, this rescue was less pro-
nounced in downstream CD19+CD117−IgM− and CD19+IgM+
B-cell stages, because these cells require IL-7 to expand. As a
consequence of this rescue in bone marrow B-cell development,
numbers of splenic marginal zone and follicular B cells were signif-
icantly increased in Flt3ltg-Il7−/−mice compared with Il7−/− (Fig. 2D).
Whereas thymic T-cell development was not rescued in Flt3ltg-
Il7−/− mice (Fig. S3), a significant increase in splenic T-cell
numbers was observed (Fig. S4) as a result of their expansion
upon FL overexpression (32).
To assess whether these rescued Flt3ltg-Il7−/− Ly6D+CD19−
progenitors could give rise to B cells in vitro, we sorted Flt3ltg-Il7−/−
Ly6D+ EPLM and plated them at limiting dilution on OP9 stromal
cells in the presence of IL-7. As shown in Fig. 3A, Flt3ltg-Il7−/−
Ly6D+ EPLM could generate B cells at similar frequencies to their
WT and Flt3ltg counterparts, whereas the few Il7−/− Ly6D+ EPLM
isolated could not. A rescue in Ly6D+ EPLM was also observed
when Il7−/− mice were injected with FL (Fig. 3E) and when plated
under the same conditions these rescued Ly6D+ EPLM also
showed a restored in vitro B-cell potential (Fig. S5A). Further,
when transplanted into irradiated Rag2−/− mice, they were able
to generate IgM+ B cells (Fig. S5 B and C). Thus, increased FL
levels restore the generation of Ly6D+ progenitors, rather than
merely expanding the few Ly6D+ EPLM/CLPs found in Il7−/−
mice. RT quantitative PCR (RT-qPCR) analysis of Ly6D+
EPLM from Flt3ltg-Il7−/− mice revealed significant expression
of Ebf1, Pax5, and Foxo1 transcription factors’ mRNA in the
absence of IL-7 (Fig. 3B). Ebf1 expression at the protein level
was confirmed by intracellular FACS staining (Fig. 3 C and D).
Even though the percentage of Flt3ltg-Il7−/− Ebf1+Ly6D+
EPLM did not reach WT levels, it was similar to the one found
in Flt3ltg mice, which produce IL-7. Therefore, Ebf1/Pax5 ex-
pression and subsequent commitment to the B-cell fate can
occur in the absence of IL-7 signaling, arguing against an in-
structive role of this cytokine in B-cell commitment.
CD127 (IL7Rα) is a receptor shared between IL-7 and thymic
stromal lymphopoietin (TSLP), a cytokine capable of rescuing
B-cell development when overexpressed in the absence of IL-7
(33). Because TSLP is produced by dendritic cells (34), which are
dramatically expanded in Flt3ltg mice (8), in vivo FL over-
expression could lead to increased levels of TSLP, thereby rescuing
B-cell development in Flt3ltg-Il7−/− mice. To investigate this pos-
sibility, we injected Il7−/− or Il7rα−/− mice with FL as described
above and assessed the rescue of Ly6D+ EPLM and downstream
CD19+ progenitors. FL injections into Il7−/− mice resulted in a
significant increase in Ly6D+ EPLM and CD19+CD117+ B-cell
progenitors, comparable to the rescue observed in Flt3ltg-Il7−/−
Fig. 2. Increased in vivo FL levels rescue B-cell generation in Il7−/− mice. (A) Representative FACS plots of EPLM (Upper) and CLP (Lower) from WT, Il7−/−,
Flt3ltg, and Flt3ltg-Il7−/− mice. (B) Numbers of EPLM (Upper Left), CLP (Lower Left), Ly6D+ EPLM (Upper Right), and Ly6D+ CLP (Lower Right) from the mouse
genotypes indicated on the x axes. For each mouse genotype, mean ± SEM is shown. (C) Numbers of CD19+CD117+ (Upper Left), CD19+CD117−IgM− (Upper
Right), and CD19+IgM+ (Lower) bone marrow cells from the mice indicated on the x axes. For each mouse genotype, mean ± SEM is shown. (D) Numbers of
CD19+CD21highCD23low marginal zone (Left) and CD19+CD21+CD23+ follicular (Right) B cells in the spleens of WT or mutant mice, as indicated on the x axes.
For each mouse genotype, mean ± SD is shown. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.
von Muenchow et al. PNAS Early Edition | 3 of 9
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mice (Fig. 3E). FL-injected Il7rα−/− mice also demonstrated a
significant rescue of Ly6D+ EPLM and CD19+CD117+ pro-B
cells, indicating that the observed rescue of B-cell commitment in
Flt3ltg-Il7−/− mice is not mediated through the action of TSLP.
IL-7 Promotes Survival, but Not Proliferation, of Ly6D+CD135 +CD127+CD19 −
Progenitors. Even though our Flt3ltg-Il7−/− mouse model suggests
that IL-7 is dispensable for B-cell commitment, the dramatic de-
crease in Il7−/− Ly6D+ EPLM/CLPs argues for a role of IL-7 in the
maintenance of this population when FL levels are limiting, by pro-
moting either their survival or their proliferation. To investigate the
potential role of IL-7 as a survival factor for Ly6D+CD135+CD127+
CD19− progenitors, we crossed Il7−/− mice with mice expressing the
prosurvival gene Bcl2 (35). Bcl2tg-Il7−/− mice demonstrated a minor
but statistically significant 2.6-fold increase in Ly6D+ EPLM and 2.2-
fold increase in Ly6D+CLP numbers compared with Il7−/−mice (Fig.
4 A and B). Cell cycle stage analysis of Ly6D+ EPLM of these mice
indicated that most of the cells rescued by Bcl2 are in a quiescent
state (Fig. S6) and do not proliferate in response to cyto-
kines, thereby compromising to some extent the rescue of these
progenitors’ numbers. Importantly, when plated on OP9 stro-
mal cells plus IL-7, Bcl2tg-Il7−/− Ly6D+ EPLM generated B
cells at frequencies similar to WT mice (Fig. 4C), indicating
that these rescued Ly6D+ cells had B-cell potential. Indeed,
when analyzing bone marrow CD19+ committed progenitors,
we could see a significant 68-fold increase in the earliest CD19+
CD117+ pro–B-cell compartment, compared with Il7−/− (Fig.
4D). Due to their quiescent state (Fig. S6) (36) and the IL-7
dependence of their proliferation, Bcl2tg-Il7−/− CD19+CD117+
numbers did not reach WT levels, whereas downstream CD19+
immature B cells showed a less pronounced, but significant
rescue (Fig. 4D). In the spleens of these mice, marginal zone
and follicular B-cell numbers were increased, whereas as pre-
viously reported (16), T-cell numbers were rescued (Fig. S7).
Therefore, providing an extra Bcl2-mediated survival signal in vivo
partially rescues Il7−/− Ly6D+CD19− progenitors with B-cell poten-
tial and restores significantly the generation of CD19+ progenitors.
This result suggests a role for IL-7 in facilitating the survival of
Ly6D+CD135+CD127+CD19− progenitors.
To evaluate the potential proliferative effect of IL-7 on
Ly6D+CD135+CD127+CD19− progenitors, we analyzed a transgenic
mouse model, in which Il7 expression is driven by an MHC class II
promoter, resulting in increased in vivo levels of IL-7 (37). These
mice exhibit a lymphoproliferative phenotype with increased
numbers of CD19+ B cells (38). In contrast to bone marrow
CD19+ cells, Ly6D+ EPLM numbers did not increase in response
to elevated IL-7 (Fig. 5 A–C). In addition, the cell cycle profile of
Ly6D+ EPLM remained unaltered in Il7tg mice compared with
WT (Fig. 5D), arguing against a proliferative action of IL-7 on
these progenitors. To exclude the possibility that a proliferative
signal by FL present in these mice compromised the effect of in-
creased IL-7 on the cell cycle status of Ly6D+ EPLM, we crossed
Il7tg with Flt3l−/− mice. Overexpression of IL-7 in vivo did not
result in a significant increase in Ly6D+ EPLM or CLP numbers in
the absence of FL (Fig. 5E and Fig. S8). In contrast, a threefold
increase in CD19+CD117+ numbers was observed (Fig. 5F), in
agreement with the proliferative effect of IL-7 on CD19+ B cells.
This resulted in a small, but significant, increase in splenic follic-
ular B cells (Fig. S9). Moreover, cell cycle analysis of Il7tg-Flt3l−/−
Ly6D+ EPLM showed no significant change in their cycling
profile compared with their Flt3l−/− counterparts (Fig. 5G). There-
fore, we conclude that, whereas IL-7 acts as a proliferative factor
for CD19+ committed B cells, it does not do so for their
Ly6D+CD135+CD127+CD19− precursors.
FL Induces Proliferation of Ly6D+CD135 +CD127+CD19 − Progenitors.
As evident in Fig. 5G, loss of in vivo FL signaling affected the
proliferative status of Ly6D+ EPLM. Comparison of Ly6D+ EPLM
numbers in mice either lacking or overexpressing FL showed a
14-fold reduction in Flt3l−/− Ly6D+ EPLM numbers compared with
WT, whereas Flt3ltg Ly6D+ EPLM increased 105-fold (Fig. 6A). A
similar response to FL levels was observed for Ly6D+ CLPs (Fig.
6A). Cell cycle analysis of Ly6D+ EPLM from these mice showed a
significant increase in the percentage of Ki67−DAPI− cells and a
decrease in the percentage of Ki67+ cells when FL signaling was
absent, whereas Flt3ltg Ly6D+ EPLM showed the reverse (Fig. 6B
and Fig. S10). Thus, our data indicate that FL promotes the pro-
liferation of Ly6D+CD135+CD127+CD19− progenitors.
To evaluate whether FL also regulates the survival of
Ly6D+CD135+CD127+CD19− progenitors, we crossed Flt3l−/−
mice with Bcl2tg mice. Thus, Bcl2tg-Flt3l−/− mice showed a minor
twofold increase in Ly6D+ EPLM numbers compared with their
Flt3l−/− counterparts (1.8-fold for Ly6D+ CLPs) (Fig. 6C). Nev-
ertheless, the in vitro B-cell potential of Flt3l−/− Ly6D+ EPLM
progenitors was not improved by Bcl2 overexpression (Fig. 6D).
Downstream CD19+ progenitors also demonstrated a partial, but
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Fig. 3. Increased in vivo FL rescues B-cell commitment in the absence of IL-7 and/
or TSLP. (A) In vitro limiting dilution analysis of Ly6D+ EPLM B-cell potential. Ly6D+
EPLM were sorted fromWT, Il7−/−, Flt3ltg, and Flt3ltg-Il7−/−mice and plated at the
indicated concentrations on OP9 stromal cells together with IL-7. One represen-
tative out of four independent experiments is shown. (B) RT-qPCR analysis showing
expression of Ebf1, Pax5, and Foxo1 mRNAs in Ly6D+ EPLM sorted from the indi-
cated mouse genotypes. Bars show fold expression relative to WT (set as 1). Error
bars represent the SEM from three to six independent experiments. (C) Repre-
sentative FACS plots showing expression of Ebf1 protein within the Ly6D+ EPLM of
the indicated WT or mutant mice. (D) Percentages of Ebf1-expressing Ly6D+ EPLM
from WT (n= 7), Il7−/− (n= 3), Flt3ltg (n= 11), and Flt3ltg-Il7−/− (n= 6) mice. Bars
showmean ± SEM (E) Ly6D+ EPLM (Left), and CD19+CD117+ (Right) numbers from
WT (n= 5), Il7−/− (n= 5), Flt3ltg (n= 3), and Flt3ltg-Il7−/− (n= 5) mice, as well as
from Il7−/− (n= 5) and Il7rα−/− (n= 6) mice injected intraperitoneally with 10 daily
doses of 10 μg FL each (indicated as+FL) or PBS (+PBS,n= 4). Shown is themean ±
SEM. n.s., not significant, **P ≤ 0.01, ***P ≤ 0.001.
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significant, rescue (Fig. 6E). Our analysis of Bcl2tg-Flt3l−/− mice
suggests that the reduction in Ly6D+CD135+CD127+CD19− pro-
genitors observed in Flt3l−/− mice can only be partially explained
by a survival role of FL. In contrast, the clear change in the numbers
and cycling profile of these progenitors in response to the absence
or overabundance of FL in vivo, as well as the inability of Bcl2 to
rescue their in vitro B-cell potential, points toward proliferation as
being the main effector function of FL at this developmental stage.
FL Does Not Instruct Commitment to the B-Cell Lineage. The striking
rescue in B-cell commitment observed in our Flt3ltg-Il7−/− mice
could be explained by a potential instructive role of FL when
present at high levels in vivo. However, increased FL did not
result in Ebf1 or Pax5 up-regulation (Fig. 3 B–D). Moreover,
analysis of Flt3l−/− Ly6D+ EPLM showed that, whereas absence
of FL in vivo leads to a reduction in the numbers of Ly6D+
EPLM (Fig. 1C), it does not significantly reduce the percentage
Fig. 4. Bcl2 overexpression partially rescues B-cell commitment in Il7−/−mice. (A) Representative FACS plots of EPLM (Upper) and CLP (Lower) fromWT, Il7−/−,
Bcl2tg, and Bcl2tg-Il7−/− mice. (B) Numbers of EPLM (Upper Left), CLP (Lower Left), Ly6D+ EPLM (Upper Right), and Ly6D+ CLP (Lower Right) from WT and
mutant mice, as indicated on the x axes. For each mouse genotype, mean ± SEM is shown. (C) In vitro limiting dilution analysis of Ly6D+ EPLM B-cell potential.
Ly6D+ EPLMwere sorted fromWT, Il7−/−, Bcl2tg, and Bcl2tg-Il7−/−mice and plated at the indicated concentrations on OP9 stromal cells together with IL-7. One
representative of three independent experiments is shown. (D) Numbers of CD19+CD117+ (Top), CD19+CD117−IgM− (Middle), and CD19+IgM+ (Bottom) bone
marrow cells from WT and mutant mice, as indicated on the x axes. For each mouse genotype, mean ± SEM is shown. *P ≤ 0.05, ***P ≤ 0.001.
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of Ebf1+ cells within the population (Fig. 7 A and B), consistent
with a permissive rather than instructive role of FL. Finally, the
decrease in the Ebf1+ fraction of Ly6D+ EPLM upon exposure
to high levels of FL was reflected in the increased ability of these
progenitors to give rise to T cells in vitro, as manifested by the
high frequency of T-cell clone generation when Flt3ltg Ly6D+
EPLM were plated on OP9-DL1 stromal cells in the presence of
IL-7 (Fig. 7C). The above data suggest that FL does not instruct
commitment to the B-cell lineage through up-regulation of Ebf1
and Pax5 expression.
Discussion
Commitment to the B-cell lineage is mediated by the expression
of Ebf1 and Pax5 transcription factors and it is initiated in
Ly6D+CD135+CD127+ progenitors before CD19 expression (30,
31). In Il7−/− mice, this Ly6D+ CLP compartment is significantly
reduced (22), a finding confirmed in the present study for both
CLP and EPLM, a B220int/+ population partly overlapping with
CLP and pre/pro-B cells (Fig. 1 B and C). The proliferative effect of
IL-7 on committed CD19+ B-cell progenitors (38) makes the in-
vestigation of its role in B-cell commitment challenging when using
CD19+ cells as readout. Hence, we assessed the role of IL-7 in B-cell
commitment by analyzing the Ly6D+ CLP/EPLM compartment in
different mouse models. Our analysis of Flt3ltg-Il7−/−mice showed
a complete rescue of Ly6D+ CLP/EPLM numbers in vivo and their
B-cell potential in vitro and in vivo, whereas Ebf1 and Pax5 were
expressed at similar levels to Flt3ltg mice, thereby indicating that
IL-7 signaling is not required for their up-regulation at the
Ly6D+CD19− stage (Figs. 2 and 3). These results suggest that IL-7 is
not acting as an instructive cytokine in B-cell commitment by initi-
ating Ebf1 and Pax5 expression at the CD135+CD127+CD19− stage,
as previously hypothesized (18–20), but rather as a permissive one.
Early investigations had shown that Bcl2 overexpression in the
absence of IL-7 signaling could rescue T-cell (39, 40) but not B-cell
development (16, 17). However, a more recent study demon-
strated a Bcl2-mediated rescue of CD19+ progenitors in condi-
tional Stat5−/−mice, as well as a strong activation of the prosurvival
gene Mcl1 expression by Stat5 (21), therefore suggesting a survival
role for IL-7 in B-cell development. Our use of Il7−/− mice instead
of Il7rα−/−, which allows the assessment of progenitor in vitro
B-cell potential, and our focus on Ly6D+CD135+CD127+CD19−
progenitors, has enabled us to confirm the latter findings and ex-
tend them to the CD19− stage where B-cell commitment events
are initiated at the molecular level. Interestingly, Il7tg mice anal-
ysis showed that IL-7 indeed acts as a proliferative factor for
committed CD19+ cells, but not for their CD19− precursors. Even
Fig. 5. IL-7 does not induce proliferation of Ly6D+CD135+CD127+CD19 − progenitors. (A) CD19 +CD117+ numbers in bone marrow of WT (n = 10), Il7−/− (n = 5),
and Il7tg (n = 8) mice. (B) EPLM numbers in bone marrow of WT (n = 14), Il7−/− (n = 7), and Il7tg (n = 5) mice. (C) Ly6D+ EPLM numbers in bone marrow
of WT (n = 14), Il7−/− (n = 7), and Il7tg (n = 5) mice. (D) Cell cycle analysis of Ly6D+ EPLM from WT (n = 5) and Il7tg (n = 2) mice. Graph shows percentages of
Ki67−DAPI−, Ki67+DAPI−, and Ki67+DAPI+ Ly6D+ EPLM. Bars in A–D show mean ± SEM. (E) Numbers of EPLM (Upper Left), CLP (Lower Left), Ly6D+ EPLM
(Upper Right), and Ly6D+ CLP (Lower Right) from WT and mutant mice, as indicated on the x axes. For each mouse genotype, mean ± SEM is shown.
(F) Numbers of CD19 +CD117+ bone marrow cells from WT and mutant mice, as indicated on the x axis. For each mouse genotype, mean ± SEM is shown. (G)
Cell cycle analysis of Ly6D+ EPLM from WT (n = 5), Flt3l−/− (n = 3), Il7tg (n = 2), and Il7tg-Flt3l−/− (n = 3) mice. Graph shows percentages of Ki67−DAPI−, Ki67+DAPI−,
and Ki67+DAPI+ Ly6D+ EPLM. Bars show mean ± SEM. *P ≤ 0.05, ***P ≤ 0.001.
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in the absence of FL, excess IL-7 was unable to significantly in-
crease Ly6D+ CLP/EPLM numbers, whereas it did so for CD19+
B-cell progenitors (Fig. 5). Hence, we propose that the main role
of IL-7 at the CD135+CD127+CD19− stage is to provide survival
signals to the progenitors until they commit to the B-cell lineage
upon Pax5 and CD19 expression, after which it additionally in-
duces their proliferation (Fig. 7D). This survival role becomes
particularly critical when FL levels are limiting, thereby explaining
the reduction in Ly6D+ CLP/EPLM seen in Il7−/−mice. Our study,
in agreement with previous data (21), identifies a common, per-
missive rather than instructive role for IL-7 in both B- and T-cell
development (39, 40).
The rescue in B-cell commitment without active IL-7 sig-
naling occurs when FL is expressed above physiological levels.
Even though a minor role for FL as a survival factor for Ly6D+
CD135+CD127+CD19− progenitors cannot be excluded, the main
effect of FL on these progenitors seems to be the induction of
their proliferation, as suggested by their expansion and their in-
creased cycling upon FL overexpression, with the reverse pheno-
type observed upon loss of FL signaling (Fig. 6). Moreover,
increased FL leads to expansion of Lin−CD117+Sca1+ cells (LSK)
(8), thereby increasing the developmental input into the Ly6D+
CD135+CD127+CD19− progenitor stage. None of the mouse
models analyzed in the present study gave any evidence for an in-
structive role of FL in B-cell commitment. In contrast, excess FL
resulted in a proportional reduction of Ebf- and Pax5-expressing
Ly6D+CD19− progenitors (Figs. 3 and 7). One explanation for this
reduction could be the increased percentage of cycling Flt3ltg
Fig. 6. FL promotes proliferation but not survival of Ly6D+CD135+CD127+CD19− progenitors. (A) Numbers of EPLM (Upper Left), CLP (Lower Left), Ly6D+
EPLM (Upper Right), and Ly6D+ CLP (Lower Right) from WT (n = 14), Flt3l−/− (n = 10) and Flt3ltg (n = 9) mice. Bars show mean ± SEM. (B) Cell cycle analysis of
Ly6D+ EPLM fromWT (n = 5), Flt3l−/− (n = 3), and Flt3ltg (n = 9) mice. Graph shows percentages of Ki67−DAPI−, Ki67+DAPI−, and Ki67+DAPI+ Ly6D+ EPLM. Bars
showmean ± SEM. (C) Numbers of EPLM (Upper Left), CLP (Lower Left), Ly6D+ EPLM (Upper Right), and Ly6D+ CLP (Lower Right) fromWT and mutant mice, as
indicated on the x axes. For each mouse genotype, mean ± SEM is shown. (D) In vitro limiting dilution analysis of Ly6D+ EPLM B-cell potential. Ly6D+ EPLM
were sorted from WT, Flt3l−/−, and Bcl2tg-Flt3l−/− mice and plated at the indicated concentrations on OP9 stromal cells together with IL-7. (E) Numbers of
CD19+CD117+ (Left), CD19+CD117−IgM− (Middle), and CD19+IgM+ (Right) bone marrow cells from WT and mutant mice, as indicated on the x axes. For each
mouse genotype, mean ± SEM is shown. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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Ly6D+CD19− progenitors, resulting in a decreased fraction initi-
ating the B-cell developmental program. Alternatively, another
environmental factor, responsible for initiation of Ebf1/Pax5 ex-
pression and B-cell commitment, could be the limiting factor in
Flt3ltg mice, thus leading to a smaller fraction of the expanded
Ly6D+CD19− compartment entering the B-cell pathway. Our
conclusion is that FL is mainly responsible for generating enough
Ly6D+CD135+CD127+CD19− progenitors, both by inducing their
proliferation and by increasing their developmental input from the
LSK compartment (Fig. 7D) (41, 42). As a result, increased levels
of FL in Flt3ltg-Il7−/− mice lead to a dramatic increase in Ly6D+
CD135+CD127+CD19− progenitor numbers, therefore surpass-
ing the need for the survival role of IL-7 at this stage and resulting
in a sufficient fraction of them committing to the B-cell lineage.
The generation of B-cell progenitors in Flt3ltg-Il7−/− mice is
reminiscent of the apparent IL-7 independency of human B
lymphopoiesis, where relatively normal numbers of B cells are
seen in patients with mutations in components of the IL-7 sig-
naling pathway (13, 14). However, all patients with such mutations
are neonates, and in neonatal Il7−/−mice, B-cell development also
takes place (43). Therefore, the apparent difference in the IL-7
dependency of B-cell development between man and mouse
could actually reflect the corresponding difference between fetal/
neonatal and adult lymphopoiesis. Our data showing that in-
creased FL signaling can rescue B-cell commitment in the absence
of IL-7 could provide a potential explanation for this differ-
ence. Fetal/neonatal CD135+CD127+CD19− progenitors might
be exposed to higher levels of FL and/or show higher sensitivity to
FL signaling than adult CD135+CD127+CD19− progenitors. In-
deed, previous studies showed that despite a preferable response
of fetal B-cell progenitors to TSLP, FL signaling remains an ab-
solute requirement for fetal B lymphopoiesis (44, 45).
The instructive or permissive progenitor regulation of lineage
commitment by cytokines is a complex process, in which cytokines
can initiate developmental transcription programs in progenitors.
However, the reverse is also true, because the particular epige-
netic, transcriptional, and signaling landscape of a cell can affect
its response to a cytokine (9). Indeed, whereas previous analysis
of Flt3ltg mice indicated an instructive role for FL in promoting
differentiation of multipotent progenitors toward lymphomyeloid
and away from erythroid fate (8), our present data show that
FL acts in a permissive manner for B-cell commitment of
CD135+CD127+CD19− progenitors. In addition, whereas IL-7
induces proliferation of committed CD19+ B-cell progenitors, it
does not do so on CD127+CD19− progenitors, suggesting that
upon commitment to the B-cell lineage, changes in the tran-
scription factor and intracellular signaling landscape influence
the effector function of IL-7. Therefore, our present data further
support the notion of a cell context-dependent cytokine action.
The Ebf1/Pax5 up-regulation and subsequent B-cell commit-
ment in Flt3ltg-Il7−/− mice shown herein raises the issue of the
potential extracellular regulation of B-cell commitment. One
possibility could be that another environmental signal from the bone
marrow microenvironment—other than IL-7, TSLP, and FL—
initiates Ebf1 expression in Ly6D+CD135+CD127+CD19− pro-
genitors, resulting in Pax5/CD19 expression and B-cell commitment.
Alternatively, as yet uncommitted Ly6D+CD135+CD127+CD19−
progenitors could express Ebf1 in a cell-autonomous, stochastic,
manner with some obtaining sufficient Ebf1 to initiate the B-cell
gene program and eventually commit to the B-cell lineage. The
intricate transcription factor network sustaining B-cell commitment
through a series of positive feedback regulatory loops (46) provides
conceptual support for the latter hypothesis.
Materials and Methods
Mice. For breeding and analysis, age- and sex-matched C57BL/6 Flt3l−/− (27), Flt3ltg
(8), Il7−/− (10), Il7rα−/− (11), Il7tg (38), and (C57BL/6 × C3H) Bcl2tg (35) mice back-
crossed with C57BL/6 for at least five generations were used at 6–11wk of age. All
mice were bred and maintained in our animal facility under specific pathogen-
free conditions. Animal experiments were carried out within institutional guide-
lines (authorization number 1888 from the cantonal veterinarian office, Basel).
Antibodies, Flow Cytometry, and Sorting. For analysis, cells were flushed from
femurs of the two hind legs of mice. The procedure was performed in PBS
containing0.5%BSAand5mMEDTA. For detectionof Ebf1 and cell cycle analysis,
cells were fixed and permeabilized after cell-surface staining using the Foxp3 Fix/
Perm buffer set (eBioscience), and subsequently stained with PE-conjugated anti-
Ebf1 (T26-818) or FITC-conjugated anti-Ki67 (B56) and DAPI, according to the
supplier’s protocol. Flow cytometry was done using a BD LSRFortessa (BD Bio-
sciences) and data were analyzed using FlowJo software (Treestar). For cell
sorting, a FACSAria IIu (BD Biosciences) was used (>98% purity).
In Vitro Limiting Dilution Assays. Experiments have been performed as previously
described (47). Briefly, OP9 or OP9-DL1 stromal cells were plated on flat-bottom
96-well plates 1 d before the initiation of cocultures, at a concentration of 3,000
cells per well. The following day, stromal cells were γ-irradiated (3,000 rad) and
the sorted progenitor cells were added at different concentrations. Cultures
were maintained in Iscove’s modified Dulbecco’s medium (IMDM) supplemented
with 5 × 10−5 M β-mercaptoethanol, 1 mM glutamine, 0.03% (wt/vol) primatone,
100 units/mL penicillin, 100 μg/mL streptomycin, 5% (vol/vol) FBS, and 10% (vol/
vol) IL-7–conditioned medium. After 14 d in culture, all wells were inspected
under an inverted microscope, and wells containing colonies of more than 50
cells were scored as positive.
RT-qPCR. RNA extraction was performed using TRI Reagent (Life Technologies)
followed by cDNA synthesis using GoScript Reverse Transcriptase (Promega).
RT-qPCR was performed using SYBR Green PCRMaster Mix (Applied Biosystems).
Fig. 7. FL does not instruct Ebf1 expression and B-cell commitment. (A) Repre-
sentative FACS plots showing expression of Ebf1 protein within the Ly6D+ EPLM
of WT, Flt3l−/−, and Flt3ltg mice. (B) Percentages of Ebf1-expressing Ly6D+ EPLM
from WT (n = 7), Flt3l−/− (n = 5), and Flt3ltg (n = 12) mice. Bars show mean ±
SEM. (C) In vitro limiting dilution analysis of Ly6D+ EPLM T-cell potential. Ly6D+
EPLM were sorted from WT and Flt3ltg mice and plated at the indicated con-
centrations on OP9-DL1 stromal cells together with IL-7. One representative of
four independent experiments is shown. (D) Schematic model for the permissive
role of IL-7 and FL acting on hematopoietic progenitors and CD19+ committed
B-cell precursors. LMPP, lymphoid-primed multipotent progenitor. ***P ≤ 0.001.
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Statistical Analysis. Statistical analysis was performed with Prism 6.0g software
(GraphPad software). Two-tailed unpaired Student t tests were used for sta-
tistical comparisons. If not differently indicated, data are presented as mean
values ± SD or SEM. n.s., not significant or P > 0.05, *P ≤ 0.05, **P ≤ 0.01,
***P ≤ 0.001, ****P ≤ 0.0001.
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SI Materials and Methods
Antibodies.The following antibodieswere used for flow cytometry (from
BDPharmingen, eBioscience, BioLegend, or produced in house): anti-
B220 (RA3-6B2), anti-CD117 (2B8), anti-CD19 (1D3), anti-NK1.1
(PK136), anti-SiglecH (551), anti-CD11c (HL3), anti-CD115 (AFS98),
anti-Ly6D (49-H4), anti-CD127 (SB/199), anti-CD135 (A2F10), anti-
Sca1 (D7), anti-IgM (M41), anti-CD21 (7G6), anti-CD23 (B3B4), anti-
CD4 (GK1.5), anti-CD8 (53.6.7), and anti-TCRβ (H57).
RT-qPCR. The primers used were as follows: Ebf1, Ebf1-F:
5′-CAGGAAACCCACGTGACAT-3′ and Ebf1-R: 5′-CCACGT-
TGACTGTGGTAGACA-3′; Pax5, Pax5-F: 5′-ACGCTGACA-
GGGATGGTG-3′ and Pax5-R: 5′-GGGGAACCTCCAAGAA-
TCAT-3′; Foxo1, Foxo1-F: 5′-AGTGGATGGTGAAGAGCGT-3′
and Foxo1-R: 5′-GAAGGGACAGATTGTGGCG-3′; Actin, Ac-
tin-F: 5′-CTGTCGAGTCGCGTCCACC-3′ and Actin-R: 5′-CGCA-
GCGATATCGTCATCCA-3′.
Fig. S1. (A) CLP FACS staining in WT mice. FACS plots showing the gating strategy used for the identification of Ly6D+ CLP. Lineage staining was as follows:
SiglecH, CD115, CD11c, NK1.1, Gr-1. (B) In vitro limiting dilution analysis of Ly6D+ and Ly6D− EPLM B-cell potential. Cells were sorted as shown in Fig. 1A and
plated at the indicated concentrations on OP9 stromal cells together with IL-7. A representative of three independent experiments is shown. (C and D) Numbers
of EPLM (C) and CLP (D) progenitors in WT (n = 13), Il7−/− (n = 5), and Flt3l−/− (n = 10) mice. EPLM were stained as shown in Fig. 1A and CLP as shown in A.
Student’s t test. ***P ≤ 0.001. Bars show mean ± SEM.
von Muenchow et al. www.pnas.org/cgi/content/short/1613316113 1 of 10
   4. Results 
 
  52 
 
Fig. S2. Rescue of CD19+ bone marrow B-cell progenitors in Flt3ltg-Il7−/−mice. Representative FACS plots for the identification of CD19+CD117+, CD19+CD117−IgM−,
and CD19+IgM+ bone marrow cells are shown.
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Fig. S3. Thymic T-cell development in Flt3ltg-Il7−/− mice. (A) Representative FACS plots showing CD4/CD8 thymocyte staining from 6- to 8-wk-old WT, Il7−/−,
Flt3ltg, and Flt3ltg-Il7−/− mice (n = 4 per group). (B) Total numbers of CD4+ (Left) and CD8+ (Right) single-positive thymocytes from the mouse genotypes
indicated on the x axes.
von Muenchow et al. www.pnas.org/cgi/content/short/1613316113 3 of 10
   4. Results 
 
  54 
 
Fig. S4. (A) Representative FACS plots illustrating T cells in the spleens of WT (first row), Il7−/− (second row), Flt3ltg (third row), and Flt3ltg-Il7−/− (fourth row) mice.
After gating on living lymphocytes, TCRβ+ cells are further subgrouped in CD4+ and CD8+ T cells. (B) Representative FACS plots illustrating B cells in the spleens of
WT (first row), Il7−/− (second row), Flt3ltg (third row), and Flt3ltg-Il7−/− (fourth row) mice. After gating on living lymphocytes, CD19+ cells are further subgrouped in
CD21highCD23low marginal zone B cells and CD21+CD23+ follicular B cells. (C and D) Numbers of splenic CD4+ (C) and CD8+ (D) T cells, stained as shown in A, from
WT and mutant mice as indicated on the x axes. ***P ≤ 0.001, ****P ≤ 0.0001. Student’s t test; n = 9–15. Data shown above are mean ± SD.
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Fig. S5. B-cell potential of Ly6D+ EPLM cells from Il7−/− mice injected with FL. Il7−/− mice were injected with FL (10 daily doses of 10 μg per mouse) and Ly6D+
EPLM were sorted from their bone marrows 1 d after the last injection. (A) In vitro limiting dilution analysis of the B-cell potential of FL-injected Il7−/− Ly6D+
EPLM. Cells were plated at the indicated concentrations on OP9 stromal cells plus IL-7. Flt3ltg Ly6D+ EPLM were used as positive controls. (Band C) In vivo B-cell
potential of FL-injected Il7−/− Ly6D+ EPLM. Five thousand Ly6D+ EPLM from FL-injected Il7−/− or Flt3ltg mice were i.v. injected into sublethally irradiated Rag2−/−
mice. Four weeks after cell transfer, spleens were analyzed for expression of CD19 and IgM. (B) Representative FACS plots of recipient spleens. (C) Numbers of
CD19+IgM+ B cells harvested from the analyzed spleens (n = 4 mice per group).
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Fig. S6. Quiescent state of Bcl2-rescued cells in vivo. (A) Cell cycle analysis of Ly6D+ EPLM from WT (n = 5), Bcl2tg (n = 2), Il7−/− (n = 2), and Bcl2tg-Il7−/− (n = 4)
mice. Graph shows percentages of Ki67−DAPI−, Ki67+DAPI−, and Ki67+DAPI+ Ly6D+ EPLM. *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001. Student’s t test. Bars showmean ± SEM.
(B) Representative Ki67/DAPI FACS plots of the Ly6D+ EPLM cell cycle analysis collectively presented in A.
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Fig. S7. Bcl2-mediated rescue of splenic T and B cells in the absence of IL-7. (A) Representative FACS plots illustrating T cells in the spleens of WT (first row),
Il7−/− (second row), Bcl2tg (third row), and Bcl2tg-Il7−/− (fourth row) mice. After gating on living lymphocytes, TCRβ+ cells are further subgrouped in CD4+ and
CD8+ T cells. (B) Representative FACS plots illustrating B cells in the spleens of WT (first row), Il7−/− (second row), Bcl2tg (third row), and Bcl2tg-Il7−/− (fourth
row) mice. After gating on living lymphocytes CD19+ cells are further subgrouped in CD21highCD23low marginal zone B cells and CD21+CD23+ follicular B cells.
(C) Numbers of splenic CD4+ (Upper) and CD8+ (Lower) T cells, stained as shown in A, from WT and mutant mice as indicated on the x axes. (D) Numbers of
splenic marginal zone (Upper) and follicular (Lower) B cells, stained as shown in B, from WT and mutant mice as indicated on the x axes. **P ≤ 0.01, ***P ≤
0.001, ****P ≤ 0.0001. Student’s t test; n = 4–9. Data shown above are mean ± SD.
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Fig. S8. Representative FACS plots of EPLM (Upper) and CLP (Lower) from WT, Flt3l−/−, Il7tg, and Il7tg-Flt3l−/− mice.
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Fig. S9. Effect of IL-7 overexpression on WT and Flt3l−/− splenic T and B cells. (A) Representative FACS plots illustrating T cells in the spleens of WT (first row),
Flt3l−/− (second row), Il7tg (third row), and Il7tg-Flt3l−/− (fourth row) mice. After gating on living lymphocytes, TCRβ+ cells are further subgrouped in CD4+ and
CD8+ T cells. (B) Representative FACS plots illustrating B cells in the spleens of WT (first row), Flt3l−/− (second row), Il7tg (third row), and Il7tg-Flt3l−/− (fourth
row) mice. After gating on living lymphocytes, CD19+ cells are further subgrouped in CD21highCD23low marginal zone B cells and CD21+CD23+ follicular B cells.
(C) Numbers of splenic CD4+ (Upper) and CD8+ (Lower) T cells, stained as shown in A, from WT and mutant mice as indicated on the x axes. (D) Numbers of
splenic marginal zone (Upper) and follicular (Lower) B cells, stained as shown in B, from WT and mutant mice as indicated on the x axes. ns, not significant or
P > 0.05, ****P ≤ 0.0001. Student’s t test; n = 3–15. Data shown above are mean ± SD.
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Fig. S10. Effect of in vivo FL levels on Ly6D+ EPLM cell cycle. Representative Ki67/DAPI FACS plots of the Ly6D+ EPLM cell cycle analysis collectively presented in
Fig. 6B.
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Interleukin-7 (IL-7) and Flt3-ligand (FL) are two cytokines important for the generation of
B cells, as manifested by the impaired B cell development in mice deficient for either
cytokine or their respective receptors and by the complete block in B cell differentiation
in the absence of both cytokines. IL-7 is an important survival and proliferation factor
for B cell progenitors, whereas FL acts on several early developmental stages, prior to
B cell commitment. We have generated mice constitutively over-expressing both IL-7
and FL. These double transgenic mice develop splenomegaly and lymphadenopathy
characterized by tremendously enlarged lymph nodes even in young animals. Lymphoid,
myeloid and dendritic cell numbers are increased compared to mice over-expressing
either of the two cytokines alone and the effect on their expansion is synergistic, rather
than additive. B cell progenitors, early progenitors with myeloid and lymphoid potential
(EPLM), common lymphoid progenitors (CLP) and lineage−, Sca1+, kit+ (LSK) cells
are all increased not only in the bone marrow but also in peripheral blood, spleen and
even lymph nodes. When transplanted into irradiated wild-type mice, lymph node cells
show long-term multilineage reconstitution, further confirming the presence of functional
hematopoietic progenitors therein. Our double transgenic mouse model shows that
sustained and combined over-expression of IL-7 and FL leads to a massive expansion
of most bone marrow hematopoietic progenitors and to their associated presence in
peripheral lymphoid organs where they reside and potentially differentiate further, thus
leading to the synergistic increase in mature lymphoid and myeloid cell numbers. The
present study provides further in vivo evidence for the concerted action of IL-7 and FL
on lymphopoiesis and suggests that extramedullary niches, including those in lymph
nodes, can support the survival and maintenance of hematopoietic progenitors that
under physiological conditions develop exclusively in the bone marrow.
Keywords: IL-7, Flt3-ligand, hematopoiesis, cytokines, B cell development
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INTRODUCTION
Cytokines are important regulators for the development and
function of immune cells. Apart from influencing the survival,
expansion and eﬀector function of mature immune cells in
peripheral lymphoid organs, cytokines also have a crucial
role in the continuous generation of all blood cell lineages
(hematopoiesis), which occurs in the bone marrow and thymus.
During hematopoiesis cytokines can influence the lineage output
of hematopoietic progenitors by selectively promoting their
survival, proliferation or developmental potential (1–3). Two of
themost important cytokines for the generation of lymphoid cells
are Flt3-ligand (FL) and Interleukin-7 (IL-7).
FL is produced by many cell types, but within the
hematopoietic system it acts mainly on early, multipotent
progenitors, which are the ones expressing its receptor, CD135
(Flt3) (4–6). CD135 is the only known receptor for FL and
belongs to the type-III tyrosine kinase receptor family, which
also includes CD117 (kit) and platelet-derived growth factor
receptor (PDGF-R). CD135 expression within the lineage−,
Sca1+, kit+ (LSK) compartment of hematopoietic progenitors is
associated with loss of self-renewal capacity and preservation of
multilineage developmental potential (7). Oligopotent myeloid
and lymphoid progenitors retain CD135 expression until they
become committed to their respective lineages. From that
point on, they down-regulate expression of the receptor,
with the exception of dendritic cells (DC), which remain
CD135+ after maturation. The importance of FL in B cell
development is manifested by the reduced capacity of Flt3l−/−
and Flt3−/− hematopoietic progenitors to reconstitute the B
cell compartment of lymphopenic mice (8, 9). In addition,
B cell regeneration after irradiation or chemically induced
myeloablation is dependent on FL (10). Since CD135 is down-
regulated in committed B cell progenitors after Pax5 expression
(11), the eﬀect of FL signaling on B cell development is
attributed to its role in maintaining normal numbers of
oligopotent CD135+ common lymphoid progenitors (CLP) and
early progenitors with lymphoid and myeloid potential (EPLM)
(12, 13).
CLP are phenotypically defined by the expression of CD127,
the α-subunit of the receptor for IL-7 (14). CD127 expression is
initiated at the CLP stage and remains expressed throughout the
early stages of B cell development until the progenitors start to
rearrange their light chain immunoglobulin genes (small pre-B
stage). IL-7 was initially identified as a growth factor for B cells
(15) and its essential role in lymphoid development has been
proven both by its ability to maintain and expand lymphoid cells
in vitro (16) and by the severe defect in B and T cell development
observed in Il7−/− and Il7rα−/− mice (17, 18). Early T cell
progenitors require IL-7 mainly for their survival, since over-
expression of the anti-apoptotic protein Bcl2 can significantly
rescue T cell development in Il7rα−/− mice (19, 20). IL-7 is also
important for the survival and homeostatic expansion of mature
T cells in the periphery (21). The fact that B cell development
in Il7rα−/− mice cannot be rescued by Bcl2 over-expression
(22, 23), together with the absence of early B-cell factor 1 (Ef1)
expression in Il7rα−/− CLP (24) has led to the hypothesis that
by initiating Ebf1 expression, IL-7 might act as an instructive
cytokine for B cell commitment. However, this could also be
explained by a survival role of IL-7 on CLP, since the Ebf1-
expressing Ly6D+ compartment of CLP is severely reduced in
Il7−/−mice (25). Furthermore, B cell commitment in the absence
of IL-7 signaling can be restored by over-expressing Bcl2 in mice
lacking the IL-7 signaling mediator STAT5 (26) and by over-
expressing FL in Il7−/− mice (13), therefore indicating that the
role of this cytokine in commitment of progenitors to the B
cell lineage is permissive, rather than instructive. Following Pax5
expression and lineage commitment, B cell progenitors require
IL-7 for their survival and expansion. This has been clearly
manifested in mice expressing high, sustained levels of IL-7,
which resulted in expansion of pre-B cell progenitors in the bone
marrow and in some cases in the development of B cell tumors
(27–29). This increase in pro-B and pre-B cell numbers resulted
in their accumulation in secondary lymphoid organs, such as
spleen and lymph nodes.
As evident from the above, both FL and IL-7 are pivotal for
the generation of normal B cell numbers, a fact highlighted by
the complete absence of B cells in mice lacking both cytokines
(30). Their combined eﬀect is mostly exerted at diﬀerent
stages of B cell development, with FL being crucial for the
generation of early multipotent progenitors and IL-7 for their
survival and expansion after B cell commitment (13). However,
they also act synergistically at the CLP/EPLM stage, where
the receptors for both cytokines are simultaneously expressed,
possibly through activation of separate signaling pathways (31).
We have previously generated mice expressing high, sustained
levels of human FL (hereafter FLtg) (32), which, when crossed
to Il7−/− mice, showed a complete rescue of Ly6D+ CLP/EPLM
numbers (13). Interestingly, however, we have observed that mice
over-expressing FL have reduced pre-B cell numbers compared to
their wild-type (WT) counterparts (32). This could not be a direct
eﬀect of FL on pre-B cells, as they do not express CD135. Since
pre-B cells are highly dependent on IL-7 for their expansion, we
hypothesized that IL-7 availability might be reduced in FLtg bone
marrow, due to the high number of CD127+ CLP and EPLM
progenitors, which might consume a large part of the available
IL-7. Binding of IL-7 to its receptor on CD127+ target cells has
been proposed as a mechanism that regulates the abundance of
the cytokine in diﬀerent tissues (33).
In order to test this hypothesis, and to further study
the synergy between FL and IL-7 in promoting lymphoid
development in vivo, we bred FLtg mice with transgenic
mice expressing high amounts of IL-7 (hereafter IL7tg) and
analyzed the F1 generation. Double transgenic mice (hereafter
FLtgxIL7tg) had a phenotype that combined features of the
single transgenic phenotypes and in terms of expansion of
lymphoid cells, revealed synergy between the two cytokines.
Thus, double transgenic mice exhibited splenomegaly and
abnormally enlarged lymph nodes (LN), in which B and T cell
numbers were increased more than in the single transgenic
mice. Moreover, large numbers of B cell progenitors as well
as CD19− multipotent progenitors were found in the LN
of FLtgxIL7tg mice. Transplantation of LN FLtgxIL7tg cells
into myelo-ablated recipients showed that they contained
Frontiers in Immunology | www.frontiersin.org 2 October 2018 | Volume 9 | Article 2258
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hematopoietic progenitors with long-term multilineage
developmental potential, suggesting that the LN niche can
support the survival and maintenance of early hematopoietic
progenitors.
MATERIALS AND METHODS
Mice
C57BL/6 (CD45.1+ and CD45.2+), FLtg, IL7tg, FLtgxIL7tg and
NOD/SCID/Il2rγ−/− mice were bred and maintained in our
animal facility unit under specific pathogen-free conditions.
All mice used were 5–9 weeks old. All animal experiments
were carried out within institutional guidelines (authorization
numbers 1886 and 1888 from cantonal veterinarian oﬃce,
Canton Basel-Stadt).
Antibodies, Flow Cytometry and Sorting
For analysis, cells were flushed from femurs and tibias of the
two hind legs of mice or single-cell suspensions of spleen
and lymph node (inguinal and axillary) cells were made. For
blood analysis, blood was taken from the heart of euthanized
animals or from the tail vein of live ones and white blood
cells were isolated after separation with Ficoll. Stainings were
performed in PBS containing 0.5% BSA and 5mM EDTA. For
intra-cellular Foxp3 staining, cells were fixed and permeabilized
after cell-surface staining using the Foxp3 Fix/Perm buﬀer set
(eBioscience), and subsequently stained with PE-conjugated anti-
Foxp3. The following antibodies were used for flow cytometry
(from BD Pharmingen, eBioscience, BioLegend, or produced
in house): anti-B220 (RA3-6B2), anti-CD117 (2B8), anti-CD19
(1D3), anti-NK1.1 (PK136), anti-SiglecH (551), anti-CD11c
(HL3), anti-Ly6D (49-H4), anti-CD127 (SB/199), anti-Sca1 (D7),
anti-IgM (M41), anti-Foxp3 (FJK-16s), anti-CD4 (GK1.5), anti-
CD8 (53.6.7), anti-Gr1 (RB6-8C5), anti-CD11b (M1.7015), anti-
MHC-II (M5/114.15.2), anti-XCR1 (ZET), anti-CD93 (PB493),
anti-CD48 (HM48-1), anti-CD150 (TC15-12F12.2), anti-Ter119
(TER-119), anti-CD3 (145-2C11), anti-CD41 (MWReg30), anti-
CD105 (MJ7/18), anti-CD16/32 (2.4G2), anti-S1PR1 (713412),
anti-CD44 (IM7), anti-CXCR4 (L276F12), anti-CD5 (53-7.3),
and anti-Ki67 (B56). Lineage cocktail included antibodies
against: CD4, CD8, CD11b, CD11c, Gr1, B220, CD19, Ter119,
and NK1.1. Flow cytometry was done using a BD LSRFortessa
(BD Biosciences) and data were analyzed using FlowJo Software
(Treestar). For cell sorting, a FACSAria IIu (BD Biosciences) was
used (>98% purity).
Flt3-Ligand And IL-7 Quantification
Sera were collected from mice of all genotypes and ELISA was
performed using the Invitrogen human Flt3-ligand and mouse
IL-7 ELISA kits, following the provider’s instructions.
Quantitative PCR
Spleens were homogenized using the FastPrep R⃝ homogenizer
(MP Biomedicals) and RNA was extracted with Trizol
(Invitrogen) following the provider’s protocol. Five hundred
micrograms of total RNA was used to synthesize cDNA using
the GoScript reverse transcriptase (Promega). Quantitative
PCR for the detection of Il7 transcripts was performed
using SYBRTM Green (Promega). Primers used: Hprt-Forw:
atcagtcaacgggggacataaa; Hprt-Rev: tggggctgtactgcttaacca; Il7-
Forw: GATAGTAATTGCCCGAATAATGAACCA; Il7-Rev:
GTTTGTGTGCCTTGTGATACTGTTAG.
In vitro Limiting Dilution B Cell Generation
Assay
Experiments were performed as previously described (34).
Briefly, OP9 stromal cells were plated on flat-bottom 96-well
plates 1 day before the initiation of co-cultures, at a concentration
of 3,000 cells per well. The following day stromal cells were γ-
irradiated (3000 rad) and the sorted EPLM cells were added at
diﬀerent concentrations. Cultures were maintained in IMDM
medium supplemented with 5 × 10−5 M β-mercaptoethanol,
1mM glutamine, 0.03% (wt/vol) primatone, 100 U/mL penicillin,
100µg/mL streptomycin, 5% FBS and 10% IL-7-conditioned
medium. After 10 days in culture all wells were inspected under
an inverted microscope and wells containing colonies of more
than 50 cells were scored as positive.
In vivo Hematopoietic Reconstitution
Assays
Ten million BM or LN cells from FLtgxIL7tg mice were injected
intravenously into CD45.1+ recipient mice, which had been sub-
lethally irradiated (400 rad) ∼2 h before injection. Mice were
euthanized 12–16 weeks after cell transfer and their spleen,
thymus and bone marrow was analyzed for the presence of
donor cells. For secondary transplantations, 6 × 106 BM cells
from recipient mice were injected intravenously into sub-lethally
irradiated CD45.1+ recipients, in the same way. Secondary
recipient spleens were analyzed after 9 weeks. For assessment
of the in vivo B cell potential of EPLM, 6 × 104 Ly6D+ EPLM
sorted from the BM or LN of FLtgxIL7tg mice were intravenously
injected into NOD/SCID/Il2rγ−/− lymphopenic mice. Recipient
spleens were analyzed for the presence of CD19+IgM+ cells 3
weeks after cell transfer.
Statistical Analysis
One-way ANOVA followed by a Tukey-test to correct for
multiple comparisons between mouse genotypes was used.
Statistical significance is indicated with asterisks in graphs. Non-
significant diﬀerences are not indicated in the figures.
RESULTS
Expansion of Hematopoietic Cells in
Secondary Lymphoid Organs of FLtgxIL7tg
Mice
FLtg and IL7tg mice heterozygous for the corresponding
transgenes were crossed, resulting in mice carrying both
transgenes (FLtgxIL7tg), as well as wild-type (WT) and single-
transgenic littermates, which were used as controls (Figure 1A).
FLtgxIL7tg mice were viable but at around 5–6 weeks after
birth, they developed large, clearly visible inguinal lymph nodes
(LN), which continued to grow and therefore mice had to be
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euthanized at the age of 9–10 weeks. None of the littermate
controls exhibited this phenotype. All analyses of FLtgxIL7tg
mice and their WT and single transgenic counterparts presented
herein were done in 6–9 week old mice. We detected a massive
increase in the amount of FL in the serum of FLtg and FLtgxIL7tg
mice, which reached 22 and 18 ug/ml, respectively (Figure 1B).
Even though IL-7 could not be detected in the serum of
FLtgxIL7tg mice, as shown previously by in situ hybridization in
IL7tg mice (35), a significant increase in Il7 mRNA transcripts
was observed in spleens of both IL7tg and FLtgxIL7tg mice
(Figure 1C). Macroscopically, double transgenic mice exhibited
a profound splenomegaly, with spleen size and average cellularity
significantly larger than in single transgenic mice, in which the
spleen was already increased compared to WT (Figures 1D,E).
LN enlargement was even more striking, as shown in Figure 1D,
with the average number of nucleated cells in all four inguinal
and axillary LN reaching almost 109 cells, compared to 3.4
× 106 for WT, 45.4 × 106 for FLtg and 145 × 106 for
IL7tg mice (Figure 1F). All other LN examined macroscopically
(brachial, mediastinal) showed similar enlargement compared
to WT and single transgenic mice. FLtgxIL7tg BM cellularity
was somewhat increased compared to WT (less than 2-fold and
not statistically significant) and similar to the single transgenic
controls (Figure 1G). On the contrary, thymus cellularity was
slightly decreased in single and double transgenic mice compared
to their WT littermates (Figure 1H).
Analysis of the enlarged spleens and LN of FLtgxIL7tg mice
showed that several mature hematopoietic cells, which normally
reside in these secondary lymphoid tissues, were remarkably
increased. Thus, spleen and LN Gr1+CD11b+ cells, including
neutrophils and macrophages, were clearly increased in response
to elevated FL levels (Supplementary Figure 1A). Also, and in
agreement with what has been described previously in single
FLtg mice (32), DC populations, including conventional DC of
both types (CD11c+MHC-II+XCR1+ cDC1 and CD11c+MHC-
II+XCR1− cDC2), as well as B220+SiglecH+ plasmacytoid
DC (pDC), were all dramatically increased in response to FL
over-expression (Supplementary Figures 1B–E), although the
statistical analysis did not show a significant eﬀect on LN cDC1
and cDC2. A clear eﬀect of over-expressing both cytokines
was also observed on splenic and LN T cells. FLtgxIL7tg
mice had increased numbers of both CD4+ and CD8+ T
cells in spleen (4.4- and 13-fold increase compared to WT,
respectively) and LN (11- and 30-fold increase compared to
WT, respectively) (Supplementary Figures 2A,B). This eﬀect
was also seen in the numbers of the CD4+Foxp3+ regulatory
T cell (Treg) fraction of CD4+ T cells, particularly in the
LN (Supplementary Figures 2A,B), as shown before under
conditions of high FL availability (36). This increase in peripheral
T cell numbers was probably not due to increased thymic output,
since analysis of T cell developmental stages in the thymi of
FLtgxIL7tg mice showed that over-expression of both cytokines
did not significantly aﬀect the numbers of T cell progenitors,
including CD4+ and CD8+ single positive and CD4/CD8 double
positive pro-T cells. Interestingly, FL over-expression resulted in
a reduction in the numbers of the earliest double negative T cell
progenitors (Supplementary Figures 2C–E).
We next examined B cell populations in the peripheral
lymphoid organs of FLtgxIL7tg and single transgenic mice.
Analysis of peritoneal B cells showed that IL-7 over-expression
significantly increased the percent of B2 cells, whereas the
frequency of the IL-7-independent (37) CD19+CD5+CD11blow
B1a population was decreased by over-expression of both
cytokines (Supplementary Figures 3A,B). Even though FL has
been shown to be critical for the generation of B1a cells (30, 38),
their relative frequency was not significantly increased upon FL
over-expression, but rather slightly decreased, possibly due to
the large expansion of myeloid cells in the peritoneal cavity
(Supplementary Figure 3B). Mature, recirculating IgM+CD93−
B cells were significantly increased in the LN of FLtgxIL7tg
mice compared to WT (21-fold), whereas over-expressing either
cytokine alone resulted in increased mature B cell numbers
compared to WT, but to a smaller extent (Figure 2A). Mature
IgM+ B cells do not express CD135 and, unlike peripheral
T cells, they are also CD127− and hence do not respond to
either FL or IL-7. We therefore reasoned that the observed
increase in their numbers in the periphery was the result of
increased B cell progenitor numbers in the BM, as shown
previously in IL7tg mice (29). Analysis of BM B cell progenitor
populations showed a moderate 1.6-fold increase in the numbers
of IgM+CD93+ immature B cells, the population that exits the
BM to recirculate in the periphery (Figures 2B,C). IgM− B cell
progenitors showed a more pronounced increase compared to
WT controls: 7.4-fold for CD19+CD117+IgM− pro-B cells, 3.7-
fold for CD19+CD117−IgM−CD127+FSClarge large pre-B and
2.3-fold for CD19+CD117−IgM−CD127−FSCsmall small pre-
B cells (Figures 2B,C). This increase in BM CD19+ B cell
progenitors was mainly an eﬀect of elevated IL-7 levels, since
FL over-expression seemed to have a negative outcome on the
numbers of pre-B and immature B cells (∼2-fold decreased in
FLtgxIL7tg mice compared to IL7tg). Thus, the reduction in pre-
B and immature B cell numbers observed in FLtg mice (32) is
also present when IL-7 is abundantly available (in FLtgxIL7tg
mice) and is therefore unlikely to be caused by decreased IL-7
availability, as previously hypothesized.
Accumulation of Lymphoid Progenitors in
Peripheral Lymphoid Organs of FLtgxIL7tg
Mice
Previous analysis of IL7tg mice has shown an abundance of
immature B cell progenitors in the spleen and LN, where these
populations are normally not found in significant numbers (29).
We therefore analyzed spleen and LN of FLtgxIL7tg mice for
the presence of early B cell progenitors. Indeed, in both spleen
and LN of IL7tg mice, all stages of CD19+ committed B cell
progenitors were detected (Figures 3A,B). Contrary to what was
observed in the BM, however, additional FL over-expression,
in FLtgxIL7tg mice, further increased the numbers of pro-B
(4.6-fold in spleen and 16-fold in LN), large pre-B (1.8-fold in
spleen and 11-fold in LN), small pre-B (2-fold in spleen and
12-fold in LN) and immature B (1.9-fold in spleen and 9.8-fold
in LN) cells. Thus, FL and IL-7 seem to act synergistically in
promoting the accumulation of immature B cell progenitors in
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FIGURE 1 | Increased cellularity of FLtgxIL7tg lymphoid organs. (A) Scheme of the breeding applied to obtain FLtgxIL7tg mice. (B) ELISA for human FL protein
quantification in the serum of WT, FLtg, IL7tg, and FLtgxIL7tg mice (n = 4). (C) Quantitative PCR for the detection of Il7 mRNA in the spleen of WT, FLtg, IL7tg, and
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the peripheral lymphoid organs of mice over-expressing both
cytokines.
Since CD135 is not detectable on CD19+ B cell
progenitors, this additional rise in their numbers in spleen
and LN upon simultaneous FL and IL-7 over-expression
is unlikely to be a direct eﬀect of FL on their survival
and/or proliferation. However, their immediate precursors,
Ly6D+ EPLM, are CD135+ and have been shown to increase
dramatically in response to elevated FL levels (13, 34 , 39 ).
Therefore, we assessed their numbers in the BM and
periphery of FLtgxIL7tg mice. As shown in Figures 4A,B,
CD11c−NK1.1−SiglecH−CD19−B220 intCD117intLy6D+ EPLM
were indeed dramatically increased upon FL over-expression
in the BM, whereas IL-7 over-expression did not increase their
numbers and even reduced them when in combination with
high FL expression (Figure 4B, FLtg compared to FLtgxIL7tg).
Ly6D+ EPLM were clearly detected in spleens of FLtg and
FLtgxIL7tg mice, whereas in LN they were strikingly expanded
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mainly upon over-expression of both cytokines. FLtg and
IL7tg LN also had higher numbers of Ly6D+ EPLM compared
to WT, in which they were barely detectable. However, this
increase was not statistically significant and was proportional
to the corresponding overall increase in LN total cellularity
(Figure 1F), whereas FLtgxIL7tg LN Ly6D+ EPLM were 120-
and 137-fold increased compared to their FLtg and IL7tg
counterparts, respectively. This expansion is ∼10 times higher
than the corresponding LN cellularity diﬀerence between these
mouse genotypes, indicating that FL and IL-7 synergistically
promote the accumulation and/or expansion of Ly6D+ EPLM
in the LN of FLtgxIL7tg mice. Since Ly6D+ EPLM are not
yet committed to the B cell lineage (39, 40), we assessed the
ability of these spleen- and LN-residing FLtgxIL7tg progenitors
to generate B cells in vitro and in vivo. Sorting and plating
FLtgxIL7tg Ly6D+ EPLM on OP9 stromal cells together with
IL-7 under limiting dilution conditions showed that these cells
were able to give rise to CD19+ B cells in vitro (Figure 4C).
We noticed that the frequency of LN-derived Ly6D+ EPLM
that could generate B cells under these conditions was slightly
reduced compared to their BM counterparts, which showed a
frequency similar to WT BM-derived Ly6D+ EPLM (13, 39).
However, after transplantation into NOD/SCID/Il2rγ−/−
lymphopenic mice, LN-derived FLtgxIL7tg Ly6D+ EPLM were
as capable as their BM-derived counterparts at generating
IgM+ B cells in vivo (Figure 4D). Thus, under conditions of
simultaneous increase in FL and IL-7 availability, functional
CD19−Ly6D+ EPLM progenitors can reside and accumulate in
the spleens and LN of mice.
Hematopoietic Progenitors With
Long-Term, Multilineage Reconstitution
Capacity Reside in the LN of FLtgxIL7tg
Mice
Apart from Ly6D+ EPLM, CLP and LSK cells are greatly
expanded in FLtg mice (32). We therefore investigated their
potential expansion in the BM and presence in the spleen and
LN of FLtgxIL7tg mice. Under conditions of high in vivo FL
availability, CD135 becomes undetectable by flow cytometry
(32), possibly due to the continuous binding of the ligand
to its receptor. Thus, we identified CLP using the original
Lin−CD117intSca1intCD127+ phenotype (14) (Figure 5B). We
found CLP numbers to be significantly increased in the BM of
mice over-expressing FL, whereas IL-7 over-expression did not
have any eﬀect (Figure 5A). This was also the case in the spleen,
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where splenic FLtgxIL7tg CLP were increased compared to WT
(Figure 5C). Similarly to EPLM, we observed a greater than 10-
fold increase in LN FLtgxIL7tg CLP numbers compared to their
single transgenic counterparts, which were already increased
compared to WT (Figures 5E,F). CD127− LSK cell analysis
showed a similar picture, with LSK being greatly increased
in the BM and found in significant numbers in the spleen
and LN of FLtgxIL7tg mice. Within the LSK compartment,
the CD48−CD150+ phenotype can be used to enrich for
hematopoietic stem cells (HSC) with multilineage developmental
potential and self-renewal capacity (41). As shown in Figure 5A
(bottom), CD48−CD150+ LSK cells were significantly reduced in
the BM of FLtg mice and this was also the case in FLtgxIL7tg BM
(6-fold decreased compared to WT). These cells were detected at
very low frequency in the spleen of FLtgxIL7tg mice (Figure 5C),
and we could not detect them in the LN of any of the mouse
genotypes analyzed (data not shown).
Taken together, our analysis shows that over-expression of
both FL and IL-7 leads to a dramatic increase in all BM
CD135+ and CD127+ progenitors and to their migration to
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FIGURE 5 | (B) Representative FACS plots for the identification of CLP, LSK, and CD48−CD150+ LSK in the bone marrow (femurs and tibias) of WT, FLtg, IL7tg, and
FLtgxIL7tg mice. Gate numbers indicate frequencies of parent gate. In every panel the upper left plot (CD117 vs. CD127) shows live, Lineage− cells. (C) Numbers of
CLP, LSK and CD48−CD150+ LSK in the spleens of WT, FLtg, IL7tg, and FLtgxIL7tg mice. (D) Representative FACS plots for the identification of CLP, LSK, and
CD48−CD150+ LSK in the spleens of WT, FLtg, IL7tg, and FLtgxIL7tg mice. Gate numbers indicate frequencies of parent gate. In every panel the upper plot (CD117
vs. CD127) shows live, Lin- cells. (E) Numbers of CLP and LSK in the LN of WT, FLtg, IL7tg, and FLtgxIL7tg mice. (F) Representative FACS plots for the identification
of LSK in the LN of WT, FLtg, IL7tg, and FLtgxIL7tg mice. Gate numbers indicate frequencies of parent gate. In every panel the upper plot (CD117 vs. CD127) shows
live, Lin- cells. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. Error bars indicate standard deviation.
the periphery, presumably due to space constrains in the BM.
In support of this hypothesis, all CD19+ B cell progenitor
stages were found significantly increased in the peripheral blood
of FLtgxIL7tg mice (Figures 6A,D). Strikingly, the same was
true for CD135+ Ly6D+ EPLM, CLP and LSK progenitors,
which were increased in the blood mainly in response to FL
over-expression (Figures 6B,C,E). This eﬀect of FL and IL-7
simultaneous over-expression in promoting themigration of cells
from the BM to the periphery was seen mainly on progenitors,
since mature B and T cell frequencies in the blood of FLtgxIL7tg
mice were not dramatically changed, whereas the relative
frequencies of cDC and NK cells were significantly increased in
the blood of FLtg animals (Supplementary Figure 4). Thus, the
synergistic eﬀect of FL and IL-7 over-expression in expanding
BM hematopoietic progenitors leads to their exit from the BM
and accumulation not only in the spleen but also in LN, where
some of these progenitors are undetectable in WT mice.
We next sought to evaluate whether these multipotent
hematopoietic progenitors identified by flow cytometry in
the LN of FLtgxIL7tg mice were functional, i.e., if they
had the ability to generate multiple hematopoietic lineages
upon transplantation. To this end, we infused 10 × 106
unfractionated LN cells from CD45.2+ FLtgxIL7tg, into sub-
lethally irradiated congenic CD45.1+ WT mice. FLtgxIL7tg
BM cells were used as a positive control for the long-term
reconstitution of hematopoietic lineages, since they contain
functional hematopoietic progenitors. Recipient mice were
analyzed 12–16 weeks after transplantation for the contribution
of CD45.2+ donor cells to the diﬀerent hematopoietic lineages.
As expected, overall engraftment of donor cells in the BM,
spleen and thymus of recipient mice was significantly lower
in LN-transplanted recipients compared to BM transplanted
ones (Supplementary Figures 5A,B). Thus, in the FLtgxIL7tg
LN transplanted hosts, 20% splenic, 5.4% BM and 6.8%
thymic cells were of donor origin. Analysis of the spleen of
FLtgxIL7tg LN-reconstituted mice showed that 21.8% CD19+
B cells, 13.8% CD3+ T cells, 16.3% NK1.1+ NK cells, 14.7%
SiglecH−CD11b−CD11c+ DC, 4.5% CD11b+CD11c− myeloid
cells and 15% Ter119+ erythroid cells were of donor origin,
with more than 80% of the transplanted mice showing donor-
derived reconstitution in all the above lineages (Figures 7A–D).
Donor contribution was also evaluated in the thymus of recipient
mice, where we found small but clearly detectable populations
of FLtgxIL7tg LN-derived CD4+, CD8+, and CD4/CD8 double
positive T cell progenitors (Figures 7E–G). Furthermore, BM
analysis showed that a significant fraction of CD19+ B cell
progenitors were of FLtgxIL7tg LN donor origin, with the
average percent ranging from 5.6% for large pre-B to 13% for
immature IgM+CD93+ B cells (Supplementary Figures 5C,D).
Remarkably, we also found small but clearly detectable
populations of donor-derived CLP (5%) and LSK (3.5%) 12 weeks
after transplantation. Thus, FLtgxIL7tg LN contain progenitors
with the long-term capacity to generate multiple hematopoietic
lineages.
The presence of early hematopoietic progenitors in the host
BM 12 weeks after transfer of FLtgxIL7tg LN cells, prompted
us to assess their self-renewal capacity by re-transplanting
them into secondary recipients. Six million unfractionated BM
cells from FLtgxIL7tg LN-reconstituted mice and FLtgxIL7tg
BM-reconstituted controls were intravenously injected into
congenic CD45.1+ irradiated WT hosts 12 weeks after the
first transplantation. Nine weeks after secondary transfer, we
could detect FLtgxIL7tg-derived donor cells in the secondary
recipients’ spleen. Importantly, CD45.2+ cells were found in
multiple hematopoietic lineages. Thus, FLtgxIL7tg LN donor-
derived cells were found in: 0.1% CD19+ B cells, 0.25%
CD3+ T cells, 0.6% CD11c+ DC and 0.07% Ter119+ erythroid
cells (Figures 8A–D). These results indicate that there are
FLtgxIL7tg LN-residing multipotent hematopoietic progenitors
with self-renewal capacity. Overall, considering the significant
multilineage contribution of FLtgxIL7tg LN-derived donor cells
in host hematopoietic reconstitution more than 12 weeks after
transfer, as well as their presence in secondary transplanted hosts
after another 9 weeks, we conclude that the LN of FLtgxIL7tg
mice contain hematopoietic progenitors with in vivo long-term
multi-lineage reconstitution ability, some of which have self-
renewal capacity.
DISCUSSION
We have previously generated and analyzed mice with increased,
sustained in vivo levels of either IL-7 (28, 29) or FL (13,
32, 39), which provided important insights to the roles of
the two cytokines at diﬀerent stages of the various lineages
of hematopoiesis. In the present study we over-expressed
both cytokines in order to evaluate the concerted action
of both FL and IL-7 on the regulation of hematopoiesis
in an in vivo setting. We find a synergistic eﬀect of the
two cytokines in promoting the generation and expansion
of lymphoid cells, resulting in a profound enlargement of
secondary lymphoid organs, such as spleen and LN, significantly
more than what can be seen in single transgenic mice
(Figure 1). Both spleen and LN of FLtgxIL7tg mice were
populated by significant numbers of multipotent hematopoietic
progenitors, which in WT mice are generally confined to the
BM.
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FIGURE 6 | plots for the identification of Ly6D+ EPLM in the blood of WT (upper left), FLtg (upper right), IL7tg (lower left), and FLtgxIL7tg (lower right) mice. Gate
numbers indicate frequencies of parent gate. In every panel the left plot (CD117 vs. B220) shows live, NK1.1−CD11c−SiglecH− cells. (C) Representative FACS plots
for the identification of LSK and CLP in the blood of WT (upper left), FLtg (upper right), IL7tg (lower left), and FLtgxIL7tg (lower right) mice. Gate numbers indicate
frequencies of parent gate. In every panel the left plot (CD117 vs. CD127) shows live, Lin− cells. (D) Percentages of pro-B (CD19+ IgM−CD117+), large pre-B
(CD19+ IgM−CD117−CD127+FSClarge), small pre-B (CD19+ IgM−CD117−CD127−FSCsmall) and immature B cell (CD19+ IgM+CD93+) progenitors in the blood of
WT (n = 9), FLtg (n = 11), IL7tg (n = 8), and FLtgxIL7tg (n = 11) mice. B cell progenitors were identified by FACS as shown in (A). (E) Percentages of Ly6D+ EPLM
(CD11c−NK1.1−SiglecH−B220intCD117intLy6D+CD19−), CLP (Lin−CD117intSca1intCD127+) and LSK (Lin−CD117+Sca1+CD127−) progenitors in the blood of
WT (n = 6), FLtg (n = 6), IL7tg (n = 7), and FLtgxIL7tg (n = 10) mice. The y-axis on all plots indicates % of live, nucleated blood cells. *p < 0.05, **p < 0.01, ***p <
0.001, and ****p < 0.0001. Error bars indicate standard deviation.
The enlarged spleens and LN of FLtgxIL7tg mice
contained significantly increased populations of myeloid
cells (Supplementary Figure 1A). This probably reflected the
expansion in BM myeloid progenitors that FL over-expression
induces (32). Indeed, when assessing early myelo-erythroid
progenitor stages in FLtgxIL7tg BM, we observed a significant
increase in the earliest identified myeloid progenitors, pre-
GM and GMP (42), whereas early erythroid/megakaryocyte
progenitors were decreased (Supplementary Figure 6), in
accordance with the anemia and thrombocytopenia caused
by elevated FL (32). Generation of DC is known to depend
on FL and we indeed found all splenic and some LN DC
populations significantly increased (Supplementary Figure 1).
This could be the result of DC expansion in peripheral
lymphoid organs, since these cells are CD135+, or could be
due to FL-mediated expansion of their progenitors. Due to
the inability to stain for CD135+ in mice over-expressing FL
(32) we were not able to assess the numbers of cDC and pDC
progenitors (43–45).
Peripheral T cells were also increased dramatically in spleens
and LN of FLtgxIL7tg mice, even though thymic size and T
cell output was not increased. Thus, this seems to be mainly
an eﬀect of IL-7, which is known to regulate homeostasis of
peripheral T cells, particularly of CD8+ (46) which was the
T cell population with the biggest expansion in FLtgxIL7tg
mice (Supplementary Figures 2A,B). Interestingly, FL over-
expression alone also resulted in some increase in mature T
cell numbers. Since these cells are CD135−, we postulate that
this is an indirect eﬀect of high FL levels. Previous experiments,
showing expansion of regulatory T cells upon increased FL
availability, suggested that this is mediated by IL-2 produced by
the expanded DC (36), thus providing a potential explanation
for the observed increase in peripheral T cells when FL is over-
expressed. The somewhat reduced thymopoiesis observed in
FLtgxIL7tg mice might be a direct or secondary result of high
FL expression by thymic stromal cells, since IL-7 over-expression
alone in the IL7tg mouse model used herein did not aﬀect T cell
development (35). Since thymus seeding progenitors that migrate
from the BM are multipotent and express CD135 (47, 48), it
is conceivable that under the influence of increased FL levels a
larger fraction of them diﬀerentiates toward myeloid or DC fates,
thus resulting in somewhat reduced CD4/CD8 double-negative
numbers.
The synergistic eﬀect of FL and IL-7 is clearly manifested
in the generation of B cells. Expression of the receptors for
the two cytokines on B cell generating progenitors occurs at
slightly diﬀerent developmental stages: CD135 is expressed on
early progenitors (LSK, CLP, EPLM) and is down-regulated upon
Pax5/CD19 expression and commitment to the B cell lineage,
whereas CD127 is expressed from the CLP up to the small pre-
B stage. Accordingly, both receptors are co-expressed during the
CLP/EPLM developmental stage, in which a potential synergy
between the two cytokines in promoting B cell development can
occur. FL is mainly acting as a proliferative factor for CLP/EPLM
progenitors, whereas IL-7 supports their survival, rather than
expanding them (13). Thus, we find the number of these
progenitors greatly expanded in the BM of FLtg and FLtgxIL7tg
mice, while IL-7 over-expression does not further increase their
numbers but rather decreases them slightly (Figures 4B, 5A). IL-
7 acts as a proliferative factor for CD19+ B cell progenitors in
the BM, leading to a 5- to 9-fold increase in their numbers upon
over-expression (when comparing IL7tg to WT or FLtgxIL7tg
to FLtg). This eﬀect of the two cytokines on the proliferation
of hematopoietic progenitors was confirmed in the present
study, since we found a significant increase in the percentage of
cycling LSK in the BM of mice over-expressing FL, whereas IL-
7 had a proliferative eﬀect mainly on CD19+ B cell progenitors
(Supplementary Figure 7). This vast expansion of CD19+ cells
upon IL-7 over-expression could explain the slight reduction in
FLtgxIL7tg Ly6D+ EPLM numbers compared to FLtg mice, since
the expanded progenitor populations have to compete for limited
space in the BM. By contrast, in peripheral lymphoid tissues, such
as the spleen and LN, which can enlarge to accommodate more
cells, the synergistic eﬀect of FL and IL-7 can be clearly seen, as
FLtgxIL7tg spleen and LN contain significantly more CLP/EPLM
and CD19+ B cell progenitors of all stages compared to their
single transgenic counterparts. Interestingly, the proliferative
eﬀect of the two cytokines observed in the BM was also seen
in the LN (Supplementary Figure 7), indicating that progenitors
continue to expand in response to the two cytokines after their
migration to the periphery. The space restrictions imposed on
cells in the BM might also be the reason for the observed
reduction in the number of BM pre-B and immature cells when
FL is over-expressed. We have previously hypothesized that this
might be the result of reduced IL-7 availability in the BM of FLtg
mice, but as the same eﬀect seems to occur in FLtgxIL7tg mice,
this is unlikely to be the reason. It is still possible that other
trophic signals required for the expansion and/or survival of pre-
B cells become limiting in the BM when CD135+ progenitors
expand massively, as is the case in FLtg and FLtgxIL7tg mice.
However, this does not happen in the periphery, where the FL-
mediated expansion of CLP/EPLM results in a corresponding
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FIGURE 7 | of the mean. Black circles represent mice where the corresponding lineage was scored as positive for the presence of donor-derived cells
(>50 cells in the CD45.2+ gate) and white circles mice with no reconstitution (<50 cells in the CD45.2+ gate). The fraction of positive-to-total mice analyzed for each
lineage is indicated above the corresponding bar. Lineages were defined as follows: CD19+: CD11b−CD11c−CD3−CD19+; CD3+: CD11b−CD11c−CD19−CD3+;
NK1.1+: CD3−CD11c−B220−SiglecH−NK1.1+; SiglecH+: CD11b−NK1.1−B220+SiglecH+; CD11c+: NK1.1−SiglecH−B220−CD11b−CD11c+; CD11b+:
NK1.1−SiglecH−B220−CD11c−CD11b+; CD11b+CD11c+: NK1.1−SiglecH−B220−CD11b+CD11c+; Ter119+: Ter119+. (B,D) Representative FACS plots
showing the CD45.2+ donor population identified within the lineages shown in (A,C). Left: recipients transplanted with FLtgxIL7tg BM; Right: recipients transplanted
with FLtgxIL7tg LN. (E) Percentage of CD45.2+ donor cells within the indicated T cell populations in thymi of mice reconstituted with FLtgxIL7tg BM (upper) and
FLtgxIL7tg LN (lower). Results from three independently performed experiments are shown. For FLtgxIL7tg BM: n = 6; for FLtgxIL7tg LN: n = 10. Bars indicate mean
± standard error of the mean. Black circles represent mice where the corresponding lineage was scored as positive for the presence of donor-derived cells (>50 cells
in the CD45.2+ gate) and white circles mice with no reconstitution (<50 cells in the CD45.2+ gate). The ratio of positive-to-total mice analyzed for each lineage is
indicated above the corresponding bar. Cells were identified as follows: DP: CD3+CD4+CD8+; CD4 SP: CD3+CD8−CD4+; CD8 SP: CD3+CD4−CD8+. (F,G)
Representative FACS plots showing the CD45.2+ donor population identified within the indicated thymic T cell populations. Upper: recipients transplanted with
FLtgxIL7tg BM; lower: recipients transplanted with FLtgxIL7tg LN.
increase in pro-B and pre-B cell numbers. Taken together, FL
and IL-7 act in concert to promote B cell development, FL
by providing suﬃcient numbers of CLP/EPLM progenitors and
IL-7 by promoting their survival and further expansion after
commitment to the B cell fate.
FL over-expression resulted in a major expansion of LSK
cells, which are largely CD135+. When IL-7 was additionally
over-expressed, this resulted in the detection of significant LSK
numbers in the spleen and LN of FLtgxIL7tg mice. Since LSK
are CD127−, we hypothesize that the reason for their increase
mainly in FLtgxIL7tg LN is again related to confined space
and/or resources in the FLtgxIL7tg BM, thus leading to their
migration to peripheral lymphoid organs when expanded by
FL over-expression. In support of this hypothesis, LSK can also
be detected in the blood of FLtgxIL7tg mice (Figures 6C,E).
Expression of molecules associated with progenitor migration
from the BM, such as S1PR1, CD44, and CXCR4 was not
dramatically diﬀerent between genotypes, with the exception
of an FL-mediated increase in the CXCR4+ fraction of B cell
progenitors, which might be an indirect eﬀect of FL, as these
cells are CD135− (Supplementary Figure 8). This indicates that
it is mainly competition for BM space/resourses that leads
to their accumulation in peripheral lymphoid organs. LSK
are mostly comprised of multipotent progenitors with mixed
lineage potentials and biases, but which are not considered to
possess self-renewal capacity (7). Self-renewing HSC within the
LSK compartment can be enriched for by staining with the
SLAM markers CD48 and CD150, and are contained within
the CD48−CD150+ LSK fraction (41). We were not able to
detect CD48−CD150+ LSK cells in the LN of FLtgxIL7tg mice.
However, as reported previously (32), and seen in Figure 5A, the
CD48−CD150+ fraction of LSK in the BM is severely reduced
in numbers upon FL over-expression. These cells are CD135−
when identified by flow cytometry, although some of them
express mRNA for the receptor (49). Therefore we do not know
if this reduction is a direct eﬀect of FL-signaling. In addition,
we cannot exclude that high FL availability might aﬀect the
expression of SLAM markers, thus resulting in some HSC losing
the CD48−CD150+ phenotype in FLtg and FLtgxIL7tg mice. The
expression level of other important markers for the identification
of progenitor stages, such as CD117 and Sca1, might also be
changed upon FL over-expression. As shown in Figures 5B,D,
Sca1 expression in the majority of FLtg and FLtgxIL7tg CLP is
relatively higher than the one of theirWT and IL7tg counterparts.
The same is true for CD117 expression in pro-B (Figure 2B). This
might be the result of altered marker expression or a selective
expansion of the (few in WT mice) cells expressing high levels
of the corresponding proteins.
In order to functionally assess the precursor activity of
hematopoietic progenitors found in the LN of FLtgxIL7tg
mice, we transplanted LN cells from these mice into myelo-
ablated WT recipients and assessed their long-term multilineage
reconstitution capacity. We found a significant contribution of
FLtgxIL7tg donor cells in lymphoid, myeloid, dendritic and
erythroid lineages 12–16 weeks after transplantation. This is
indicative of the presence of multipotent progenitors in the
double transgenic LN, since myeloid and dendritic cells are
not long-lived and therefore these donor cells could not be
mature myeloid/dendritic cells transferred from the FLtgxIL7tg
LN. In addition, we found donor contribution in all stages of
recipient T cell development, suggesting that the FLtgxIL7tg
LN contain progenitors with thymus-seeding potential. The
exact nature of these precursors is not known, but they
are known to have multilineage developmental capacity (47,
48). Furthermore, we detected donor progenitor cells in the
BM of recipient animals, which upon transplantation into
secondary recipients showed a small but clearly detectable
contribution in the regeneration of diﬀerent lineages. We
conclude from this data that the LN of FLtgxIL7tg mice
contain hematopoietic progenitors with long-term multilineage
hematopoietic regeneration capacity. These could be HSC, which
do not display the CD48−CD150+ phenotype due to alterations
in SLAM marker expression, or downstream multipotent
progenitors that have acquired self-renewal capacity under
conditions of high FL availability – possibly by an autocrine FL
eﬀect.
Irrespective of the precise nature of the multipotent
hematopoietic progenitor that resides in FLtgxIL7tg LN, it is
clear from our data that not only the spleen but also the
LN of these double transgenic mice can support the survival
of immature precursors, such as LSK, CLP, EPLM, and pre-
B cells, which are normally only found in the BM. Extra-
medullary hematopoiesis has been described in patients and
has been mostly associated either with bone marrow failure or
with myeloproliferative disease (50, 51). Similarly, disruption of
hematopoiesis in mice caused by drug treatment (52), mutations
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FIGURE 8 | Hematopoietic reconstitution potential of FLtgxIL7tg LN cells after secondary transplantation. (A,C) Percentage of CD45.2+ donor cells within the
indicated lineages in spleens of secondary CD45.1+ recipients, which received BM of CD45.1+ mice reconstituted with FLtgxIL7tg BM (A) or FLtgxIL7tg LN (C).
Results from three independently performed experiments are shown. Bars indicate mean ± standard error of the mean. Black circles represent mice where the
corresponding lineage was scored as positive for the presence of donor-derived cells (>50 cells in the CD45.2+ gate) and white circles mice with no reconstitution
(<50 cells in the CD45.2+ gate). The ratio of positive-to-total mice analyzed for each lineage is indicated above the corresponding bar. Lineages were defined as
follows: CD19+: CD11b−CD11c−CD3 −CD19+; CD3 +: CD11b−CD11c−CD19−CD3 +; NK1.1+: CD3 −CD11c−B220−SiglecH−NK1.1+; SiglecH+:
CD11b−NK1.1−B220+SiglecH+; CD11c+: NK1.1−SiglecH−B220−CD11b−CD11c+; CD11b+: NK1.1−SiglecH−B220−CD11c−CD11b+; CD11b+CD11c+:
NK1.1−SiglecH−B220−CD11b+CD11c+; Ter119+: Ter119+. (B,D) Representative FACS plots showing the CD45.2+ donor population identified within the lineages
shown in (A,C). Left: FLtgxIL7tg BM as primary donor; right : FLtgxIL7tg LN as primary donor.
(53–55) or cytokine over-expression (56, 57) can lead to extra-
medullary hematopoiesis. However, the main extra-medullary
site where hematopoietic progenitors are detected in both
patients and mice is the spleen, whereas no such precursors have
been reported in LN in these cases. Hematopoietic progenitors
have been shown to circulate to the periphery through blood and
lymph, but only very small numbers have been detected in lymph
under normal conditions and they were practically undetected
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in LN (58). A human NK precursor has been detected in LN
(59), while it has been shown that at early time points after BM
transplantation T cell lymphopoiesis can occur in extra-thymic
sites, including LN (60). Interestingly, repeated administration
of FL in mice has led to pronounced presence of immature
hematopoietic progenitors in the spleen, as seen in our FLtg and
FLtgxIL7tgmice, but not in LN (61). It appears that in FLtgxIL7tg
mice, the expansion of both lymphoid and myeloid progenitors
due to the combined action of both cytokines is suﬃcient to
cause the accumulation of hematopoietic progenitors not only in
the spleen but also in LN. This indicates that the environment
in secondary lymphoid organs is able to support hematopoiesis
in “emergency” situations, such as the one in FLtgxIL7tg mice,
which manifest a pronounced myelo- and lympho-proliferative
disease. However, it remains unknown whether this ability of
the FLtgxIL7tg LN to support the accumulation of progenitors
is due to alterations in the LN niche caused by high FL and
IL-7 expression, e.g., up-regulated expression of other cytokines
or adhesion molecules by LN stromal cells. Moreover, an
interesting question is whether the FLtgxIL7tg LN is a site of
on-going hematopoiesis, or if the progenitors only migrate there
and accumulate without diﬀerentiating further. In support of
the former hypothesis, FLtgxIL7tg LN-residing progenitors are
functional in reconstituting hematopoietic cells after transfer
to irradiated recipients (Figures 7, 8) and all hematopoietic
developmental stages are represented in the LN in ratios similar
to the ones found in WT BM. Further experiments would be
needed to address this issue.
Collectively, our present analysis of FLtgxIL7tg mice
demonstrates the in vivo synergistic action of FL and IL-7
in promoting lymphoid development and expansion. This is
summarized in Supplementary Figure 9. Our data provide
evidence that secondary lymphoid organs can support the
maintenance of hematopoietic progenitors in conditions of
abnormal hematopoiesis. Further studies of these mice might
elucidate the requirements for extra-medullary residence and
hematopoietic activity of HSC; an issue of clinical importance
for the treatment of lympho-proliferative disorders and blood
malignancies.
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Supplementary Figure 1 
Myeloid and dendritic cells are increased in spleens and LN of FLtgxIL7tg mice. 
A) Numbers of myeloid cells in the spleen and lymph nodes (axillary and inguinal) of WT, FLtg, IL7tg 
and FLtgxIL7tg mice. Myeloid cells were identified as Gr1+CD11b+. B, D) Dendritic cell numbers in 
the spleen and lymph nodes of WT, FLtg, IL7tg and FLtgxIL7tg mice. C, E) Representative FACS 
plots for the identification of cDC1 (B220-SiglecH-MHC-II+CD11c+XCR1+), cDC2 (B220-SiglecH-
MHC-II+CD11c+XCR1-) and pDC (B220+SiglecH+) in the spleen (C) and lymph nodes (E) of WT, 
FLtg, IL7tg and FLtgxIL7tg mice. Numbers on gates indicate percentage of parent gate. *: p<0.05, 
**:p<0.01,, ****:p<0.0001. Error bars indicate standard deviation. 
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Supplementary Figure 2 
T cell populations in FLtgxIL7tg mice 
A, B) Numbers of TCRβ+CD8+ (left panel), TCRβ+CD4+ (middle panel) and CD4+Foxp3+ (right panel) 
T cells in the spleens (A) and lymph nodes (axillary and inguinal) (B) of WT, FLtg, IL7tg and 
FLtgxIL7tg mice. C) Representative FACS plots for the identification of double negative (DN) CD4-
CD8- populations (DN1-4), double positive (DP; CD4+CD8+), CD4+ and CD8+ thymocytes in the thymi 
of WT, FLtg, IL7tg and FLtgxIL7tg mice. Lineage cocktail contained antibodies against: CD3, B220, 
CD11c and Gr1. Numbers on gates indicate percentage of parent gate. D) Numbers of DN, DP, CD4+ 
and CD8+ thymocytes in the thymi of WT, FLtg, IL7tg and FLtgxIL7tg mice. E) Numbers of DN1 
(Lin-CD4-CD8-CD117+CD44+CD25-), DN2 (Lin-CD4-CD8-CD117+CD44+CD25+), DN3 (Lin-CD4-
CD8-CD117-CD44-CD25+) and DN4 (Lin-CD4-CD8-CD117-CD44-CD25-) T cell progenitors in the 
thymi of WT, FLtg, IL7tg and FLtgxIL7tg mice. *: p<0.05, **:p<0.01, ***:p<0.001, ****:p<0.0001. 
Error bars indicate standard deviation. 
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Supplementary Figure 3 
B1 cells in the peritoneal cavity of FLtgxIL7tg mice. 
A) Representative FACS plots for the identification of B1a (CD19+CD11b+CD5+), B1b 
(CD19+CD11b+CD5-), B2 (CD19+CD11b-) and CD11b+ (CD19-CD11b+) myeloid cells in the 
peritoneal cavity of WT, FLtg, IL7tg and FLtgxIL7tg mice. Gate numbers indicate frequencies of 
parent gate. B) Percentages of B1a (left panel), B2 (middle panel) and myeloid cells (right panel) in 
the peritoneal cavity of WT, FLtg, IL7tg and FLtgxIL7tg mice. *: p<0.05, **:p<0.01, ***:p<0.001, 
****:p<0.0001. Error bars indicate standard deviation. 
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Supplementary Figure 4 
Mature hematopoietic cell frequencies in peripheral blood of FLtgxIL7tg mice. 
Percentages of T cells (CD3+), B cells (CD19+), NK cells (CD3-NK1.1+), plasmacytoid DC (pDC; 
B220+SiglecH+), conventional DC (cDC; CD3-NK1.1-B220-CD11b-CD11c+) and myeloid cells (CD3-
NK1.1-B220-CD11c-CD11b+) in the peripheral blood of WT, FLtg, IL7tg and FLtgxIL7tg mice (n=4 
for all genotypes). *: p<0.05, **:p<0.01, ****:p<0.0001. Error bars indicate standard deviation. 
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Supplementary Figure 5 
Hematopoietic reconstitution potential of FLtgxIL7tg LN cells. 
A) Percentage of total CD45.2+ donor cells in spleen, bone marrow and thymus of mice reconstituted 
with FLtgxIL7tg BM (upper graph) or FLtgxIL7tg LN (lower graph). Black circles represent mice 
where the total donor contribution was scored as positive (>50 cells in the CD45.2+ gate). The fraction 
of positive-to-total mice analyzed for each organ is indicated above the corresponding bar. Results 
from four independently performed experiments are shown. Bars indicate mean ± standard error of the 
mean. B) Representative FACS plots indicating the total chimerism in the BM (upper plots), spleen 
(middle plots) and thymus (lower plots) of mice reconstituted with FLtgxIL7tg BM (left plots) and LN 
(right plots). C) Percentage of CD45.2+ donor cells within the indicated progenitor populations (LSK: 
Lin-CD127-CD117+Sca1+; CLP: Lin-CD117intSca1intCD127+; pro-B: CD19+IgM-CD117+; large pre-B: 
CD19+IgM-CD117-CD127+FSClarge; small pre-B: CD19+IgM-CD117-CD127-FSCsmall; and immature 
B: CD19+IgM+CD93+) in the bone marrow of mice reconstituted with FLtgxIL7tg BM (up) or 
FLtgxIL7tg LN (down). Black circles represent mice where the corresponding cells were scored as 
positive for the presence of donor-derived cells (>50 cells in the CD45.2+ gate) and white circles mice 
with no reconstitution (<50 cells in the CD45.2+ gate). The ratio of positive-to-total mice analyzed for 
each progenitor population is indicated above the corresponding bar. Results from four independently 
performed experiments are shown. Bars indicate mean ± standard error of the mean. D) Representative 
FACS histograms showing the percentage of CD45.2+ FLtgxIL7tg BM- (left) and LN-derived (right) 
donor cells within the indicated progenitor populations of reconstituted mice. 
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Supplementary Figure 6 
Myelo-erythroid progenitors in the BM of FLtgxIL7tg mice. 
A) Representative FACS plots for the identification of pre-GM, GMP and pre-MegE progenitors in the 
BM of WT, FLtg, IL7tg and FLtgxIL7tg mice. Top FACS plots show cells that have been pre-gated 
as: live, CD117+Sca1-CD127-CD41- cells. B) Numbers of pre-GM (left), GMP (middle) and pre-MegE 
(right) progenitors in the bone marrow of WT, FLtg, IL7tg and FLtgxIL7tg mice. Pre-GM: pre-
granulocyte-macrophage progenitor (Lin-kit+Sca1-CD127-CD41-FcγRII/III-CD105-CD150-); GMP: 
granulocyte-macrophage progenitor (Lin-kit+Sca1-CD127-CD41-FcγRII/III+); pre-MegE: pre-
megakaryocyte-erythroid progenitor (Lin-kit+Sca1-CD127-CD41-FcγRII/III-CD105-CD150+). *: 
p<0.05, **:p<0.01, ***:p<0.001, ****:p<0.0001. Bars indicate mean ± standard deviation. 
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Supplementary Figure 7 
Effect of FL and/or IL-7 over-expression on the cell-cycle status of BM and LN progenitors. 
A) Representative FACS histograms showing the percentage of Ki67+ cells within the indicated BM 
progenitor populations ((LSK: Lin-CD127-CD117+Sca1+; CLP: Lin-CD117intSca1intCD127+; pro-B: 
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CD19+IgM-CD117+; pre-B: CD19+IgM-CD117- and IgM+CD93+) of WT, FLtg, IL7tg and FLtgxIL7tg 
mice. B) Frequencies of Ki67+ cells within the indicated BM progenitor populations of WT, FLtg, 
IL7tg and FLtgxIL7tg mice (n=4 for all genotypes). *: p<0.05, **:p<0.01, ***:p<0.001. Error bars 
indicate standard deviation. C) Representative FACS histograms showing the percentage of Ki67+ cells 
within the indicated LN progenitor populations of WT, FLtg, IL7tg and FLtgxIL7tg mice. D) 
Frequencies of Ki67+ cells within the indicated LN progenitor populations of WT, FLtg, IL7tg and 
FLtgxIL7tg mice (n=4 for all genotypes). *: p<0.05, **:p<0.01, ***:p<0.001, ****:p<0.0001. Error 
bars indicate standard deviation. 
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Supplementary Figure 8 
Expression of migratory-related proteins S1PR1, CD44 and CXCR4 on BM hematopoietic 
progenitors of FLtgxIL7tg mice. 
A) Representative FACS plots and histograms showing the percentages of S1PR1+, CXCR4+, 
S1PR1+CXCR4+ and CD44+ cells within the indicated BM progenitor populations (LSK: Lin-CD127-
CD117+Sca1+; CLP: Lin-CD117intSca1intCD127+; Ly6D+ EPLM: NK1.1-CD11c-SiglecH-CD19-
B220+CD117+Ly6D+; pro-B: CD19+IgM-CD117+; pre-B: CD19+IgM-CD117-; and ImmB: 
CD19+IgM+CD93+) of WT, FLtg, IL7tg and FLtgxIL7tg mice. B) Percentages of S1PR1+, CXCR4+, 
S1PR1+CXCR4+ and CD44+ cells within the indicated BM progenitor populations of WT, FLtg, IL7tg 
and FLtgxIL7tg mice (n=4 for all genotypes). *: p<0.05, **:p<0.01, ***:p<0.001, ****:p<0.0001. 
Error bars indicate standard deviation. 
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Supplementary Figure 9 
Summary of the effect of increased FL and/or IL-7 levels in the numbers of hematopoietic 
progenitor and mature cells. 
Schematic representation of BM hematopoietic progenitors (open circles) and peripheral mature blood 
cells (grey cells). Arrows indicate developmental relationships. Blue circles indicate progenitors that 
express CD135 (Flt3) on their surface, red circles progenitors that express CD127 (IL7Rα) and purple 
circles progenitors that express both. Colored vertical arrows indicate an increase or decrease in the 
numbers of the corresponding cells in FLtg (blue arrows), IL7tg (red arrows) and FLtgxIL7tg mice 
(purple arrows). For progenitor cells the picture summarizes data from the BM and for mature cells 
from peripheral lymphoid organs. LSK: Lineage-Kit+Sca1+; GMP: Granulocyte-Macrophage 
Progenitor; MkP: Megakaryocyte Progenitor; ErP: Erythrocyte Progenitor; CLP: Common Lymphoid 
Progenitor; EPLM: Early Progenitor with Lymphoid and Myeloid potential; ETP: Early Thymic 
Progenitors, DN: CD4/CD8 Double-Negative, DP: CD4/CD8 Double-Positive. 
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Running title: Duxbl eliminates pre-T cells during β-selection 
 
Non-standard abbreviations:  CPM = counts per million, Dll = Delta-like, DN = double negative, 
DP = double positive, FDR = false discovery rate, PCA = principal component analysis, pTa = 
pre-T cell receptor a 
 
Summary: During β-selection T cells without productive TCRβ rearrangements are eliminated. 
Klein et al show that the transcription factor Duxbl regulates this process by inducing apoptosis 
through activation of the Oas/RNaseL pathway. Successful TCRβ rearrangement rescues cells 
by pre-TCR-mediated Duxbl suppression.
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Abstract 
 
T-cell development is critically dependent upon successful rearrangement of antigen-
receptor chains. At the β-selection checkpoint only cells with a functional rearrangement 
continue in development. However, how non-selected T cells proceed in their dead-end fate is 
not clear. We identified low CD27 expression to mark pre-T cells that have failed to rearrange 
their β-chain. Expression profiling and single-cell transcriptome clustering identified a 
developmental trajectory through β-selection and revealed specific expression of the 
transcription factor Duxbl at a stage of high recombination activity prior to β-selection. 
Conditional transgenic expression of Duxbl resulted in a developmental block at the DN3-to-
DN4 transition due to reduced proliferation and enhanced apoptosis, whereas RNA silencing 
led to a decrease in apoptosis. Transcriptome analysis linked Duxbl to elevated expression of 
the apoptosis-inducing Oas/RNaseL-pathway. RNaseL deficiency or sustained Bcl2 
expression led to a partial rescue of cells in Duxbl transgenic mice. These findings identify 
Duxbl as a regulator of β-selection by inducing apoptosis in cells with a non-functional 
rearrangement. 
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1. Introduction 
 
T-cell development occurs in the thymus and is initiated by a bone marrow derived 
multipotent progenitor, named thymus settling progenitor (Zlotoff and Bhandoola, 2011). The 
identity of the exact cell type that migrates to the thymus is still under debate, since several 
possible candidates have been described (Kondo et al., 1997; Krueger and von Boehmer, 
2007; Rodewald et al., 1994; Saran et al., 2010; Serwold et al., 2009). There is consensus that 
this progenitor retains the ability to give rise to several lineages including B cells, natural killer 
cells, dendritic cells as well as other myeloid lineages (Balciunaite et al., 2005b; Bell and 
Bhandoola, 2008; Ceredig et al., 2007; Luis et al., 2016; Wada et al., 2008). Final commitment 
to the T-cell pathway is achieved upon Notch engagement (Balciunaite et al., 2005a; Radtke 
et al., 1999; Sambandam et al., 2005).  
Thymic T-cell development is a stepwise process that involves several successive 
stages, which are phenotypically distinguished by the expression of various cell surface 
markers. The most immature populations are characterized by the absence of CD4 and CD8 
and are therefore named double negative cells (DN) (Ceredig and Rolink, 2002). The DN 
population can be further subdivided based on the expression pattern of CD25, CD44, and 
CD117 (Godfrey et al., 1993; Godfrey et al., 1992; Massa et al., 2006). High level expression 
of CD44, CD117 and the absence of CD25 mark DN1 cells, which retain the potential to give 
rise to different lineages. At the next stage, DN2, progenitors are additionally characterized by 
expression of CD25. Upon progression to the DN3 stage, which displays lower CD44 and 
CD117 expression, final commitment to the T-cell lineage takes place (Yui and Rothenberg, 
2014). Downregulation of CD25 marks the onset of the DN4 stage that is negative for all three 
surface markers (Godfrey et al., 1994). After the DN4 stage CD4 as well as CD8 become 
upregulated and therefore cells are named double positive (DP). Finally, CD4 or CD8 single 
positive cells expressing a functional T-cell receptor (TCR) will undergo positive and negative 
selection, thereby completing their maturation in the thymus (Germain, 2002). 
T-cell development can also be subdivided into developmentally distinct stages by the 
use of the rearrangement status of the β- and the α-chain of the TCR. β-chain rearrangement 
starts at the DN2 and is completed at the DN3 stage (Capone et al., 1998) whereas 
rearrangement of the α-chain takes place at the DP stage (Livak et al., 1999). An essential 
checkpoint for this process, called β-selection, selects cells with a productive rearrangement 
of their β-chain to continue in their development, whereas cells with a non-functional 
rearrangement will undergo apoptosis (Dudley et al., 1994). Pairing of productively rearranged 
β-chains with the pre-T cell receptor α (pTα) chain and the CD3 molecules results in the 
expression of the pre-T cell receptor (pre-TCR) (Saint-Ruf et al., 1994), which induces survival 
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and a massive proliferative expansion of these cells (Kreslavsky et al., 2012) by autonomous 
signaling (Irving et al., 1998; Jacobs et al., 1996; Saint-Ruf et al., 1994). The requirement of 
pre-TCR signaling during this checkpoint is manifested in the arrest of T-cell development in 
mice with defects in the pTα chain (Fehling et al., 1995), the CD3 signaling components 
(Malissen et al., 1995) or the genes responsible for the recombination of the β-chain (Shinkai 
et al., 1992). Additionally, Notch1 signaling and engagement of the chemokine receptor Cxcr4 
by its ligand Cxcl12 were shown to be essential for a successful passage through this selection 
point, since they are crucial for the survival as well as for the proliferation of the cells (Ciofani 
et al., 2004; Ciofani and Zuniga-Pflucker, 2005; Maillard et al., 2006; Trampont et al., 2010; 
Tussiwand et al., 2011). The upregulation of several co-stimulatory surface molecules, such 
as CD27, CD28, and CD71 (Brekelmans et al., 1994; Gravestein et al., 1996; Williams et al., 
2005) can also be used to subdivide the DN3 population into cells expressing an intracellular 
β-chain (DN3b) and cells that do not yet do so (DN3a) (Taghon et al., 2006). The fact that VDJ-
recombination can result in a non-productive rearrangement, together with the inability of some 
β-chains to build a functional pre-TCR, lead to the elimination of the vast majority of cells during 
β-selection. The exact mechanism and regulation of this process remain still unresolved. 
In this study we identify CD27 downregulation at the DN3 stage to be a marker for cells 
that have failed rearrangement of the β-chain and will therefore undergo apoptosis. Gene 
expression analysis revealed high expression of the transcription factor Duxbl within this 
population. We show that conditional transgenic over-expression of Duxbl resulted in a block 
in T-cell development at the DN3-to-DN4 transition due to reduced proliferation and increased 
apoptosis, whereas in vitro Duxbl knock-down decreased apoptosis, instead. Our results 
identify Duxbl as an important regulator of the elimination of cells with a non-functional 
rearrangement at the β-selection checkpoint. 
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2. Materials and Methods 
 
2.1.  Mice  
C57BL/6 wild-type controls, pTα-/- (Fehling et al., 1995), Nur77GFP (Moran et al., 2011), 
pTαCre (Luche et al., 2013), Bcl2tg (Domen et al., 1998), Rag2-/- (Shinkai et al., 1992), Duxblind, 
and RNaseL-/- mice were bred and maintained in our animal facility unit under specific 
pathogen-free conditions. All mice used were 5-7 weeks old and were of the C57BL/6 strain or 
were bred to it for more than 10 generations (Bcl2tg). As controls littermates were used in 
every experiment. All animal experiments were carried out within institutional guidelines 
(authorization numbers 1886 and 1888 from cantonal veterinarian office, Canton Basel-Stadt). 
Duxblind and RNaseL-/- mice were generated at the Center for Transgenic Models in 
Basel. Duxblind mice were produced by pronuclear DNA microinjection of C57BL/6 zygotes 
essentially as described in (Palmiter et al., 1982). RNaseL-/- mice were generated using 
Cas9/CRISPR technology. All Cas9 reagents were purchased from IDT. Briefly, RNPs 
consisting of Cas9 protein (40 ng/ul), trcrRNA (20 ng/ul) and crRNAs (10 ng/ul each) targeting 
exon 1 of the Rnasel gene were microinjected into C57BL/6 zygotes essentially as described 
in (Jacobi et al., 2017). Embryos surviving the DNA and Cas9 RNP microinjections were 
transferred into pseudopregnant females generated by mating with genetically vasectomized 
males (Haueter et al., 2010) and the offspring were allowed to develop to term. 
Figure S4A illustrates the construct used to generate the Duxblind mice by random 
integration. Figure S4E describes the generation of RNaseL-/- mice. The following 20-mers 
sequences were used to produce the crRNAs that guided Cas9 for the induction of double 
strand breaks in exon 1 of the Rnasel gene (5´to 3´): AATGCCTGTGAAGACACCTG and 
GACAAAAGGCGATTGAAGCA. 
 
2.2.  Flow cytometry and cell sorting 
For analysis, cells were flushed from femurs of the two hind legs of mice or single-cell 
suspensions of spleen, thymus, and lymph node (inguinal and axilliary) cells were made. 
Stainings were performed in PBS containing 0.5% BSA and 5mM EDTA. For intra-cellular beta-
chain staining, cells were fixed and permeabilized after cell-surface staining using a Fix/Perm 
buffer set (eBioscience), and subsequently stained with Bv421-conjugated anti-TCRβ (H57). 
The following antibodies were used for flow cytometry (from BD Biosciences, eBioscience, 
BioLegend, RnD Systems, or produced in house): anti-CD3 (145-2C11), anti-B220 (RA3-6B2), 
anti-CD4 (GK1.5), anti-CD8 (53-6.7), anti-CD25 (PC61), anti-CD44 (IM7), anti-CD117 (2B8), 
anti-CD27 (LG.3A10), anti-CD28 (37.51), anti-TCRβ (H57-597), anti-TCRγ (GL3), anti-CD69 
(H1.2F3), anti-MHCI (Y3), anti-CD62L (MEL-14), anti-S1PR1 (713412). For flow cytometry a 
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BD LSRFortessa (BD Biosciences) was used and data were analyzed using FlowJo Software 
(Treestar). MACS enrichment was performed using an autoMACS separator (Miltenyi) after 
cells were stained with anti-CD4/CD8-bio and anti-biotin microbeads (Miltenyi). For cell sorting, 
a FACSAria IIu (BD Biosciences) was used (>98% purity). 
 
2.3.  Cell cycle analysis  
Cells were sorted with an Aria II FACS sorter (BD). Sorted cells were resuspended in 
1mL 70% ethanol and stored at 4°C over-night. Cells were then harvested at 2000rpm for 5min 
at 4°C and subsequently resuspended in 250μL RNaseA (0.5mg/mL). After 15min of 
incubation at 37°C, 250μL Pepsin (0.5mg/mL) was added and incubated for 15min at 37°C. 
Finally, nuclei were stained by adding 500μL ethidium bromide solution and incubation for 
10min at room temperature before analysis by flow cytometry. 
 
2.4.  Retroviral Production 
 For Duxbl knock-down MSCV-LMP empty vector plus four different MSCV-LMP vectors 
containing Duxbl directed shRNAs were generated using the following oligo templates: sh2-1, 
TGCTGTTGACAGTGAGCGAACTCTTCGTGTGTGGTTTGAATAGTGAAGCCACAGATGTA
TTCAAACCACACACGAAGAGTGTGCCTACTGCCTCGGA; sh2-2, 
TGCTGTTGACAGTGAGCGCAGAATCCCAATCCTGATCTAGTAGTGAAGCCACAGATGTA
CTAGATCAGGATTGGGATTCTTTGCCTACTGCCTCGGA; sh3-1, 
TGCTGTTGACAGTGAGCGCTTGCATGCTGTTCTGAAGAAATAGTGAAGCCACAGATGTA
TTTCTTCAGAACAGCATGCAAATGCCTACTGCCTCGGA; sh3-2, 
TGCTGTTGACAGTGAGCGAAGTTTGCATGCTGTTCTGAAGTAGTGAAGCCACAGATGTA
CTTCAGAACAGCATGCAAACTCTGCCTACTGCCTCGGA. 
A total of 5x106 Plat-E cells were plated one day prior to transfection in 10cm dishes 
(Falcon) with 10mL DMEM (Sigma) supplemented with 10% fetal bovine serum, 100 U/mL 
penicillin (BioConcept), 100 mg/mL streptomycin (BioConcept), and 1mM sodium pyruvate 
(Sigma). The next day 20μg plasmid and 80μg polyethylenimine were mixed in 1ml DMEM 
without supplements, incubated for 15 minutes at room temperature, and subsequently added 
dropwise to the Plat-E cells. 24 hours after transfection supernatant was replaced with fresh 
medium. Viral supernatants were collected 48 hours and 72 hours post transfection and either 
used directly for transductions or stored at -80°C. 
 
2.5.  Cell culture 
For culturing of sorted DN3 cells 96-well Maxisorp Nunc-Immuno plates (Thermo 
Fisher) were used. Wells were precoated overnight or longer with 10 μg/mL anti-human IgG-
Fc (clone Huf-5.4, generated in house) in PBS (50μL per well) at 4°C. Thereafter, wells were 
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washed twice with IMDM supplemented with 5% fetal bovine serum, 5x10-5M b-
mercaptoethanol, 1mM glutamine, 0.03% w/v Primatone, 100 U/mL penicillin, and 100 mg/mL 
streptomycin and then coated with Delta-like (Dll) 4-Fc at 3μg/mL in IMDM (50μL per well) 
overnight at 4°C. Before addition of the cells wells were washed again twice with IMDM. Sorted 
cells were adjusted to a concentration of 2x105 cells/mL with IMDM supplemented additionally 
with 10nM Cxcl12 and cultured for 3 or 5 days (200μL per well). 
For the establishment of in vitro T-cell differentiation fetal liver cells were cultured on 
OP9-Dll1 stromal cells. In short, 3x104 OP9-Dll1 cells were seeded in 24-wells the day before 
addition of fetal liver cells with 500μL IMDM supplemented with 10% fetal bovine serum, 5x10-
5M b-mercaptoethanol, 1mM glutamine, 0.03% w/v Primatone, 100 U/mL penicillin, and 100 
mg/mL streptomycin. The next day cells were irradiated with 2000rad. Fetal liver cells were 
taken from E14.5 C57BL/6 embryos and mononuclear cells were separated by centrifugation 
on a Ficoll-Paque PLUS (GE Healthcare) gradient. A total of 5x104 cells per 24-well were 
added to the irradiated OP9-Dll1 and cultured in 1mL of the previously described medium plus 
10% IL-7 supernatant. After 5 days cells were harvested and 106 cells were transduced with 
1.5mL of viral supernatants of either MSCV-LMP empty vector or the corresponding Duxbl 
shRNAs using 3 hours of spinoculation with 10μg/mL polybrene. Subsequently, 5x104 
transduced cells were put back into culture onto freshly prepared irradiated OP9-Dll1 in the 
presence of 10% IL-7 for another 5 days. Finally, a total of 105 cells were passed again onto 
freshly prepared OP9-Dll1 and cultured for 4 more days in the absence of IL-7. Then cells were 
harvested and stained with the corresponding surface markers as described in 2.2., as well as 
with AnnexinV (BD Biosciences) and 7AAD (Biolegend) in AnnexinV Binding Buffer (BD 
Biosciences) following the manufacturer´s protocol. 
 
2.6.  Quantitative PCR 
Total RNA was extracted using RNAqueous – Micro Kit (Invitrogen) followed by cDNA 
synthesis using GoScript Reverse Transcriptase (Promega) according to the manufacturer’s 
protocol. Quantitative PCR was performed using SYBR green PCR Master Mix (Applied 
Biosystems) and samples were run on an Applied Biosystems StepOnePlus qPCR machine. 
The following primers were used for PCR amplification (5´to 3´): β-actin, 
TGGAATCCTGTGGCATCCATGAAAC and TAAAACGCAGCTCAGTAACAG; Duxbl, 
AAGCAGAGTTTGCATGCTGTT and TTGTGAAGTGCGTTCTGCTC; Rnasel, 
TTGATCAGAGCATCCGATGGATGGGAGAG and 
TTCTCCAGGAGAAAACAGGCAATGAATGAGGT; Oas1a, ATTACCTCCTTCCCGACACC 
and AAGGAACACCACCAGGTCAG; Oas1b, TCTGCTTTATGGGGCTTCGG and 
TCGACTCCCATACTCCCAGG; Oas2, GGCCTGGTACAGCCTTGGAA and 
AAAGCCTTGGTCCTGCCACA; Oas3, AAGCCGACACCCAACGTGTA and 
   4. Results 
 
  102 
TTTCGGGGCTCAGTGAAGCA; Oasl1, GCATCGGCCGACGAAGCTGA and 
CCGTGGCGAGGCCTTCATCC. 
 
2.7.  Bulk and single-cell RNA-sequencing 
 For bulk RNA-seq, total RNA was isolated from 100,000-200,000 cells with an Ambion 
RNAqueous Micro Kit (Invitrogen). RNA quality was assessed with a Fragment Analyzer 
(Advanced Analytical). Fifty nanograms of RNA were used for library preparation (Illumina 
Truseq stranded kit) and sequencing was perfomed on an Illumina NexSeq 500 machine at 
the Genomics Facility Basel of the ETH Zurich. Single-end 51-mers reads were obtained and 
their quality was assessed with the FastQC tool (version 0.11.3). Reads were mapped to the 
mouse mm10 genome assembly with STAR (version 2.5.2a) (Dobin et al., 2013) with default 
parameters, except reporting only one hit in the final alignment for multimappers 
(outSAMmultNmax=1) and filtering reads without evidence in the spliced junction table 
(outFilterType=“BySJout”). All subsequent gene expression data analysis was performed 
using the R software (version 3.4).  
The qCount function of the Bioconductor package QuasR (version 1.18) (Gaidatzis et 
al., 2015) was used to count the number of reads (5' ends) overlapping with the exons of the 
Ensembl 84 annotation, assuming an exon union model. Read and alignment quality was 
evaluated using the qQCReport function of QuasR. 
Differentially expressed genes were identified with the Generalized Linear Model 
(GLM) framework in the edgeR package (version 3.20.9) (Robinson et al., 2010). For the DN3a 
CD27high/DN3a CD27low/DN3b dataset, a “replicate” covariate was incorporated into the model 
to control for systematic differences across flow cytometry sorting runs. Genes with a false 
discovery rate lower than 5% were considered differentially expressed. Gene set enrichment 
analysis was performed with the function camera (Wu and Smyth, 2012) from the edgeR 
package (using the default parameter value of 0.01 for the correlations of genes within gene 
sets) using gene sets from the hallmark collection (Liberzon et al., 2015) of the Molecular 
Signature Database (MSigDB v6.0) (Subramanian et al., 2005). We considered only sets 
containing more than 10 genes and gene sets with a false discovery rate lower than 5% were 
considered significant. For the heatmap combining the two RNA-seq datasets, data were 
corrected for batch effects for visualization purposes, using the function removeBatchEffect 
from the Bioconductor limma package (version 3.34.9). 
 For single-cell RNA-seq, DN2, DN3, and DN4 cells were sorted from six mice and 
counted. An estimate of 5,000 cells from the DN2 and DN4 populations were loaded on one 
well each and 10,000 cells from the DN3 population on two wells of a 10× Genomics Chromium 
Single Cell Controller. Single-cell capture and cDNA and library preparation were performed 
with a Single Cell 3’ v2 Reagent Kit (10× Genomics) according to manufacturer’s instructions. 
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Sequencing was perfomed on an Illumina NexSeq 500 machine at the Genomics Facility Basel 
of the ETH Zurich. Paired-end reads were obtained and their quality was assessed with the 
FastQC tool (version 0.11.3). The length of the first read was 26-mers, composed of individual 
cells barcodes (16nt) and molecular barcodes (unique molecular identifiers; 10nt). The length 
of the second read, composed of the transcript sequence, was 58-mers. The samples in the 
different wells were identified using sample barcodes of 8nt. Sequencing files were processed 
with the Cell Ranger software (version 2.1.0, provided by 10× Genomics and available at 
https://support.10xgenomics.com/single-cell-gene-expression/software/downloads/latest) to 
perform sample and cell demultiplexing, read alignment to the mouse mm10 genome assembly 
with STAR, and to generate read count table (using the reference transcriptome“refdata-
cellranger-mm10-1.2.0” based on Ensembl release 84, provided by 10× Genomics and 
available at https://support.10xgenomics.com/single-cell-gene-
expression/software/downloads/latest). Default settings and parameters were used, except for 
the version of STAR updated to 2.5.3a, and the STAR parameters outSAMmultNmax set to 1 
and alignIntronMax set to 10000. Samples were merged with the “cellranger aggregate” 
procedure without downsampling.  
Further analysis was performed using the scran (1.6.9) (Lun et al., 2016) and scater 
(1.6.3) (McCarthy et al., 2017) Bioconductor packages on the UMI counts matrix, following 
mostly the steps illustrated in the simpleSingleCell Bioconductor (release 3.6) workflow. 
Cells with log library sizes (or log total number of features detected) more than two 
median absolute deviations (MADs) below the median log library size (or log total number of 
features detected) were filtered out. Cells with more than 10% of UMI counts attributed to the 
mitochondrial genes were removed. Cells with less than 20% of UMI counts attributed to the 
ribosomal proteins genes were removed. Cells with more than 1% of UMI counts attributed to 
the Hemoglobin genes were removed. Low-abundance genes with average log2CPM values 
lower than 0.005 were filtered out. 
Expression values of 11,448 genes for 18,128 cells were obtained after filtering. The 
raw UMI counts were normalized with the size factors estimated from pools of cells to avoid 
dominance of zeros in the matrix (Lun et al., 2016). A mean-dependent trend was fitted to the 
variances of the log expression values of endogenous genes to distinguish between genuine 
biological variability and technical noise, under the assumption that most genes are not 
differentially expressed across cells, and their variance is mainly technical (trendVar function 
of the scran package with loess trend and span of 0.4 to better fit the sparse data). The fitted 
technical noise was subtracted and the residual “biological” component of the genes variance 
was used to denoise the PCA with the denoisePCA function of the scran package. 
Clustering of cells into putative subpopulations was done on normalized log-counts 
values using hierarchical clustering on the Euclidean distances between cells (with Ward’s 
   4. Results 
 
  104 
criterion to minimize the total variance within each cluster). The clusters of cells were identified 
by applying a dynamic tree cut, which resulted in seven putative subpopulations. Marker genes 
specific for each cluster were identified with the findMarkers function of the scran package, 
which fits a linear model to the expression values for each gene using the limma framework. 
In all analyses, reads assigned to the Duxbl1 (ENSMUSG00000048502), Duxbl2 
(ENSMUSG00000072675), and Duxbl3 (ENSMUSG00000072672) genes, 100% identical at 
the cDNA level, were all assigned to Duxbl1. 
 
2.8.  Data availability 
The RNA-sequencing data generated are available at the Gene Expression Omnibus 
database under accession number GSE118059. 
 
2.9.  Online supplementary materials 
Fig. S1 illustrates the gating strategy used to define the different double negative stages 
of T-cell development in WT and pTa-/- mice. Fig. S2 compares the transcriptomic sequencing 
data of DN3a CD27low, DN3a CD27high and DN3b cells showing a heatmap of spearman 
correlation and a principal component analysis. Fig. S3 shows the single-cell RNA sequencing-
based clustering of DN2, DN3, and DN4 cells. Fig. S4 illustrates the generation of conditional 
Duxbl transgenic and RNaseL-/- mice. Fig. S5 shows cell cycle analysis, intracellular b-chain 
expression, apoptosis, and peripheral T cell numbers in DuxblindxpTaCre mice. 
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3. Results 
 
3.1.  CD27 downregulation marks cells failing β-chain rearrangement 
In mice with a defective pTα chain developing thymocytes are arrested at the DN3 
stage and undergo apoptosis due to their inability to form the pre-TCR (Fehling et al., 1995). 
Comparison of the DN compartments of WT versus pTα-/- mice by tSNE (t-distributed 
stochastic neighbor embedding) confirmed the absence of DN3-4 and DN4 cells in pTα-/- mice, 
but also a clear phenotypical change of the DN3 compartment, which showed lower CD27, 
CD44, CD117 and higher CD25 expression (Fig. 1A-B, S1). While in pTα-/- mice most cells 
undergo apoptosis due to the complete absence of pre-TCR signaling, in WT mice only a 
fraction of the DN3 population are eliminated. We therefore sought to phenotypically identify 
this fraction in the WT DN3 population. CD27 downregulation is also observed in WT mice, 
whereas high CD27 and CD28 expression marks DN3b cells, which have successfully 
rearranged their β-chain (Fig. 1C). In pTα-/- and Rag2-/- mice this CD27low population is 
significantly increased, whereas the DN3b population is barely detectable or completely absent 
(Fig. 1C+D). Comparison of WT DN3a CD27low with CD27high cells displays similar differences 
with regards to lower CD44, CD117 and increased CD25 expression, as observed in the WT 
versus pTα-/- comparison (Fig. 1E).  
Previously, high expression of CD27 was linked to intracellular β-chain expression at 
the DN3 stage (Taghon et al., 2006). In order to assess whether CD27 downregulation is 
associated with failure of the β-selection checkpoint, intracellular β-chain expression as well 
as the cell cycle status of the cells was examined. The DN3a CD27low population exhibited 
decreased intracellular β-chain expression as well as almost complete absence of cycling cells 
(Fig 1F). In addition, analysis of Nur77 reporter mice, reporting activation of TCR or pre-TCR 
signaling, revealed a signal exclusive to the DN3a CD27high and not in the CD27low population, 
whereas the vast majority of DN3b cells were positive (Fig. 1G+H). Co-staining for intracellular 
β-chain expression further revealed that Nur77 expression marks DN3a cells which started to 
express a β-chain (Figure 1I). Cultivation of ex vivo isolated DN3 cells in wells coated with Dll 
(Delta-like) 4 and supplemented with Cxcl12 results in a progression of cells with a functional 
rearrangement to the DP stage, which is accompanied by a proliferative burst (Tussiwand et 
al., 2011). This progression is vastly reduced in the DN3a CD27low compared to the CD27high 
population (Figure 1J). Injection of anti-CD3ε antibody in pTα-/- mice, which provides a signal 
that compensates for the absent pre-TCR signaling (Fehling et al., 1997), resulted in an almost 
complete disappearance of the CD27low population and in an upregulation of CD28 in the 
CD27high cells, showing their induced progression to the DN4 stage (Fig. 1K+L). 
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Thus, CD27 downregulation is associated with an unsuccessful β-chain rearrangement 
and/or pre-TCR formation. On the other hand, high CD27 expression is associated with pre-
TCR signaling and successful passage through the β-selection checkpoint. 
 
3.2.  Specific expression of the transcription factor Duxbl during β-selection 
 RNA-sequencing of DN3a CD27high, DN3a CD27low, and DN3b cells was performed to 
further investigate the mechanism of β-selection. All three populations were clearly separated 
from each other on the first axes of a principal component analysis (PCA). However, there was 
a closer relationship between DN3a CD27high and CD27low samples, whereas the DN3b 
samples were more distant (Fig. S2).  
Gene set enrichment analysis for MsigDB hallmark signatures comparing DN3a 
CD27low and DN3b cells revealed a higher expression of genes involved in apoptosis-related 
pathways in DN3a CD27low cells, with the significant enrichment of the tumor necrosis factor 
alpha (TNFA) signaling, interferon alpha and gamma responses, p53, and apoptosis pathways. 
On the other hand, hallmark signatures that were significantly decreased in the CD27low 
population were related to cell cycle and DNA replication, such as the Myc and E2F targets, 
mTORC1 signaling, mitotic spindle, and genes involved at the G2 to M checkpoint in the cell-
cycle (Fig. 2A). This enrichment of genes involved in cell cycle and proliferation is visible in the 
top 50 genes downregulated in the DN3a CD27low compared to DN3b population (Fig. 2B). 
Therefore, global gene expression analysis is in agreement with the previous findings of cell 
cycle arrest and the developmental blockade of cells that will undergo apoptosis in the DN3a 
CD27low population, whereas DN3b cells, after receiving pre-TCR signaling, undergo 
proliferative expansion. The DN3a CD27high population seems to be located in between these 
two populations as indicated by the gene expression levels shown in Figure 2B and the 
hierarchical clustering shown in Figure S2A.  
The homeobox transcription factor Duxbl (double homeobox B-like gene) was found to 
be the DNA binding protein with the highest fold change between the DN3a CD27low and DN3b 
populations (Fig. 2B-D). This factor was of specific interest since its deregulated expression 
was shown to result in an impaired DN thymocyte development in an in vitro setting (Kawazu 
et al., 2007). While Duxbl was expressed in the DN3a CD27high population almost 2-fold less 
compared to DN3a CD27low population, it was expressed at very low levels in DN3b cells (Fig. 
2E). Quantitative PCR analysis confirmed these data and additionally highlighted that Duxbl is 
very specifically upregulated at the DN3a stage during T-cell development and immediately 
downregulated at the DN3b stage after cells have passed β-selection (Fig. 2F-G). This 
prompted us to test whether pre-TCR signaling is involved in the downregulation of Duxbl 
expression. To this end, we quantified Duxbl expression in Nur77- as well as Nur77+ DN3a 
CD27high cells in Nur77GFP mice. Our analysis revealed diminished Duxbl expression in Nur77+ 
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cells (Fig. 2H). Furthermore, Duxbl expression was also decreased in DN3 cells from pTα-/- 
mice that were injected with anti-CD3ε antibodies compared to the PBS injected controls (Fig. 
2I). 
The prominent expression of Duxbl at the stage where β-selection occurs, as well as 
its induced downregulation by pre-TCR signaling, suggest a potential role of this transcription 
factor in the selection process. 
 
3.3.  Single-cell transcriptome clustering of DN cells elucidates Duxbl expression prior to β-
selection 
To further characterize the β-selection checkpoint, single-cell RNA-sequencing of WT 
DN2, DN3, and DN4 cells was performed. In total, after quality filtering, we obtained 3,952 
DN2, 8,675 DN3, and 5,501 DN4 cells, with an average of 1,988 genes per cell detected. A 
PCA clearly separated the individual cells of the DN2 population from the other populations on 
the second principal component (Fig. 3A). While most of the DN3 cells separated from the DN4 
population on the first principal component, some merged into the DN4 population. Clustering 
analysis resulted in 7 clusters, with two clusters composed of DN2 cells, two clusters 
composed of DN3 cells, two clusters composed of both DN3 and DN4 cells, and one cluster 
composed of DN4 cells (Fig. 3B-C, Fig. S3A).  
Progression from the DN2 to the DN4 stage is accompanied by specific developmental 
gene expression changes. We used well-defined expression patterns of surface markers, 
genes involved in recombination, as well as transcriptional regulators of T-cell development in 
order to establish a developmental trajectory of the obtained clusters (Yui and Rothenberg, 
2014). As genes specific for the DN2 stage Cd117, Cd44, Hoxa9, Lmo2, Mef2c, Gfi1b, Lyl1, 
Spi1, Bcl11a, Mycn, and Hhex were used. Il2ra, Il7r, Erg, Notch1, Hes1, and Runx1 were used 
as genes expressed in both DN2 and DN3 cells. DN3 cells in particular were defined by high 
expression of CD3γ, CD3δ, CD3ε, Rag1, Rag2, Ptcra, Tcf12, Ets, Ahr, Notch3, and SpiB. From 
the DN3 stage onwards Tcf12, Ets1, Bcl11b, Ets2, Lef1, Thy1, and Themis are highly 
expressed, whereas Cd4, Cd8, Rorc, and Id3 are increased once the cells have reached DN4 
stage. The heatmap shown in Figure S3B illustrates the expression patterns of these marker 
genes throughout the developmental trajectory. Although these markers are mainly studied at 
the protein expression level, their expression at the transcriptome level was overall in very 
good agreement with the expectation. As expected, clusters containing DN2 cells display high 
expression of the marker genes sets that are early expressed during development. On the 
other hand, DN3 specific genes split the four clusters containing DN3 cells into two, since they 
are highly expressed in the clusters exclusively consisting of DN3 cells (clusters 3 and 4), 
whereas the clusters that map with DN4 cells (5 and 6) show reduced expression of these 
genes. The fact that many of these DN3-specific genes relate to recombination and pre-TCR 
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signaling, suggests a separation of DN3 cells into pre- (clusters 3 and 4) and post β-selection 
(clusters 5 and 6). Expression of DN4 specific genes in clusters 5 and 6 further supports this 
hypothesis. This is confirmed by isolating from the data the top genes that are the best at 
discriminating the seven different clusters: recombination- and pre-TCR signaling-related 
genes are highly expressed in clusters 3 and 4, while their expression is lower in clusters 5 
and 6 (Fig. 3D, genes in green). Furthermore, clusters 5 and 6 showed increased expression 
of genes associated with cell cycle and proliferation (in blue), which are only induced after 
passage of the β-selection checkpoint, and upregulation of genes involved in the negative 
regulation of apoptotic processes (in red). 
Confirming our previous results, Duxbl expression was almost exclusively detected in 
the clusters consisting of DN3 cells, with maximal expression in cluster 4 (Fig 3E-F), whose 
cells have expression profile that is the farthermost from cells that have passed β-selection 
(clusters 5 and 6; Fig. 3B, S3A). Thus, cluster 4 most likely represents cells that are undergoing 
recombination, including the cells that have failed productive rearrangement and are going to 
die. The highly specific expression of Duxbl within this cluster further suggests a potential role 
for this transcription factor during the β-selection process. 
 
3.4.  Conditional Duxbl transgenic mice display perturbed T-cell development 
In order to further investigate the role of Duxbl during T-cell development and 
specifically during β-selection, we generated conditional transgenic mice that over-express 
Duxbl and eGFP after removal of a mCherry stop-casette by cre-mediated recombination 
(hereafter Duxblind) (Fig. S4A). To achieve specific expression at the DN3a stage during T-cell 
development, these mice were crossed to mice expressing the cre recombinase under the 
control of the pTα promoter (hereafter DuxblindxpTαCre) (Luche et al., 2013). The loss of 
mCherry and gain of eGFP expression pattern in these mice confirmed specificity of the system 
(Fig. S4B-D). 
Thymic cellularity of DuxblindxpTαCre mice was reduced 10-fold compared to WT and 
Duxblind control mice. By contrast, the cellularity of the spleen and the bone marrow was not 
significantly changed (Fig. 4A). Staining with CD4 and CD8 revealed an increase in DN 
percentage with simultaneous decrease in DP (Fig. 4B). As a result, DN numbers were not 
increased, whereas DP cell numbers were reduced ~45-fold. Mature CD4 and CD8 T-cell 
compartments were reduced, ~5-fold and ~3-fold respectively (Fig. 4C). The γδ-T-cell 
compartment was not significantly altered, indicating that Duxbl specifically acts during αβ-T-
cell development. 
The separation of the DN stages using CD25, CD44, and CD117 expression revealed 
a reduction in DN1, DN2, DN3, as well as DN4 fractions, whereas the DN3-4 stage, comprising 
cells with intermediate levels of CD25, was increased in DuxblindxpTαCre mice (Fig. 4B, D). This 
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clearly indicates a block in the development of T cells at the transition from the DN3 to the DN4 
stage. Cells accumulating at the DN3-4 stage were much smaller in size compared to the ones 
in WT or Duxblind mice (Fig. 4E). Cell cycle analysis of DN3, DN3-4, and DN4 cells from all 
mouse strains revealed a decreased percentage of cycling cells in DuxblindxpTαCre mice (Fig. 
4F, S5A). On the other hand, the subsequent selection of cells with successful rearrangement 
of the β-chain seemed not to be affected by Duxbl, since the majority of cells stained positive 
for intracellular β-chain at the DN3-4 stage in all genotypes (Fig. 4G + S5B). Ultimately, the 
disturbed T-cell development resulted in reduced peripheral CD4 and CD8 T-cell 
compartments in DuxblindxpTαCre mice (Fig. S5C). On the contrary, γδ-T cells were increased 
in the periphery (Fig. S5C). 
To test the abnormalities in the progression to the DP stage in more detail we sorted 
WT and DuxblindxpTαCre DN3 cells and cultivated them for up to five days in wells coated with 
Dll4 and medium supplemented with Cxcl12. As shown in Figure 4H and I, WT cells expanded 
~2-fold after 3 days and ~3.5-fold after 5 days and expressed CD4 and CD8 on their surface. 
This progression was almost completely blocked in cells derived from DuxblindxpTαCre mice, 
demonstrated by the reduction in cell numbers over time and the absence of CD4 and CD8 
expression after five days, thus recapitulating the situation observed in vivo. For analysis of 
apoptosis, AnnexinV and 7AAD staining was performed after 3 days of culture (Fig. S5D). A 
strong decrease in the number of living cells in accordance with an increase in the number of 
early and late apoptotic cells in cultures containing DN3 cells from DuxblindxpTαCre mice was 
observed (Fig. 4J).  
Taken together, conditional over-expression of Duxbl specifically affects the β-selection 
checkpoint by blocking the developmental progression of cells that should normally continue 
to their next stage, as shown by the tremendous reduction in DP cells. Induction of apoptosis 
and cell cycle arrest seem to cause the observed block, indicating that Duxbl is involved in the 
elimination of cells that fail β-selection. 
 
3.5.  Silencing of Duxbl results in decreased apoptosis at the DN3 stage 
 We designed four different shRNA vectors for retroviral knock-down of Duxbl 
expression via RNA interference. Additionally, transduced cells were marked by GFP 
expression. Efficiency of the different shRNAs was tested on a cell line that over-expressed 
Duxbl due to transposon-mediated integration of a construct containing the Duxbl cDNA under 
control of a constitutive active promoter. Transduction of this cell line with the different shRNAs 
and subsequent sorting of the GFP+ fraction revealed reduced mRNA expression of Duxbl as 
determined by qPCR analysis (Figure 5A). The shRNA with the highest knock-down efficiency 
(sh3-2) was selected for further experiments.  
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For the establishment of an in vitro simulation of T-cell development, fetal liver cells 
were cultured on OP9-Dll1 stromal cells. After several days of culture, the majority of cells 
adopted a DN2 phenotype and only after removal of IL-7 transition through β-selection was 
initiated, which resulted in the generation of DP cells (data not shown).  Since pre-TCR-
signaling results in CD25 downregulation, we specifically assessed the potential effect of Duxbl 
knock-down on CD44-CD25high cells, the majority of which represent cells prior to β-selection 
and in which Duxbl is expressed. Knock-down of Duxbl in this system diminished apoptosis at 
the DN3 stage specifically in the GFP+ fraction, whereas untransduced GFP- cells showed no 
significant change compared to the empty vector (EV) control (Figure 5B-C).  
Thus, in accordance with apoptosis induction after Duxbl over-expression (Figure 4), 
silencing Duxbl expression results in reduced apoptosis in DN3 cells, further supporting its role 
in mediating the elimination of DN3 cells that failed β-selection. 
 
3.6.  Activation of apoptosis in DuxblindxpTαCre mice 
 To reveal the mechanism involved in the Duxbl-mediated apoptosis induction in T-cell 
development we investigated gene expression changes in DuxblindxpTαCre DN3-4 cells by 
RNA-sequencing of these cells in parallel with their WT counterparts. Comparison of these two 
populations with the previous RNA-seq data revealed a close similarity between WT DN3-4 
cells and DN3b cells (Fig. 6A), which is expected since at the level of surface protein 
expression they only differ slightly in their CD25 expression level. Interestingly, after batch-
effect correction, DN3-4 cells derived from DuxblindxpTαCre mice exhibited a gene expression 
profile most similar to WT DN3a CD27low cells, even though they have a successfully 
rearranged β-chain. This further suggests that continuous Duxbl expression prevents 
developmental progression and instead induces a transcriptomic phenotype resembling the 
cells that fail β-selection.  
 Amongst the most differentially expressed genes between WT DN3-4 cells and DN3-4 
cells derived from DuxblindxpTαCre mice, the Oas/RNaseL pathway was clearly over-expressed 
in transgenic samples (Fig. 6B). This system is important in interferon responses and was 
shown to be mainly involved in anti-viral immunity by inducing apoptosis in infected cells 
(Silverman, 2007). RNaseL deficiency also results in an increased resistance of thymocytes to 
apoptosis, suggesting further involvement of this pathway in thymic development (Zhou et al., 
1997). Quantitative-PCR analysis of the expression of different Oas genes, as well as of the 
Rnasel gene, during T-cell development revealed that some, such as Rnasel and Oas1b, are 
specifically upregulated at the DN3a stage (Fig. 6C). Even more striking was the silencing of 
all Oas/RNaseL genes in DN3b cells after β-selection passage (Fig. 6C). This specific 
expression together with the upregulation in DuxblindxpTαCre DN3-4 cells indicates that this 
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pathway is involved in the β-selection checkpoint, potentially acting downstream of Duxbl, and 
thus mediating the T-cell developmental block observed in the DuxblindxpTαCre mice.  
In order to test whether RNaseL is involved in the Duxbl-mediated T-cell developmental 
block, we generated RNaseL defective mice (Fig. S4) and crossed them to the DuxblindxpTαCre 
line. Thymic cellularities of DuxblindxpTαCrexRNaseL-/- mice were significantly increased 
compared to their DuxblindxpTαCre counterparts, due to higher numbers of DN, DP, CD4 and 
CD8 T cells, as well as γδ-T cells (Fig. 7A-C). The DP stage was particularly affected, since 
this population was also increased in percentage, confirming that the T-cell developmental 
block was at least partly suppressed (Fig. 7B, D). The observed upregulation of the 
Oas/RNaseL system by transgenic Duxbl expression is therefore in part responsible for the 
disturbed developmental progression of DN3 cells in DuxblindxpTαCre mice. Of note, since 
DuxblindxpTαCrexRNaseL-/- mice retain an altered T-cell development compared to WT mice 
(Fig. 7B), other mechanisms must be additionally involved. 
We further investigated the connection of Duxbl to apoptosis by crossing the 
DuxblindxpTαCre to Bcl2tg mice, in order to examine whether an additional survival signal would 
extenuate the block in T-cell development of these mice, as observed in the case of interleukin-
7 receptor deficient mice (Akashi et al., 1997). Indeed, the thymic cellularity of 
DuxblindxpTαCrexBcl2tg DN, CD4 and CD8 and γδ-T cells, but especially of the DP (~3.5-fold 
change), were all significantly increased compared to DuxblindxpTαCre mice. The number of DP 
cells did not reach WT levels and phenotypically the block showing an increased DN and 
decreased DP compartment was still apparent (Fig. 8A-F), indicating that the development is 
not completely rescued by additional expression of Bcl2 alone. However, the partial rescue of 
DP cells in DuxblindxpTαCrexBcl2tg mice provides further evidence for a role of Duxbl in 
mediating the elimination of non-selected DN3 cells by inducing apoptosis. 
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4. Discussion 
 
Thymic selection of αβ-T cells requires a series of events in which TCR engagement 
follows defined rules. The majority of cells will undergo apoptosis during β-selection and the 
underlying mechanisms of this process have not been completely resolved. In the present 
study CD27 downregulation within the DN3 population was identified as a marker for cells that 
have failed to rearrange their β-chain and therefore are eliminated.  Transcriptome analysis 
both at population and single-cell level revealed high expression of the transcription factor 
Duxbl exclusively in a cluster of cells that have not yet passed β-selection and display high 
rearrangement activity. Conditional transgenic expression of Duxbl led to a disrupted DN3-to-
DN4 transition due to suppressed proliferation and induction of apoptosis, with the 
developmentally arrested cells highly resembling WT DN3a CD27low Duxblhigh cells. Silencing 
of its expression, on the other hand, resulted in decreased apoptosis. We identified up-
regulation of the apoptosis-inducing Oas/RNaseL pathway as a potential mechanism by which 
Duxbl facilitates the elimination of non-selected cells at the β-selection checkpoint. 
CD27 expression was previously described to separate intracellular β-chain positive 
from negative cells, since it gets slightly upregulated in DN3b cells (Taghon et al., 2006). 
However, the observation of CD27 downregulation in DN3a cells extends the current resolution 
of the developmental staging during T-cell development, as it marks cells that failed successful 
rearrangement and that will therefore undergo apoptosis (Fig. 1-2). The DN3a CD27high 
population, on the other hand, seems to be one stage before the rescue-versus-apoptosis 
decision as indicated by its gene expression profile, which clusters in between CD27low and 
DN3b cells (Fig. 2). This suggests that DN3a CD27high cells are still in the process of β-
selection, and are not yet assigned to a specific fate. 
The expression of Duxbl in DN3a cells, which mostly occurs in the CD27low population, 
indicates a role during β-selection (Fig. 2C-D). An association, whose molecular mechanisms 
was not defined, was suggested by in vitro studies in which expression of Duxbl affected the 
development of the DN stages (Kawazu et al., 2007). Our findings provide in vivo proof for this 
role of Duxbl and further identify this transcription factor as initiator of developmental arrest 
and apoptosis in DN3a cells that fail β-selection. It is currently unknown what signals initiate 
Duxbl expression at the DN3a stage and two scenarios can be envisaged. In the first case, 
Duxbl could be induced specifically in cells with a non-functional rearrangement. In the second 
case, it could be induced in all cells that enter the DN3a stage, thus acting as a timer for 
successful rearrangement. Duxbl expression would increase over time in cells failing β-chain 
rearrangement leading to apoptosis induction. On the contrary, cells with successful 
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rearrangement would receive a pre-TCR signal that silences Duxbl expression and leads to 
their rescue and developmental progression (Fig 2F-G).  
Our studies also showed a profound heterogeneity within the DN3 population. Indeed, 
single-cell RNA sequencing of DN2, DN3, and DN4 cells unveiled four different clusters in DN3 
thymocytes, of which two were shared with DN4 cells (Fig. 3A-C, Fig. S3A). These findings 
showed partitioning of the DN3 population into cells that have not yet undergone β-selection, 
(clusters 3 and 4) and cells that already passed this checkpoint (clusters 5 and 6). 
Consequently, the latter cells are closer to the gene expression profile of DN4 cells. 
Interestingly, Duxbl expression was mainly detected in cluster 4, which is transcriptionally 
farthermost from the DN4 clusters (Fig. 3E-F). Considering the high expression of genes 
involved in β-chain recombination and the pre-TCR in this cluster, it probably consists of cells 
continuing the process of rearrangement, including some that have failed rearrangement.  
While reduced Duxbl expression leads to a decrease in apoptosis at the DN3 stage, 
the detrimental effect of its expression in cells undergoing β-selection is exhibited in mice 
conditionally over-expressing Duxbl. The increased DN and decreased DP stages in the 
thymus of these mice showed arrest of T-cell development after the DN3 stage (Fig. 3). 
However, the block is not absolute, since mature CD4 and CD8 T cells can still be found in the 
thymus as well as in the periphery. DN3-4 cells of DuxblindxpTαCre mice stain positive for a 
functionally rearranged β-chain (Fig. 3F). Thus, these cells receive a survival and proliferation 
signal from the pre-TCR and at the same time express Duxbl, which is inhibiting their cell cycle 
and induces apoptosis (Fig. 3G; Fig. 4A-C). In a WT situation Duxbl expression is silenced 
after pre-TCR activation, but in our system Duxbl expression remains also in cells that already 
received signals via the pre-TCR, which seems to prevent their further differentiation. We 
therefore envisage that Duxbl downregulation upon pre-TCR signaling is an absolute 
requirement for further differentiation of the cells. In the few cells that have reached the DP 
stage in DuxblindxpTαCre mice pre-TCR signaling must have overcome the negative signals of 
the continuous Duxbl expression. However, as indicated by the ex vivo differentiation this 
seems to be rarely the case (Fig. 4A-C). Another interesting finding was the impact of Duxbl 
specifically on α/β T-cell development, since there was no detrimental effect on the 
development of γδ-T cells in DuxblindxpTαCre mice. In contrast, γδ-T cells were even increased, 
similar to what was described for pTα-/- mice (Fehling et al., 1995). 
The link of Duxbl to apoptosis and in particular to the activation of the Oas/RNaseL 
pathway was further strengthened by the crossing of the DuxblindxpTαCre to Bcl2tg and RNaseL-
/- mice, respectively. Both approaches resulted in a significant increase in thymic cellularity 
(Fig. 7, 8). Remarkably, the DP stage in particular was rescued in these mice, as manifested 
by a ~3.5-fold increase in DuxblindxpTαCrexBcl2tg and ~3.2 in DuxblindxpTαCreRNaseL-/- mice. 
However, neither of the two resulted in completely normalized T-cell development. In the case 
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of Bcl2 expression this can be explained by the fact that only the apoptotic effects of Duxbl are 
antagonized, whereas the antiproliferative effects that we observed are not affected. In fact, 
Bcl2 over-expression itself has a negative effect on the proliferation of cells (O'Reilly et al., 
1996), thus potentially compromising the full assessment of its anti-apoptotic effect. Similarly, 
activation of the Oas/RNaseL system seems to be just part of the mechanism by which Duxbl 
is preventing developmental progression. Therefore, we can conclude that apoptosis and the 
Oas/RNaseL system are connected to the Duxbl-mediated effects in T-cell development, and 
that additional pathways are potentially involved. 
Knock-down experiments confirmed the link of Duxbl to apoptosis induction. As implied 
by the increase of apoptosis in Duxbl transgenic DN3 cells (Figure 4), silencing resulted in a 
reduced number of apoptotic cells at the DN3 stage (Fig 5B, C). This further indicates that 
Duxbl mediates the elimination of cells that have failed β-selection and therefore its decreased 
expression rescues these cells from cell death. Since our experimental setting only leads to a 
reduction in Duxbl levels and is not resulting in its complete absence it can be envisaged that 
the remaining Duxbl is still able to efficiently eliminate a fraction of the cells, thus resulting in 
only a partial rescue.   
The Duxbl gene is part of a triplicated region in the mouse genome, which spans more 
than 300kb and contains three almost identical Duxbl copies, thus making the generation of a 
conditional knock-out mouse particularly challenging. Each of the three identical Duxbl copies 
contains two homeodomains that are responsible for sequence-specific DNA binding. The 
amino acid sequences of these homeodomains exhibit the highest similarity to those of human 
DUX4 (Wu et al., 2010). The physiological role of DUX4 in humans has not been identified so 
far. However, mis-expression of DUX4 in skeletal muscle cells is associated with 
facioscapulohumeral dystrophy, triggered by DUX4-induced apoptosis. A recent study also 
identified the RNaseL pathway to be involved in DUX4 mediated toxicity. Silencing of RNaseL 
resulted in increased survival following DUX4 transgene induction in a rhabdomyosarcoma cell 
line (Shadle et al., 2017). Thus, human DUX4 has characteristics resembling the herein 
described function of mouse Duxbl with regards to apoptosis and the link to the Oas/RNaseL 
pathway. In accordance with that, high expression of DUX4 was detected in the thymus, 
suggesting its actual function in this tissue (Das and Chadwick, 2016). Therefore, it is 
presumable that, as with Duxbl in mice, DUX4 might be involved in human T-cell development. 
Collectively, the findings described in the present study demonstrate that failed β-chain 
rearrangement coincides with low expression of CD27 in DN3 T cell progenitors. Detailed 
analysis of this CD27low population revealed the homeobox transcription factor Duxbl as a key 
regulator of β-selection by inducing apoptosis in cells that have failed to rearrange their β-
chain. 
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Figure 1 | CD27 downregulation marks cells failing β-selection  
A) tSNE (t-distributed stochastic neighbor embedding) based comparison of pTα-/- and WT DN 
cells using the surface markers CD3/B220, CD4, CD8, CD25, CD27, CD28, CD44, CD71, and 
CD117. DN stages were identified by FACS as shown in Figure S1. B) Histograms of markers 
used in (A) of WT and pTα-/- DN3 cells. (A, B) Two independent experiments were performed, 
with representative data from one experiment shown. C) Representative FACS plots for the 
separation of DN3 cells in pTα-/-, Rag2-/-, and WT mice using CD27 and CD28 expression. 
Three independent experiments were performed, with representative data from one 
experiment shown. D) Frequencies of DN3a CD27high (left panel), DN3a CD27low (middle 
panel), and DN3b (right panel) cells as percentage of DN3 in WT (n=6), pTα-/- (n=6), and Rag2-
/- (n=5) mice. Data were collected from three independent experiments. E) Histograms of 
markers used in (A) of WT DN3a CD27high and DN3a CD27low cells. Three independent 
experiments were performed, with representative data from one experiment shown.  F) 
Representative histograms showing intracellular β-chain expression (left panel) or DNA 
content (right panel) of WT DN3a CD27low, DN3a CD27high, and DN3b cells. Three independent 
experiments were performed, with representative data from one experiment shown. G) 
Representative FACS plot of Nur77 expression in CD27high and CD27low DN3a cells in Nur77GFP 
mice. Three independent experiments were performed, with representative data from one 
experiment shown.  H) Frequencies of Nur77+ cells within the DN3a CD27high or CD27low and 
DN3b population. Data were collected from three independent experiments. I) Representative 
histograms showing intracellular β-chain expression in Nur77- or Nur77+ DN3a and DN3b cells. 
DN1 DN3-4
WT  pTα-/- A
DN4DN2 DN3
tSNE-1
tS
N
E-
2
B
WT pTα-/-
CD4 CD8
CD27 CD28
CD3/B220
CD25
CD44 CD71 CD117
D
WT  pTα-/- 
E
%
 o
f D
N
3
CD27high CD27low
CD3/B220 CD4 CD8
CD25 CD27 CD28
CD44 CD71 CD117
Nur77
C
D
27
87.8 4.84
0.147.25
gated on DN3a 
44.4%
4.66%
0.28%
DNA content
89.1%
8.28%
2.73%
β-chain
DN3a CD27high
DN3b
aft
er 
3 d
ay
s
aft
er 
5 d
ay
s
0
50
100
150
200
 Ex vivo differentiation
DN3a CD27low
DN3a CD27high
WT  
C
G
J K
DN3
nu
m
nb
er
 o
f l
iv
e 
ce
lls
as
 %
 o
f i
np
ut
%
 o
f D
N
3
PB
S
a-C
D3
0
20
40
60
CD27low
****
C
D
27
PBS α-CD3
45.4
3.36
38.335.5
47.6
1.42
CD28
F
L
DN3a CD27low
CD28
C
D
27
DN3a
CD27high
DN3b
DN3a
CD27low
ga
te
d 
on
 D
N
3
Rag2-/- 
0
20
40
60
80
WT pT
α-
/-
Ra
g2
-/-
DN3a CD27high
****
***
0
20
40
60
DN3a CD27low
****
****
WT pT
α-
/-
Ra
g2
-/-
0
5
10
15
20
DN3b
****
****
***
WT pT
α-
/-
Ra
g2
-/-
%
 o
f D
N
3a
/D
N
3b
H
DN
3a
 N
ur7
7-
DN
3a
 N
ur7
7+
DN
3b
 
DN
3a
 C
D2
7h
igh
DN
3a
 C
D2
7l
ow
DN
3b
 0
200
400
600
800
Nur77 expression β-chain expression
M
FI
0
2
4
6
80
90
β-chain
DN3a
Nur77-
DN3a
Nur77+
DN3b
I
   4. Results 
 
  117 
Two independent experiments were performed, with representative data from one experiment 
shown. J) Numbers of sorted WT DN3a CD27high and DN3a CD27low cells as percentage of 
input after three and five days of culture in wells coated with Dll4 and supplemented with 
Cxcl12. Two independent experiments were performed, with representative data from one 
experiment shown. K) Representative FACS plots of CD27 and CD28 expression in pTα-/- DN3 
cells one day after intraperitoneal injection of 100μg anti-CD3ε antibodies or PBS. Three 
independent experiments were performed, with representative data from one experiment 
shown. L) Frequency of DN3a CD27low cells as percentage of DN3 in pTα-/- mice one day after 
intraperitoneal injection of 100μg anti-CD3ε antibodies (n=6) or PBS (n=5). Data were 
collected from three independent experiments. Gate numbers in FACS plots and histograms 
indicate frequencies of parent gate. Statistical analysis was done with two-tailed unpaired 
Student’s t test. *: p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001. Error bars indicate standard 
deviation. 
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Figure 2 | Transcriptome comparison reveals specific upregulation of the transcription 
factor Duxbl in DN3a CD27low cells 
A-C) Bulk RNA sequencing of DN3a CD27high, DN3a CD27low, and DN3b cells, performed as 
described in Materials and Methods. A) Heatmap illustrating the results of the gene set 
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enrichment analysis (GSEA) of DN3a CD27low versus DN3b cells using gene sets from the 
hallmark collection of the Molecular Signature Database. Only sets containing more than ten 
genes and with a false discovery rate (FDR) lower than 5% are illustrated. The fraction of 
genes overlapping across gene sets is indicated by the color intensity on the heatmap. 
Downregulated hallmark signatures related to cell cycle/division and DNA replication are 
highlighted with blue font, and upregulated ones related to apoptosis pathways in red font. B) 
Heatmap displaying the centered gene expression levels of the top 50 significantly over-
expressed genes and top 50 significantly under-expressed genes in DN3a CD27low compared 
to DN3b cells. Genes are clustered using hierarchical clustering but the dendrogram is not 
displayed. Duxbl is marked in bold font. The color gradient illustrates the normalized log2 
counts per million (CPM) values centered across all samples for each gene. C) Heatmap 
displaying the centered gene expression levels of the top ten transcription factors (i.e., 
annotated to Gene Ontology category GO:0003677) with the highest absolute fold change 
among differentially expressed genes (FDR<0.05) between DN3a CD27low and DN3b cells. 
Duxbl is marked in bold font. The color gradient illustrates the normalized log2CPM values 
centered across all samples for each gene. D) Volcano plot of differentially expressed genes 
between DN3a CD27low and DN3b cells. Genes with an FDR < 0.05 are marked in red, genes 
with an FDR > 0.05 in black.  E, F) Normalized log2CPM obtained from the bulk RNA 
sequencing (E) and relative expression obtained by quantitative PCR (F) of Duxbl in DN3a 
CD27high, DN3a CD27low, and DN3b cells. G) Relative expression of Duxbl in DN1, DN2, DN3a, 
DN3b, DN3-4, and DN4 cells. H) Relative expression of Duxbl in Nur77- and Nur77+ DN3a 
CD27high cells isolated from Nur77GFP mice. I) Relative expression of Duxbl in DN3 cells 
isolated from pTα-/- mice one day after intraperitoneal injection of 100μg anti-CD3ε antibodies 
(n=7) or PBS (n=5). As housekeeping gene β-actin was used. Data were collected from four 
(G, H) or three (F, I) independent experiments. DN stages were identified by FACS as shown 
in Figure S1. Statistical analysis was done with two-tailed unpaired Student’s t test.  *: p<0.05, 
**: p<0.01, ***: p<0.001, ****: p<0.0001. Error bars indicate standard deviation. 
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Figure 3 | Singe-cell RNA sequencing elucidates a developmental trajectory through β-
selection 
Single-cell RNA sequencing of DN2, DN3, and DN4 cells, performed as described in the 
Materials and Methods. A, B) PCA based on the 500 most variable genes across all cells. The 
colors represent cells from the different populations (A) or the different clusters (B). Contour 
lines indicate the density of the DN2, DN3, and DN4 cells in the PCA space. C) Relative 
frequency of DN2, DN3, and DN4 cells within the different clusters. D) Heatmap displaying the 
centered and scaled expression across the 18,128 cells of the top cluster-specific genes 
(resulting from the union of the top 23 differentially expressed genes from each pairwise 
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comparison between clusters). The color gradient illustrates the normalized log-counts values 
centered and scaled across all samples for each gene. Colors at the top indicate the 
membership of cells to the different clusters. Font colors indicate genes involved in 
recombination and pre-TCR (green), cell cycle/division and DNA replication (blue), and 
negative regulation of apoptosis (red). E) Expression of Duxbl shown in the PCA space. Size 
and color intensity of the dots indicate relative expression level of Duxbl in each cell and the 
colors correspond to the respective population (left panel) or cluster (right panel). F) Bar plot 
showing the average normalized log-counts of Duxbl across all cells from each cluster. 
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Figure 4 | Blocked T-cell development in DuxblindxpTαCre mice 
A) Total numbers of live, nucleated cells in the thymus, spleen, and bone marrow of WT (n=6), 
Duxblind (n=5), and DuxblindxpTαCre (n=6) mice. Data were collected from three independent 
experiments. B) Representative FACS plots of CD4 and CD8 expression in total live cells 
(upper panel) and CD44 and CD25 expression in DN cells (lower panel) of WT, Duxblind, and 
DuxblindxpTαCre mice. DN cells were gated as CD4, CD8, CD3 and B220 negative. Three 
independent experiments were performed, with representative data from one experiment 
shown. C) Numbers of DN, DP, CD4 T cells, CD8 T cells, and γδ-T cells in WT (n=6), Duxblind 
(n=5), and DuxblindxpTαCre (n=6) mice. D) Frequencies of DN1, DN2, DN3, DN3-4, and DN4 
cells as percentage of DN cells in WT (n=6), Duxblind (n=5), and DuxblindxpTαCre (n=6) mice. 
(C, D) Data were collected from three independent experiments. E) Representative histogram 
showing the size (FSC-A) of DN3-4 cells in WT, Duxblind, and DuxblindxpTαCre mice. Three 
independent experiments were performed, with representative data from one experiment 
shown. F, G) Histograms showing the DNA content (F) and intracellular β-chain expression 
(G) of DN3, DN3-4, and DN4 cells in WT, Duxblind, and DuxblindxpTαCre mice. Four independent 
experiments were performed, with representative data from one experiment shown. H) 
Numbers of sorted DN3 cells from WT and DuxblindxpTαCre mice as percentage of input after 
three and five days of culture in wells coated with Dll 4 and supplemented with Cxcl12. I) 
Representative FACS plots of sorted DN3 cells from WT and DuxblindxpTαCre mice showing 
CD4 and CD8 expression after five days of culture. J) Frequencies of living, early apoptotic, 
and late apoptotic cells after three days of culture of sorted DN3 cells from WT and 
DuxblindxpTαCre mice. Living cells were defined as AnnexinV- 7AAD-, early apoptotic cells as 
AnnexinV+ 7AAD-, and late apoptotic cells as AnnexinV+ 7AAD+. (H-J) Three independent 
experiments were performed, with representative data from one experiment shown. Gate 
numbers in FACS plots and histograms indicate frequencies of parent gate. DN stages were 
identified by FACS as shown in Figure S1. Statistical analysis was done with two-tailed 
unpaired Student’s t test. *: p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001. Error bars indicate 
standard deviation. 
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Figure 5 | Decreased apoptosis in 
DN3 cells after Duxbl knock-down 
A) Knockdown efficiency of four 
different shRNAs illustrated by 
relative expression of Duxbl in the 
40E1 cell line over-expressing Duxbl 
with or without additional transduction 
of the described shRNAs. As 
housekeeping gene β-actin was used. 
Two independent experiments were 
performed, with representative data 
from one experiment shown. B) 
Frequencies of AnnexinV+ cells within 
GFP+ (left panel) or GFP- (right panel) 
cells transduced with an empty vector 
control or shRNA 3-2 four days after 
removal of IL-7 from the fetal liver 
OP9-Dll1 cultures. Data were 
collected from three independent 
experiments. C) Representative 
FACS plots showing CD4 and CD8 
expression (left panel), CD44 and 
CD25 expression within DN (middle 
panel), and AnnexinV and 7AAD 
levels within DN3 cells (right panel) four days after removal of IL-7 from the fetal liver OP9-Dll1 
cultures. Plots were gated either on GFP+ or GFP- cells. Three independent experiments were 
performed, with representative data from one experiment shown. Gate numbers in FACS plots 
indicate frequencies of parent gate. Statistical analysis was done with two-tailed unpaired 
Student’s t test. *: p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001. Error bars indicate standard 
deviation. 
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Figure 6 | Gene expression analysis identifies upregulation of the Oas/RNaseL system 
in Duxbl transgenic DN3-4 cells 
A, B) Bulk RNA sequencing of WT and DuxblindxpTαCre DN3-4 cells, performed as described 
in the Materials and Methods. A) Heatmap and hierarchical clustering based on the matrix of 
Spearman correlation across the samples of WT and TG (derived from DuxblindxpTαCre mice) 
DN3-4 cells together with WT DN3a CD27high, DN3a CD27low, and DN3b cells (using the 25% 
most variable genes). Data were corrected for batch effects across datasets. B) Boxplots 
showing the normalized log2 CPM of Rnasel, Oas1a, Oas1b, Oas1c, Oas1g, Oas2, Oas3, 
Oasl1, and Oasl2 in WT and TG (derived from DuxblindxpTαCre mice) DN3-4 cells. Log2 FC and 
FDR are indicated for each gene. C) Relative expression of Rnasel, Oas1a, Oas1b, Oas2, 
Oas3, and Oasl1 in WT DN2, DN3a, DN3b, and DN4 cells. As housekeeping gene β-actin was 
used. Data were collected from four independent experiments. Statistical analysis was done 
with two-tailed unpaired Student’s t test. *: p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001. 
Error bars indicate standard deviation (B) or standard error of the mean (C). 
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Figure 7 | Disruption of the Oas/RNaseL system in DuxblindxpTαCre mice extenuates the 
perturbed T-cell development  
A) Total number of live, nucleated cells in the thymus of WT (n=8), DuxblindxpTαCre (n=8), 
RNaseL-/- (n=7), and DuxblindxpTαCrexRNaseL-/- (n=8) mice. Data were collected from four 
independent experiments. B) Representative FACS plots of CD4 and CD8 expression in total 
live cells (upper panel) and CD44 and CD25 expression in DN cells (lower panel) of WT, 
DuxblindxpTαCre, RNaseL-/-, and DuxblindxpTαCrexRNaseL-/- mice. DN cells were gated as CD4, 
CD8, CD3 and B220 negative. Four independent experiments were performed, with 
representative data from one experiment shown. C) Numbers of DN, DP, CD4 T cells, CD8 T 
cells, and γδ-T cells in WT (n=8), DuxblindxpTαCre (n=8), RNaseL-/- (n=7), and 
DuxblindxpTαCrexRNaseL-/- (n=8) mice. D) Frequencies of DN, DP, CD4 T cells, CD8 T cells, 
and γδ-T cells in WT (n=8), DuxblindxpTαCre (n=8), RNaseL-/- (n=7), and 
DuxblindxpTαCrexRNaseL-/- (n=8) mice. (C, D) Data were collected from four independent 
experiments. Gate numbers in FACS plots indicate frequencies of parent gate. DN stages were 
identified by FACS as shown in Figure S1. Statistical analysis was done with two-tailed 
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unpaired Student’s t test. *: p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001. Error bars indicate 
standard deviation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   4. Results 
 
  128 
 
 
Figure 8 | Transgenic Bcl2 expression restores T-cell populations in DuxblindxpTαCre 
mice 
A) Total number of live, nucleated cells in the thymus of WT (n=6), DuxblindxpTαCre (n=6), 
Bcl2tg (n=5), and DuxblindxpTαCrexBcl2tg (n=7) mice. Data were collected from four 
independent experiments. B) Representative FACS plots of CD4 and CD8 expression in total 
live cells (upper panel) and CD44 and CD25 expression in DN cells (lower panel) of WT, 
DuxblindxpTαCre, Bcl2tg, and DuxblindxpTαCrexBcl2tg mice. DN cells were gated as CD4, CD8, 
CD3 and B220 negative. Four independent experiments were performed, with representative 
data from one experiment shown.  C) Numbers of DN, DP, CD4 T cells, CD8 T cells, and γδ-
T cells in WT (n=6), DuxblindxpTαCre (n=6), Bcl2tg (n=5), and DuxblindxpTαCrexBcl2tg (n=7) mice. 
Data were collected from four independent experiments. Gate numbers in FACS plots indicate 
frequencies of parent gate. DN stages were identified by FACS as shown in Figure S1. 
Statistical analysis was done with two-tailed unpaired Student’s t test. *: p<0.05, **: p<0.01, 
***: p<0.001, ****: p<0.0001. Error bars indicate standard deviation. 
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Figure S1 | Gating strategy for identification of DN stages 
Representative FACS plots showing the gating strategy to identify DN stages in WT (upper 
panel and pTα-/-  (lower panel) mice. The different populations were all defined as CD4-CD8-
CD3-B220- and additionally as follows: DN1: CD25-CD44highCD117high; DN2: 
CD25highCD44highCD177high; DN3: CD25highCD44lowCD117low; DN3-4: 
CD25intCD44lowCD117lowCD28+; DN4: CD25-CD44-CD117-CD28+. Two independent 
experiments were performed, with representative data from one experiment shown. 
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Figure S2 | Gene expression analysis of WT DN3a CD27high, DN3a CD27low and DN3b 
cells 
Bulk RNA-sequencing on DN3a CD27high, DN3a CD27low, and DN3b cells, performed as 
described in the Materials and Methods. A) Heatmap of Spearman correlation coefficients 
across samples (using the 25% most variable genes). B) Projection of the samples on the 2 
first axes of a principal component analysis (based on 25% most variable genes).  
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Figure S3 | Single-cell RNA sequencing-based clustering of DN2, DN3, and DN4 cells 
Single-cell RNA sequencing of DN2, DN3, and DN4 cells, performed as described in the 
Materials and Methods. A) Projection of the cells belonging to each cluster on the two first 
component of a PCA. Colors represent the different populations. Contour lines represent the 
density of the DN2, DN3, and DN4 cells in the PCA space. B) Heatmap of average expression 
across cells of each cluster of marker genes involved in T-cell development, grouped based 
on their known expression profile either in DN2, DN2/DN3, DN3, DN3/DN4, or DN4 cells, for 
the different clusters. The color gradient indicates the centered and scaled average normalized 
log-counts of each marker across all cells from each cluster.  
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Figure S4 | Generation of conditional Duxbl transgenic mice 
A) Schematic figure of the construct used for the generation of conditional Duxbl transgenic 
mice. CAG promotor driving the expression is followed by an mCherry stop-casette that is 
flanked by lox-P sites, followed by Duxbl1 cDNA coupled via an internal-ribosomal-entry-site 
(IRES) to the enhanced green fluorescent protein (eGFP) gene, ending with the bovine growth 
m
C
he
rry
eGFP
Duxblind x pTαCreDuxblind 
A
B
CAG promoter mCherry Duxbl1 IRES EGFP
loxP loxP bpA
STOP
93,1 0,45
0,156,28
98,9 0,11
3,07E-31,02
0
100,0 0
00,023
104 105
103
104
105 3,02 31,7
64,80,50
0 103 104 105
0
103
104
105
93,4 0,59
4,631,43
105
98,1 0,35
1,060,46
0,013 0
0100,0
0,056 0,034
0,01199,9
0,22 0,047
0,3499,4
WT
C
D
DN1
DN2
DN3a
DN3b
DN3-4
DN4
WT DN
eGFP
0%
2%
95%
99%
100%
100%
0%
DN1
DN2
DN3a
DN3b
DN3-4
DN4
WT DN
mCherry
100%
100%
100%
99%
58%
52%
0%
Th
ym
us
Sp
le
en
Bo
ne
 M
ar
ro
w
Exon:    1 2 3 4 5 6
STOP
STOPSTOP
ATG
ATG
Cas9 induced DSBs
Rnaselwt
Rnasel-/-
E
   4. Results 
 
  133 
hormone polyadenylation site (bpA). B) Representative FACS plots of mCherry and eGFP 
expression in the thymus (upper panel), spleen (middle panel), and bone marrow (lower panel) 
of WT, Duxblind, and DuxblindxpTαCre mice. C, D) Representative histograms showing the 
frequencies of eGFP (C) and mCherry (D) positive cells of DN1, DN2, DN3a, DN3b, DN3-4, 
DN4 cells in the thymus of DuxblindxpTαCre mice, and WT DN cells. (B-D) Three independent 
experiments were performed, with representative data from one experiment shown. E) 
Schematic figure of the genome editing performed for the generation of RNaseL-/- mice. Two 
double-strand breaks (DSBs) were introduced in exon 1 of the Rnasel gene using the 
CRISPR/Cas9 system. This resulted in a 328 base-pair deletion, thereby inducing a frame shift 
and a premature stop-codon (STOP). For analysis mice were bred to homozygosity. Gate 
numbers in FACS plots and histograms indicate frequencies of parent gate. DN stages were 
identified by FACS as shown in Figure S1. 
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Figure S5 | Analysis of DuxblindxpTαCre mice 
A) Frequency of cells in cycle in DN3, DN3-4, and DN4 cells of WT and DuxblindxpTαCre mice 
based on the content of DNA in each cell detected by FACS. B) Frequency of cells positive for 
intracellular β-chain expression in DN3, DN3-4, and DN4 cells of WT and DuxblindxpTαCre mice. 
C) Frequencies of CD4 T cells (left panel), CD8 T cells (middle panel), and γδ-T cells (right 
panel) in the spleen and lymph nodes of WT (spleen: n=6, lymph nodes: n=4), Duxblind (spleen: 
n=5, lymph nodes: n=4), and DuxblindxpTαCre  (spleen: n=6, lymph nodes: n=4) mice. (A-C) 
Data were collected from four (A, B) or three (C) independent experiments. D) Representative 
FACS plots of sorted DN3 cells from WT and DuxblindxpTαCre mice after three days of culture 
showing living, early apoptotic, and late apoptotic cells based on AnnexinV and 7AAD 
expression of sorted DN3 cells from WT and DuxblindxpTαCre mice. Living cells were defined 
as AnnexinV- 7AAD-, early apoptotic cells as AnnexinV+ 7AAD-, and late apoptotic cells as 
AnnexinV+ 7AAD+. Three independent experiments were performed, with representative data 
from one experiment shown. Gate numbers in FACS plots indicate frequencies of parent gate. 
DN stages were identified by FACS as shown in Figure S1. Statistical analysis was done with 
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two-tailed unpaired Student’s t test. *: p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001. Error 
bars indicate standard deviation. 
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5.	Discussion	
  
 During life blood cells have to be continuously produced in the bone marrow. The 
developmental process starts with the hematopoietic stem cells at the apex, which gradually 
differentiate into the different cell types of the hematopoietic system. Multiple extrinsic and 
intrinsic molecular mechanisms guide this progress by regulating transcriptional networks and 
thereby establishing gene expression profiles that direct the cells through intermediate 
progenitor stages up to their final maturation. For the generation of the adaptive immunity, in 
addition, random recombination of the gene segments encoding antigen receptors has to be 
initiated and controlled ensuring the production of the incredible diversity of the antigen 
receptor specificities resulting in the protection against any pathogen. Any alteration in these 
strictly controlled processes can result in severe disturbances of the body’s immune system, 
which can cause the development of immunodeficiency, autoimmunity, and leukemia. 
Therefore, investigation of the molecular mechanisms and regulations that guide the 
differentiation and selection processes is important for the understanding and potential 
treatment of immune pathology. 
 
5.1.		 The	roles	of	Flt3-ligand	and	IL-7	in	lymphopoiesis		
With the use of different transgenic and knockout mouse models we explored the role 
of the cytokines Flt3-ligand and IL-7 in lymphocyte development.  The crucial function of IL-7 
for the generation of B and T cells has been previously demonstrated by the dramatic effect of 
the absence either of the cytokine or its receptor (Peschon et al., 1994; von Freeden-Jeffry et 
al., 1995). Upon Bcl2 over-expression, T-cell but not B-cell development was rescued, 
indicating that IL-7 acts in an instructive manner on B-cell progenitors (Akashi et al., 1997; 
Kondo et al., 1997a; Maraskovsky et al., 1997; Maraskovsky et al., 1998). This hypothesis was 
further strengthened by the observation of reduced Ebf1 expression in CLPs of IL-7 deficient 
mice, suggesting that IL-7 initiates the B-cell fate by induction of Ebf1 and subsequently of 
Pax5 expression (Dias et al., 2005). However, more recently results opposing that hypothesis 
were reported. Thus, Bcl2 over-expression in conditional Stat5-/- mice was shown to be 
sufficient to rescue the development of CD19+ cells (Malin et al., 2010). Moreover, it was shown 
that Stat5 signaling is responsible for the induction of the anti-apoptotic factor Mcl1, suggesting 
a role of IL-7 as survival factor. In accordance with that, the Ebf1 reduction within the CLP 
compartment in Il7-/- mice (Tsapogas et al., 2011) could also be explained by the specific loss 
of Ebf1+ cells within the Ly6D+ CLP compartment, caused by missing survival signals rather 
than an active induction of Ebf1 by IL-7.  
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 Even though the role of IL-7 in survival of CD19+ cells has been elegantly shown by 
over-expressing Bcl2 in Stat5-/- mice (Malin et al., 2010), these studies could not address the 
potential role of IL-7 in instructing B cell commitment, which is initiated at the molecular level 
prior to CD19 expression, at the Ly6D+ CLP/EPLM stage (Jensen et al., 2018; Mansson et al., 
2008). Indeed, in the conditional Rag1CrexStat5-/- mice used by Malin et al no reduction was 
observed in the number of CLP, as it is the case with IL-7-/- mice (Dias et al., 2005; Tsapogas 
et al., 2011), suggesting that efficient deletion of Stat5 occurred only after commitment to the 
B-cell lineage and CD19 expression. Therefore, we further investigated the role of IL-7 in the 
Ly6D+ CLP and EPLM compartments. Breeding of IL-7-/- to Flt3-ligand transgenic mice 
(hereafter FLtg and FLtgxIL-7-/- mice) resulted in a complete rescue of the Ly6D+ CLP/EPLM 
compartment as well as of the early B-cell populations (section 4.1.1.; Figure 2). The main 
effect of Flt3-ligand is induction of proliferation of Flt3+CD19- cells, as seen by increased 
cycling and the expansion of the CLP/EPLM progenitors in FLtg mice (section 4.1.1.; Figure 
1+6). Furthermore, it expands also upstream precursors within the LSK compartment, thereby 
further increasing the input into the CLP/EPLM compartment (Tsapogas et al., 2014). 
Transgenic expression of IL-7 on the other hand does not lead to an expansion of Ly6D+ 
CLP/EPLM cells or any significant change in their cycling profile, therefore excluding a 
proliferative role at that stage in development (section 4.1.1.; Figure 5). Due to the use of ligand 
and not receptor knockout mice we were further able to assess the B-cell potential of these 
cells in vitro. In agreement with the recovery of early B-cell populations in FLtgxIL-7-/- mice, the 
B-cell potential of Ly6D+ uncommitted progenitors was fully restored (section 4.1.11; Figure 
3A). Interestingly, the same rescue of potential was also observed after crossing of the IL-7-/- 
mice to the Bcl2 transgenic strain, confirming that the major role of IL-7 prior to commitment is 
survival (section 4.1.1.; Figure 4). Thus, the dramatic increase of Ly6D+ CLP and EPLM due 
to high levels of Flt3-ligand surpasses the need of IL-7 as survival factor at this stage, resulting 
in enough cells committing to the B-cell lineage for efficient populating of the early B-cell 
progenitor pool. This clearly indicates a rather permissive role of IL-7 in B-cell differentiation, 
acting as a survival factor on uncommitted progenitor cells. However, Flt3-ligand cannot 
replace the proliferative function of IL-7 on pre-B cells, explaining the still apparent reduction 
of the IgM+ compartments in these mice (section 4.1.1.; Figure 2C+D). 
 The observation that high levels of Flt3-ligand can replace the need of IL-7 for the 
generation of B-cells might also be the explanation for the discrepancy on the IL-7 dependency 
of fetal and adult B-cell development. It can be postulated that fetal Ly6D+ CLP/EPLM 
progenitors are exposed to higher levels of Flt3-ligand and/or are more sensitive to its 
downstream signaling than their adult counterparts, thus eliminating the need for IL-7. This 
hypothesis is supported by the strong dependency of fetal B lymphopoiesis on Flt3-ligand 
(Jensen et al., 2008).  
   5. Discussion 
 
  142 
 Even though these results clearly demonstrate the importance of Flt3-ligand for the 
generation of B cells, there is no evidence for an instructive role, but rather for a permissive 
proliferative function on the uncommitted progenitor cells. This is evident by the reduced levels 
of Ebf1 and Pax5 in FLtg Ly6D+ EPLM progenitors compared to their WT counterparts, which 
is most likely due to reduced numbers of Ebf1+Ly6D+CD19- progenitor cells (section 4.1.1.; 
Figure 3B-D). Since Flt3 and Pax5 are not expressed on the same cells, one possible 
explanation is that enhanced Flt3 signaling keeps the uncommitted CD19- cells in a more 
“undifferentiated” state (Holmes et al., 2006), or it might be that another not yet known factor 
that is responsible for Ebf1 and Pax5 induction is limited in FLtg mice. Moreover, as recently 
shown by Rodrigues et al, Ly6D+IL-7R+Flt3+CD19- progenitors can also differentiate to pDCs 
(Rodrigues et al., 2018). Thus, high Flt3-ligand could lead to more cells differentiating towards 
this pathway, resulting in a reduced fraction of the progenitors committing to the B-cell 
pathway. Indeed, pDCs are one of the most increased populations in FLtg mice (Tsapogas et 
al., 2014). 
 Remarkably, even though high levels of Flt3-ligand can rescue the initiation of B-cell 
commitment in IL-7-/- mice, over-expression of Flt3-ligand results in reduced numbers of pre-B 
and immature B cells under physiological IL-7 levels (Tsapogas et al., 2014). As Flt3 is not 
expressed by pre-B cells this effect can only be indirect. Since IL-7R+ progenitor populations 
and pDCs are heavily increased in these mice, we hypothesized that IL-7 availability might 
become limited for pre-B cells, which would dampen sufficient proliferation at that stage. 
Binding of IL-7 to its receptor was previously suggested as a mechanism that is regulating the 
abundance of the cytokine (Mazzucchelli and Durum, 2007).  Previous experiments have 
shown that injection of IL-7/anti-IL-7 complexes into FLtg mice indeed restored the numbers 
of pre-B cells (Tsapogas et al., 2014). In order to further test this theory and to investigate the 
synergistic role of Flt3-ligand and IL-7 in lymphopoiesis, we crossed FLtg with mice over-
expressing IL-7 (hereafter IL-7tg and FLtgxIL-7tg). Analysis of bone marrow B-cell 
development in FLtgxIL-7tg mice revealed a similar decrease in numbers of the pre-B and 
immature B cells stage compared to IL-7tg mice (section 4.1.2.; Figure 2B+C). Thus, reduced 
IL-7 availability can be excluded as the reason for the reduced pre-B cells in FLtg mice.  It is 
still feasible that a not yet known, but required factor gets limited upon Flt3-ligand over-
expression. Alternatively, a factor that has a detrimental effect on pre-B cells might be elevated 
in FLtg mice. Potential candidates that could cause such an effect are type I interferons, which 
inhibit the IL-7 dependent growth of B-cell progenitors as wells as of DN thymocytes (Lin et al., 
1998; Su et al., 1997; Wang et al., 1995). Elevated levels of type I interferons in FLtg mice 
could be a result of the massive expansion of cells like pDCs, which are the main source of 
type I interferons in the context of viral infections, or bone marrow resident macrophages. 
Similar to B-cell progenitors, early DN stages in the thymus are reduced upon Flt3-ligand over-
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expression (section 4.1.2.; Suppl. Figure 2). A secondary effect, such as elevated interferon 
levels, could be envisaged for this observation as well. Since already DN1 cells are also 
affected by high Flt3-ligand levels, the homing capacity of the thymus seeding progenitor might 
be changed due to high levels of Flt3-ligand, resulting in a reduced number of seeding cells, 
even though all the potential thymus seeding progenitor (TSP) populations are dramatically 
increased in the bone marrow of these mice. Alternatively, the TSP or ETP lineage potential 
might be altered due to high levels of Flt3-ligand, leading to the divergence from T-cell 
generation to the production of, for instance, myeloid cells.  
 Further analyses of FLtgxIL-7tg mice revealed a synergistic effect of the two cytokines 
in lymphopoiesis. This is evident in the tremendous expansion of progenitor and mature 
lymphocyte populations, resulting in a huge enlargement of secondary lymphoid organs like 
the spleen and lymph nodes (section 4.1.2.; Figure 1-5).  High levels of Flt3-ligand expand the 
early progenitor population such as MPPs, CLPs, and EPLMs. Additional IL-7 expression does 
not affect the proliferation of CLPs and EPLMs, but it acts as a survival factor on these cells. 
However, IL-7 instead promotes the proliferation of committed CD19+ progenitors. Together 
the elevated levels of both cytokines result in a not only additive effect on the expansion of the 
cells, but rather in a synergistic one in comparison to the single transgenic counterparts. This 
is most profoundly manifested in the secondary lymphoid organs which can enlarge their size 
to incorporate more cells, contrary to the bone marrow where space is restricted. Strikingly, 
the spleen and also the lymph nodes of FLtgxIL-7tg mice contained not only mature, but also 
significant numbers of all B-cell progenitor stages (section 4.1.2.; Figure 3). Since Flt3-ligand 
expands also MPPs, we wondered whether these cells are present in the secondary lymphoid 
organs of the double transgenic mice as well. Indeed, we were able to detect substantial 
numbers of MPPs in the spleen and also within lymph nodes (section 4.1.2.; Figure 5). This 
effect cannot be attributed to high levels of IL-7, since MPPs are negative for its receptor. One 
potential explanation for the accumulation of all these progenitor populations in the periphery 
is that they are pushed into migration due to space and resource restrictions in the bone 
marrow. Indeed, an increase of all precursor B-cell stages as well as uncommitted progenitors 
such as CLPs, EPLMs, and even MPPs could be detected in the blood of FLtgxIL-7tg mice 
(section 4.1.2.; Figure 6). Interestingly, true HSCs, defined as CD48-CD150+ LSK, could not 
be detected in the lymph nodes and only in small numbers in the spleen, and were even 
decreased in the bone marrow (section 4.1.2.; Figure 5). This reduction was already previously 
described for FLtg mice and is therefore a consequence of increased availability of Flt3-ligand 
(Tsapogas et al., 2014). Again, this reduction might be caused by an indirect effect, since 
HSCs themselves are surface negative for Flt3. However, it has to be considered that low 
amounts of the receptor might be expressed below the FACS detection limit, since in some of 
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them Flt3 mRNA could be detected (Mooney et al., 2017). Moreover, an effect on SLAM marker 
expression by high Flt3-ligand levels cannot be excluded.  
 The functionality of the precursors found in lymph nodes of FLtgxIL-7tg mice was 
assessed by transplantation experiments, revealing multilineage reconstitution after the 
primary and even after a secondary transplantation (section 4.1.2.; Figure 7+8). Thus, lymph 
nodes of double transgenic mice can support the accumulation of functional multipotent 
progenitors and potentially even HSCs, since reconstitution of multiple lineages after a 
secondary transplantation is indicative of self-renewal capacity. Furthermore, the functionality 
of the precursors indicates that the lymph node is a site of active ongoing hematopoiesis, but 
further investigations are needed to fully resolve this notion. As a result of the described data, 
it becomes evident that hematopoiesis can take place also in secondary lymphoid organs 
under extreme circumstances as it is the case in FLtgxIL-7tg mice. These animals exhibit the 
phenotype of a lympho- and myelo-proliferative disease. Therefore, these findings have also 
a clinical significance. In patients with leukemia or a lympho-proliferative disease, apart from 
the bone marrow, peripheral lymphoid organs should also be considered as a site where 
therapy-resistant leukemic cells could reside after treatment.  
Collectively, the presented data on the role of Flt3-ligand and IL-7 demonstrate their 
collaborative promotion of B-cell development. Flt3-ligand instructs the cells at the MPP stage 
into the direction of the lymphoid and myeloid lineages and further supports their proliferation 
as well as the expansion of downstream uncommitted lymphoid progenitors such as CLPs and 
EPLMs. IL-7 on the other hand is mainly responsible for survival of the CLP and EPLM 
populations, whereas it becomes essential as a survival and proliferation factor for early CD19+ 
B-cell progenitors. Thus, Flt3-ligand as well as IL-7 possess permissive functions for the 
effective development of lymphocytes and are crucial for the establishment of a functional 
adaptive immune system. 
 
5.2.		 Regulation	of	β-selection	by	Duxbl	
 The second part of the thesis was focused on the molecular mechanisms that guide 
the development of T-cell progenitors, and in particular their passage through β-selection. The 
major aim of T-cell development is the successful production of a TCR. Prerequisite for 
success is the passage of several important checkpoints that ensure the developmental 
progression only of cells with functional rearrangements of their antigen-receptor chains. 
During β-selection almost half of the cells fail to productively rearrange their β-chain and 
therefore have to undergo apoptosis in order to prevent the accumulation of non-functional 
cells (Mallick et al., 1993). However, until now only little is known about the exact molecular 
mechanisms that regulate the efficient elimination of these cells.  
   5. Discussion 
 
  145 
 High CD27 expression within the DN3 population was previously linked to successful 
passage through β-selection, as the majority of these cells stained positive for the β-chain 
intracellularly (Taghon et al., 2006). In the present study we were able to show that in addition 
to that, the downregulation of CD27 is associated with the failure of productive recombination 
(section 4.2.1.; Figure 1). Thus, these CD27- cells are blocked in their development and will 
undergo apoptosis. Using this addition to the currently established set of markers for the 
description of T-cell development, the DN3 stage could be further subdivided into CD27+CD28+ 
DN3b cells, that have successfully passed β-selection, CD27-CD28- DN3a cells, which are 
prone to undergo apoptosis due to unproductive rearrangements, and CD27+CD28- DN3a 
cells, whose fate seems to be not yet decided and are still in the process of recombination. 
These findings enabled us to investigate the transcriptional changes and events that occur 
during β-selection in much more detail than ever before.  
 Transcriptomic analysis of the different DN3 subsets revealed an up-regulation of 
apoptosis related pathways in CD27- DN3a cells (section 4.2.1.; Figure 2). This confirmed our 
initial conclusions that this population mainly contains cells, which will be eliminated because 
of unsuccessful β-chain rearrangements. In particular, p53 pathway associated genes were 
increased, which matches with previous reports that argued for a main function of this pathway 
during apoptosis induction at the β-selection checkpoint (Anderson et al., 2007; Bogue et al., 
1996; Costello et al., 2000; Haks et al., 1999; Mombaerts et al., 1995; Rashkovan et al., 2014; 
Saba et al., 2011; Stadanlick et al., 2011). By focusing on the differential gene expression of 
transcriptional regulators, our attention was drawn to the specific expression of the 
transcription factor Duxbl in DN3a cells and in the CD27low population in particular (section 
4.2.1.; Figure 2B-G). A single-cell RNA-seq analysis of the DN2, DN3, and DN4 stages further 
confirmed the heterogeneity observed in the DN3 population, by subdividing them into cells 
prior to and post β-selection (section 4.2.1.; Figure 3A-C). Similarly, in this dataset Duxbl 
expression was restricted to cells that have not yet passed β-selection and that are 
transcriptionally farthermost from cells of the DN4 stage (section 4.2.1.; Figure3E+F). 
Considering additionally the high expression at this stage of genes associated with the 
recombination process and pre-TCR formation, these data confirm that Duxbl expressing cells 
are most likely either in the process of rearrangement or have failed to do so. Together with a 
previous in vitro report that described Duxbl as a regulator of DN thymocyte development 
(Kawazu et al., 2007), this precise expression pattern indicated a potential role of Duxbl in the 
process of β-selection. Indeed, conditional transgenic expression of Duxbl resulted in a 
blocked DN3-to-DP transition due to reduced cell-cycle induction and increased apoptosis 
(section 4.2.1.; Figure 4). Therefore, we propose Duxbl to be a key regulator of β-selection that 
mediates developmental arrest and the elimination of DN3 cells that failed successful β-chain 
recombination. Since the mechanism that initiates Duxbl expression is currently unknown, two 
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potential scenarios of how Duxbl mediates effective and specific elimination are conceivable. 
In the first scenario, Duxbl expression is specifically induced in cells that failed to productively 
rearrange their β-chain on both alleles. Alternatively, Duxbl expression could be induced in all 
cells that initiate β-chain recombination, coming into effect in a time dependent manner. For 
instance, in cells that fail successful rearrangements, Duxbl expression would increase over 
time ultimately resulting in cell death. On the contrary, in cells with a productive β-chain that 
subsequently is able to pair with pTa to form the pre-TCR, Duxbl expression would be turned 
off, allowing these cells to proceed to further differentiation. The latter hypothesis is supported 
by the fact that Duxbl expression is terminated upon triggering of the pre-TCR (section 4.2.1.; 
Figure 2H+I).  
The fact that T-cell development is not completely blocked in conditional Duxbl 
transgenic mice might arise from the obscurity that cells which managed to rearrange a 
productive β-chain receive two conflicting signals in these mice. On one side, since they 
express a β-chain, they get proliferation and survival signals from the pre-TCR, whereas at the 
same time contradictory Duxbl expression inhibits their cycling and induces apoptosis. Thus, 
in Duxbl transgenic mice, in order for DN3 progenitors to reach the next developmental stages, 
the pro-survival signals must overcome the detrimental effects of Duxbl expression. This could 
explain the accumulation of cells between the DN3 and DN4 stage of Duxbl transgenic mice. 
Nevertheless, the majority of cells are eliminated by Duxbl as clearly indicated by the almost 
complete block observed during ex vivo differentiation of DN3 cells isolated from Duxbl 
transgenic mice (section 4.2.1.; Figure 4H-J).  
Interestingly, high Duxbl expression exclusively affects α/β T-cell development. γ/δ T-
cell numbers are even slightly increased (section 4.2.1.; Figure 4C), even though the pTαCre 
induces Duxbl expression also in the γ/δ T-cell lineage (Luche et al., 2013). In order to 
investigate the effects of transgenic Duxbl expression on other hematopoietic cell types two 
additional Cre lines were used. Targeted expression in B cells was achieved using the mb1Cre 
line. Strikingly, transgenic Duxbl expression blocked the development of B cells at the pre-
BCR checkpoint (unpublished observation). Since no endogenous Duxbl expression can be 
detected during B-cell development this must be a result of the artificial over-expression of 
Duxbl in these cells. However, the concordance with its effect on T-cell development, as it 
blocks both at the pre-BCR and pre-TCR checkpoint, suggests that the reason for its impact 
on the development of B cells results from the high similarities between these processes. 
Expression of Duxbl in all hematopoietic lineages was induced by the use of the vavCre line. In 
accordance with the pTαCre and the mb1Cre intercrosses, T- and B-cell development showed 
the corresponding block as described above. Of particular interest was also the potential effect 
of transgenic Duxbl expression on pDCs, as they are the only hematopoietic cells apart from 
DN3 thymocytes that display endogenous Duxbl expression. pDCs numbers were not affected 
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by over-expression of Duxbl (unpublished observation). However, a potential role for the 
functionality of pDCs cannot be excluded from these experiments and further investigations 
are needed to unravel the reason for Duxbl expression in these cells. In accordance with the 
unchanged phenotype of pDCs, all other populations we analyzed, such as conventional DCs, 
NK cells, granulocytes, and macrophages/monocytes were not affected by transgenic Duxbl 
expression (unpublished observation). Thus, no general detrimental effect of Duxbl could be 
detected, indicating a specific context-dependent action of Duxbl on α/β DN3 thymocytes, with 
the exception of pre-B cells, that display a similar phenotype at the corresponding 
developmental stage in development.  
The connection of Duxbl expression to apoptosis induction was further strengthened 
by the profound up-regulation of the Oas/RNaseL pathway upon Duxbl over-expression 
(section 4.2.1.; Figure 6). Previously, deficiency of RNaseL was shown to result in resistance 
of thymocytes to apoptosis and thereby to increased total thymocyte numbers (Castelli et al., 
1998; Zhou et al., 1997).  We approached this potential link by the generation and breeding of 
RNaseL-/- to Duxbl transgenic mice. In these double-mutant mice thymocyte numbers were 
significantly increased at all developmental stages, clearly indicating that Duxbl acts via the 
Oas/RNaseL pathway in pre-T cells (section 4.2.1.; Figure 7). However, the still present block 
of development indicates that other mechanisms and pathways must be additionally involved. 
The same holds true for the rescue in thymocyte numbers after crossing of the Duxbl 
transgenic to the Bcl2 transgenic mouse line (section 4.2.1.; Figure 8). While it nicely 
demonstrated that the observed block after transgenic expression of Duxbl is connected to 
apoptosis, the incomplete rescue argues that further mechanisms must be involved. For 
instance, Bcl2 expression is only antagonizing the pro-apoptotic effects of Duxbl, whereas its 
observed anti-proliferative action is not rescued. This might be of particular importance, since 
Bcl2 itself exhibits a negative effect on the proliferation of cells (O'Reilly et al., 1996). 
A full characterization of how Duxbl mediates the elimination of pre-T cells that fail β-
selection requires loss-of-function analysis of Duxbl during T-cell development. However, the 
triplication of the Duxbl gene on mouse chromosome 14 prevented the successful generation 
of a conditional Duxbl deficient mouse until now (Wu et al., 2010). We overcame these 
difficulties by collapsing the triplicated locus to one remaining copy by the use of CRISPR/Cas9 
mediated integration of loxP-sites into an intron of all three Duxbl copies (Figure 9). 
Subsequent provision of Cre resulted in a stepwise recombination of the introduced loxP-sites, 
first reducing the number to two remaining Duxbl copies, and finally to only one remaining 
copy. Only using this time-consuming approach, we can now specifically target the remaining 
Duxbl copy for the generation of a conditional or even full knock-out mouse strain. Since this 
process takes several years, we additionally attempted a loss-of-function approach using 
short-hairpin RNA-mediated knock-down of Duxbl expression in fetal liver derived pro-T 
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cultures on OP9-Δ1 stromal cells. A decreased amount of apoptotic cells at the DN3 stage in 
Duxbl knock-down cultures, confirmed the pro-apoptotic function of Duxbl during β-selection 
(section 4.2.1.; Figure 5).  
 
 
Figure 9 | Generation of Duxbl deficient mice. Schematic representation of the performed collapse of the Duxbl 
locus. First loxP-sites were introduced into an intron of each Duxbl copy, with the use of the CRISPR/Cas9-system. 
Addition of the Cre recombinase resulted in the deletion of the genomic region between the first and last loxP-sites. 
Thus, only one Duxbl copy remains.  
 
Another unresolved issue is the identification of potential downstream target genes of 
Duxbl. The Oas/RNaseL pathway was shown to be part of the mechanism Duxbl is using to 
induce apoptosis, but whether these genes are directly targeted remains unknown. To address 
this issue, we generated a mouse strain in which Duxbl is tagged by a short additional peptide 
at the C-terminus. Specific biotinylation of this tag allows for efficient chromatin 
immunoprecipitation followed by sequencing, which results in sequencing peaks for regions in 
the chromatin where Duxbl is bound. Using these data, potential targets genes, which are 
bound by Duxbl in their promoter or enhancer regions, can be further investigated with regards 
to a potential role during β-selection downstream of Duxbl. 
The two homeodomains within the Duxbl gene that are responsible for sequence-
specific DNA binding share the highest amino acid sequence similarity to those of human 
DUX4 (Wu et al., 2010). Interestingly, mis-expression of DUX4 in skeletal muscle cells triggers 
the induction of apoptosis, which results in a disease called facioscapulohumeral dystrophy. 
The mechanism behind this was shown to involve the RNaseL pathway, since RNaseL knock-
down experiments resulted in an increased survival after DUX4 induction (Shadle et al., 2017). 
Duxbl1 Duxbl2 Duxbl3
Cre
Duxbl
Cas9
loxP-site
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Thus, human DUX4 function resembles the one we observe in Duxbl transgenic pre-T cells. 
However, the physiological role of DUX4 in human T-cell development has not been described 
so far, but the thymus was one of the organs with highest DUX4 expression in humans (Das 
and Chadwick, 2016). Therefore, it can be envisaged that, similar to Duxbl in mice, DUX4 is 
involved in the regulation of human T-cell development. Further studies including human T-
cell differentiation assays are necessary in order to investigate this possibility in detail. 
In conclusion, we were able to identify a novel molecular mechanism that regulates β-
selection. We discovered that CD27 downregulation can be used as a marker for cells that 
have failed to productively rearrange their TCRβ locus. This enabled us to demonstrate the 
key role of the transcription factor Duxbl during the β-selection checkpoint. Transgenic mouse 
models as well as in vitro silencing revealed that Duxbl functions as a key mediator of β-
selection by inducing apoptosis in cells with a non-functional rearrangement.  
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6.	Abbreviations	
ALP ...................................................................................................... all lymphoid progenitor 
BCR .................................................................................................................. B-cell receptor 
BLP ..................................................................................... B-cell biased lymphoid progenitor 
cDC ................................................................................................. conventional dendritic cell 
CLP ............................................................................................ common lymphoid progenitor 
CMP ............................................................................................. common myeloid progenitor 
cTEC ............................................................................................ cortical thymic epithelial cell 
DC ........................................................................................................................ dendritic cell 
DN ................................................................................................................... double negative 
DP .................................................................................................................... double positive 
EPLM ..................................................... early progenitor with lymphoid and myeloid potential 
ETP ...................................................................................................... early thymic progenitor 
FACS ................................................................................. fluorescence-activated cell sorting 
Flt3 .................................................................................................. Fms-like tyrosine kinase 3 
FoB ................................................................................................................... follicular B cell 
GM-CSF .....................................................granulocyte-macrophage colony-stimulating factor 
GMP .................................................................................... granulocytic-monocytic progenitor 
HSC .................................................................................................... hematopoietic stem cell 
IL-7 ....................................................................................................................... interleukin-7 
IL-7R ...................................................................................................... interleukin-7 receptor 
ILC ............................................................................................................ innate lymphoid cell 
Jak ...................................................................................................................... Janus kinase 
LMPP ......................................................................... lymphoid-primed multipotent progenitor 
LTi cell.......................................................................................... lymphoid tissue inducer cell 
M-CSF........................................................................... macrophage colony-stimulating factor 
MEP ................................................................................ megakaryocytic-erythroid progenitor 
MHC ...................................................................................... major histocompatibility complex 
MPP ...................................................................................................... multipotent progenitor 
mTEC ....................................................................................... medullary thymic epithelial cell 
MZB ......................................................................................................... marginal zone B cell 
NK cell............................................................................................................ natural killer cell 
pDC ................................................................................................ plasmacytoid dendritic cell 
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pTa .......................................................................................................... pre-T cell receptor a 
S1PR1 ............................................................................. sphingosine-1 phosphate receptor 1 
SCF .................................................................................................................. stem cell factor 
SCID ................................................................................severe combined immunodeficiency 
SP ..................................................................................................................... single positive 
Stat ................................................................. signal transducer and activator of transcription 
TCR .................................................................................................................. T-cell receptor 
TNF ......................................................................................................... tumor necrosis factor 
TSLPR ......................................................................... thymic stromal lymphopoietin receptor 
TSP ................................................................................................ thymus seeding progenitor 
vWF ....................................................................................................... von Willebrand factor 
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Two Distinct Pathways in Mice 
Generate Antinuclear Antigen-
Reactive B Cell Repertoires
Martin Faderl†‡, Fabian Klein‡, Oliver F. Wirz†‡, Stefan Heiler, Llucia Albertí-Servera,  
Corinne Engdahl, Jan Andersson* and Antonius Rolink
Developmental and Molecular Immunology, Department of Biomedicine, University of Basel, Basel, Switzerland
The escape of anti-self B cells from tolerance mechanisms like clonal deletion, receptor 
editing, and anergy results in the production of autoantibodies, which is a hallmark 
of many autoimmune disorders. In this study, we demonstrate that both germline 
sequences and somatic mutations contribute to autospecificity of B cell clones. For this 
issue, we investigated the development of antinuclear autoantibodies (ANAs) and their 
repertoire in two different mouse models. First, in aging mice that were shown to gain 
several autoimmune features over time including ANAs. Second, in mice undergoing a 
chronic graft-versus-host disease (GVHD), thereby developing systemic lupus erythema-
tosus-like symptoms. Detailed repertoire analysis revealed that somatic hypermutations 
(SHM) were present in all Vh and practically all Vl regions of ANAs generated in these 
two models. The ANA B  cell repertoire in aging mice was restricted, dominated by 
clonally related Vh1-26/Vk4-74 antibodies. In the collection of GVHD-derived ANAs, the 
repertoire was less restricted, but the usage of the Vh1-26/Vk4-74 combination was 
still apparent. Germline conversion showed that the SHM in the 4-74 light chain are 
deterministic for autoreactivity. Detailed analysis revealed that antinuclear reactivity of 
these antibodies could be induced by a single amino acid substitution in the CDR1 of the 
Vk4-74. In both aging B6 and young GVHD mice, conversion of the somatic mutations in 
the Vh and Vl regions of non Vh1-26/Vk4-74 using antibodies showed that B cells with 
a germline-encoded V gene could also contribute to the ANA-reactive B cell repertoire. 
These findings indicate that two distinct pathways generate ANA-producing B cells in 
both model systems. In one pathway, they are generated by Vh1-26/Vk4-74 expressing 
B cells in the course of immune responses to an antigen that is neither a nuclear antigen 
nor any other self-antigen. In the other pathway, ANA-producing B cells are derived from 
progenitors in the bone marrow that express B cell receptors (BCRs), which bind to 
nuclear antigens and that escape tolerance induction, possibly as a result of crosslinking 
of their BCRs by multivalent determinants of nuclear antigens.
Keywords: antinuclear antibodies, autoantibodies, monoclonal antibodies, mouse model, systemic lupus 
erythematosus-like disease, somatic hypermutation
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INTRODUCTION
A hallmark of the autoimmune disease systemic lupus erythema-
tosus (SLE) is the presence of antinuclear autoantibodies (ANAs) 
in the serum (1–6). These antibodies are directed against histones, 
DNA, histone–DNA complexes, and various ribonuclear com-
plexes (anti-SM, anti-Ro, and anti-La) (3–6) and may be found in 
immune complexes that play an important role in the pathogen-
esis of SLE. The disease occurs more frequently in females than 
males (ratio 10:1) with a peak incidence at 45–65 years. Based 
on the findings that ANA producing B cells have undergone Ig 
class switching and carry large numbers of somatic mutations, it 
is very likely that ANAs arise from B cells participating in T cell 
dependent antigen responses (3–6).
Studies using mouse models spontaneously developing an 
SLE-like disease have improved our knowledge of the etiology of 
this disease (7–9). In particular, these studies have highlighted the 
complex genetic contribution to the development of the disease as 
well as the important role of somatic mutations of antibody genes 
in the formation of autoantibodies (7–13).
The generation of a self-tolerant B cell repertoire is critically 
dependent upon the processes of clonal deletion, receptor editing, 
and anergy (14–19). Exactly how B cells escape central tolerance 
is, however, still not completely understood. Ample evidence 
has been provided indicating that non-autoreactive B cells can 
become autoreactive through somatic mutations in their variable 
heavy (Vh) and light (Vl) chain regions (6, 10, 13, 20). Equally, 
B cells using germline-encoded Vh and Vl regions escaping cen-
tral tolerance induction in the bone marrow could also generate 
autoreactive B cells (21).
Recently we showed that almost all aging (8–12 months old) 
C57BL/6 (B6) mice develop several features characteristic of 
autoimmunity. This included germinal center formations in the 
spleen, kidney depositions of IgM, lymphocyte infiltrates in the 
salivary glands, as well as the production of high titers of IgG 
ANAs. Furthermore, this IgG ANA generation was shown to be 
T cell dependent (22). However, aging B6 mice do not develop 
real signs of disease. Here, we compare the ANA B cell repertoire 
of such aging B6 mice with that of (B6 × B6.H-2bm12)F1 mice 
undergoing a chronic graft-versus-host disease (cGVHD) and 
thus developing an SLE-like disease and death (23). Results 
indicate that the ANA B cell repertoire of aging B6 mice is more 
restricted than that of mice undergoing GVHD and is only 
partially overlapping. Moreover, we show that the ANA produc-
ing B cells in aging mice and in GVHD mice are derived from 
progenitors expressing B cell receptors (BCRs) either recognizing 
or not recognizing nuclear antigens. These findings indicate that 
ANA producing B cells in both aging mice and in GVHD mice are 
generated by two pathways: by defective tolerance induction in 
the bone marrow or by hypermutation in the V-regions of B cells 
responding to a foreign antigen.
MATERIALS AND METHODS
Mice and Induction of cGVHD
C57BL/6 and (C57BL/6 × B6(C)-H2-Abbm12/KhEgJ)F1 mice were 
bred under specific pathogen free conditions in our animal unit. 
A cGVHD was induced by i.v. injection of 8 × 107 spleen plus 
lymph node cells from B6 mice into 8–10 weeks old B6 × bm12 
mice, following established protocols (23).
Generation of Hybridomas
Spleen cells derived from aging B6 mice (aged 8–12 months) 
or B6 × bm12 mice undergoing a cGVHD were fused to the 
Sp2/0-Ag14 fusion partner following standard protocols. In 
brief, 2 ×  107 Sp2/0 cells were used for the PEG1500 (Roche 
Diagnostics)-mediated fusion of all lymphoid cells prepared 
from an entire spleen. The fused cells were plated into 25 flat-
bottom 96-well plates containing 200 µl HAT-medium (2%FBS; 
GIBCO, 2% IL6, in house, 1× HAT supplement, Sigma) per 
well and incubated at 37°C in 10% CO2 in air. After 10–12 days, 
supernatants were tested for IgG production by ELISA and for 
antinuclear reactivity by immunofluorescence (see below). Cells 
from IgG ANA positive wells were thereafter sub-cloned at limit-
ing dilution. We routinely obtained fusion frequencies between 
10−3 and 5  ×  10−3. Thus, for each mouse, we have screened 
between 5,000 and 20,000 hybrids for IgG ANA production. 
Since the vast majority of B cell hybrids produce IgM, we tested 
for the success of sub-cloning by performing simultaneous 
ELISA for IgM and IgG (see below) in supernatants of growing 
clones. The IgG containing supernatants were re-tested for ANA 
reactivity, before being further processed for Ig V-gene analyses 
(see below).
Determination of IgG Sub-Class and Anti-
Histone/DNA/Sm/SS-B/La Reactivity
Determination of IgG sub-class, l-chain, and detection of anti-
DNA antibodies was done by standard ELISA. For determination 
of anti-histone, anti-Sm or anti-SS-B/La ELISA plates were coated 
with 2.5 μg/ml of the respective antigens in PBS (all purchased 
from Immunovision). Alkaline phosphatase labeled goat anti-
mouse IgG, goat anti-mouse l-chain or goat anti-human IgG 
(Southern Biotech) was used for detection. The ELISA was 
performed as previously described (24–26).
Antinuclear Autoantibody Determination
Kidney cryosections from Rag2−/− mice of homozygous mat-
ings were incubated with supernatants or purified antibodies 
as described in Ref. (27). For detection, either FITC labeled 
goat anti-mouse IgG (Jackson ImmunoResearch) or FITC 
labeled rabbit anti-human IgG (Jackson ImmunoResearch) 
were used.
Vh and Vl Sequencing Analysis
RNA from ANA positive hybridomas was extracted using TRI 
Reagent (Sigma) followed by cDNA synthesis (GoScript Reverse 
Transcriptase) according to the manufacturer’s protocol and 
using primers as specified in Table S5 in Supplementary Material. 
Amplification of the heavy and light chain V-regions was per-
formed using Vent polymerase (New England Biolabs) and, 
subsequently, the Vh and Vl regions were ligated into the pJet1.2 
blunt end cloning vector (Thermo Fisher Scientific). For sequenc-
ing, plasmids were sent to Microsynth (Balgach, Switzerland). 
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TABLE 1 | Characteristics of ANA-reactive mAbs derived from aging B6 mice.a,b
Mouse number Hybridoma number IgG isotype Ig-heavy chain v-region Ig-light chain v-region
Aging B6 # 1 5.D3.D10 IgG2b Vh1-26 D1-1 J4 Vk4-74 Jk4
5.D3. E12 IgG2b Vh1-26 D1-1 J4 Vk4-74 Jk4
7.E8.B11 IgG2b Vh1-26 D1-1 J4 Vk4-74 Jk4
7.F9.F1 IgG2b Vh1-75 D2-4 J2 Vk?
8G3.E6 IgG2a Vh1-26 D1-1 J4 Vk4-74 Jk4
8.H7.D3 IgG2b Vh1-26 D1-1 J4 Vk4-74 Jk4
15.G10.F10 IgG2b Vh1-26 D1-1 J4 Vk4-74 Jk4
15.H12.E4 IgG2b Vh1-26 D1-1 J4 Vk4-74 Jk4
16.B9.C9 IgG2b Vh1-26 D1-1 J4 Vk4-74 Jk4
16.D7.A9 IgG2a Vh1-26 D1-1 J4 Vk4-74 Jk4
17.A9.E6 IgG2b Vh1-26 D1-1 J4 Vk4-74 Jk4
22.C9.G7 IgG2b Vh1-26 D1-1 J4 Vk4-74 Jk4
Aging B6 # 2 1.G5.B8 IgG1 Vh1-39 D4-1 J1 Vk4-57 Jk5
8.G9.G4 IgG2b Vh1-26 D1-1 J4 Vk6-32 Jk2
Aging B6 # 3 13.4.5.A IgG2a Vh1-26 D2-4 J3 Vk4-74 Jk2
13.18.A IgG2a Vh1-26 D2-4 J3 Vk4-74 Jk2
13.27.B IgG2a Vh1-26 D2-4 J3 Vk4-74 Jk2
13.31A IgG2a Vh1-26 D2-4 J3 Vk4-74 Jk2
13.69.B IgG2a Vh1-26 D2-4 J3 Vk4-74 Jk2
13.85B IgG2a Vh1-26 D2-4 J3 Vk4-74 Jk2
Aging B6 # 4 1A2.1 IgG2a Vh1-26 D2-2 J4 Vk4-74 Jk2
2F8.1 IgG2b Vh1-26 D1-1 J4 Vk4-74 Jk2
Aging B6 # 5 12.G3.G7 IgG2a Vh1-26 D1-1 J4 Vk5-43 Jk2
15.D10B3 IgG2a Vh1-26 D1-1 J4 Vk5-43 Jk2
Aging B6 # 6 3.2.2A IgG2b Vh1-74 D2-4 J3 Vk6-23 Jk5
3.10.1A IgG2b Vh1-26 D1-1 J2 Vk4-61 Jk1
5.13.1A IgG2b Vh1-26 D1-1 J2 Vk4-74 Jk2
6.15.1A IgG2a Vh8-12 D3-1 J1 Vk4-91 Jk2
7.7.3A IgG2b Vh1-22 D2-2 J1 Vk10-96 Jk2
20.15.1A IgG2a Vh1-50 D4-1 J2 Vk4-74 Jk2
23.6.1A IgG2a Vh1-22 D2-2 J1 Vk10-96 Jk2
24.18.1A IgG2b Vh1-22 D2-2 J1 Vk10-96 Jk2
25.8.1A IgG2b Vh3-6 D3-3 J3 Vk4-74 Jk2 
Aging B6 # 7 3.25A IgG2b Vh1-50 D2-4 J2 Vk?
3.36A IgG2a Vh1-80 D2-4 J3 Vk4-58 Jk2
3.73A IgG2a Vh1-26 D1-1 J4 Vk4-74 Jk2
aAll the mAbs converted into germline sequences are boxed in orange.
bAll the mAbs using Vh1-26 have been boxed in yellow and those using Vk4-74 in red.
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Resulting sequences were inspected using DNASTAR and 
aligned to the germline heavy and light chain sequences of the 
international ImMunoGeneTics information system® (http://
imgt.org).
Reversion of Somatic Mutations Back into 
Germline Configuration
Double-stranded DNA encoding the variable regions of heavy and 
light chains obtained from ANA positive hybridomas as well as 
their germline and mutated versions were ordered as gBlock gene 
fragments from IDT (Integrated DNA Technologies). These frag-
ments were cloned into heavy and light chain expression vectors 
driven by the human cytomegalovirus promoter and containing 
the human IgG1 constant region for the heavy chain and the human 
kappa constant region for the light chain (28) (a kind gift from 
Dr. Hedda Wardemann, Deutsches Krebsforschungszentrum, 
Heidelberg, Germany). Subsequently, antibodies were produced 
in HEK 293 cells (ATCC, No. CRL-1573) and purified by affinity 
chromatography on Protein A Sepharose® (GE Health Care, 
Uppsala, Sweden) as described (28, 29).
RESULTS
IgG ANA Producing Hybridomas from 
Aging B6 Mice
Hybridomas were generated independently from spleen cells of 
seven individual aging B6 mice, which had high titers of serum 
ANA. The resulting IgG producing hybridomas were then tested 
for ANA reactivity by immunofluorescence, and positive cultures 
were sub-cloned. In total, 36 hybridomas producing IgG ANA 
were generated (Table 1). Of these, 16 were IgG2a, 19 were IgG2b, 
and only one was IgG1. This heavy chain selection suggests 
that IgG ANA formation in aging B6 mice is mainly driven by 
a Th1 response (30). All ANAs contained a kappa light chain. 
Sequence analysis of the corresponding Vh and Vk regions used 
by these hybridomas revealed a restricted repertoire (V, D, and 
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FIGURE 1 | ANA reactivity is directed against histones. Histone, dsDNA, ssDNA, Sm, or SS-B/La binding of ANA-reactive mAbs derived from (A) aging B6 (Table 1) 
or (B) young B6 × bm12 mice undergoing a cGVH reaction (Table 2). Significant binding was defined as an O.D. of five times over background in ELISA. (−), no 
significant binding at 5 μg/ml; (+), binding at 5 μg/ml; (++), binding at 1.7 µg/ml; (+++), binding at 0.55 µg/ml; and (++++), binding at 0.19 µg/ml or lower.
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J annotations are according to the IMGT data base). Thus, 25 
(69.4%) hybridomas used the Vh1-26 gene and this usage was 
found among hybridomas of all seven individual mice. Moreover, 
a very high frequency of Vk4-74 gene usage was also found. Thus, 
23 (63.9%) hybridomas, derived from 5 of 7 individual mice, used 
this particular Vk light chain gene. Strikingly, 21 of the 23 Vk4-74 
expressing hybridomas expressed the Vh1-26 heavy chain. Thus, 
the IgG ANA B cell repertoire of aging B6 mice is dominated by 
those expressing a Vh1-26 heavy chain gene in combination with 
a Vk4-74 light chain gene.
We also tested these ANAs for their capacity to bind to 
histones, Sm antigens, SS-B/La antigens, and DNA. By ELISA, 
26 of the 36 showed strong and 5 showed weak histone binding, 
whereas binding to the other nuclear antigens was undetectable 
(Figure 1A).
In Individual Mice, Hybridomas Using 
Vh1-26/Vk4-74 Were Clonally Related
The fact that we obtained 11 hybridomas from mouse 1, and 6 
hybridomas from mouse 3 using the Vh1-26/Vk4-74 combination 
with the same D, Jh, and Jk elements already strongly suggested 
a clonal relationship among the B cells that had fused to gener-
ate these hybridomas (Table 1). The finding that the amino acid 
sequences of the IgH and IgL CDR3 regions of these hybridomas 
were practically identical (Tables S1 and S2 in Supplementary 
Material) also supports this conclusion. Thus, at least in mouse 
1 and 3, the ANA production seems to be dominated by a single 
B cell clone.
IgG ANA from B6 × bm12 Mice 
Undergoing a Chronic Graft-versus-Host 
Reaction
We then asked whether the restricted IgG ANA B cell repertoire 
in aging B6 mice, which do not show obvious signs of disease, was 
similarly restricted in B6 × bm12 mice undergoing a chronic graft-
versus-host reaction and, thus, developing an SLE-like disease. 
Hybridomas were independently generated from spleen cells of 
five mice with the highest ANA titers. These fusions resulted in 34 
hybridomas with IgG ANA activity (Table 2). A total of 23 ANAs 
(68%) reacted to histones but again, none reacted to the other 
nuclear antigens (Figure 1B). IgG constant region usage analysis 
revealed a distribution rather similar to that in aged mice with 18 
IgG2a, 13 IgG2b, and only 3 IgG1, the latter all from mouse 5. Thus, 
as in aging B6 mice, in B6 × bm12 mice undergoing a cGVHD, 
the IgG ANA formation appears to be Th1 cell driven. Again, all 
ANAs contained a kappa light chain.
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TABLE 2 | Characteristics of ANA-reactive mAbs derived from graft-versus-host 
disease (GVHD) mice.a,b
Mouse 
number
Hybridoma 
number
IgG 
isotype
Ig-heavy chain 
v-region
Ig-light chain 
v-region
GVHD # 1 1.12.1A IgG2b Vh8-8 D2-14 J4 Vk4-74 Jk2
1.28.1 IgG2a Vh1-26 D1-1 J1 Vk4-74 Jk2
1.308.1 IgG2a Vh1-55 D2-4 J3 Vk3-4 Jk1
1.356.1 IgG2a Vh1-55 D2-4 J3 Vk3-4 Jk1
1.741.1 IgG2a Vh1-55 D2-4 J3 Vk3-4 Jk1
1.802.1 IgG2b Vh1-26 D1-1 J1 Vk4-63 Jk5
GVHD # 2 2.24.0 IgG2a Vh1-52 D1-1 J1 Vk14-111 Jk5
2.53.8 IgG2b Vh14-2 D2-2 J2 Vk14-111 Jk1
2.58.2 IgG2b Vh14-2 D2-2 J2 Vk14-111 Jk1
2.70.8 IgG2a Vh14-4 D1-1 J3 Vk3-10 Jk1
2.80.9 IgG2a Vh14-4 D1-1 J3 Vk3-12 Jk1
2.152.9 IgG2a Vh1-52 D1-1 J1 Vk3-10 Jk1
2.300.2 IgG2b Vh1-55 D2-1 J2 Vk3-10 Jk5
2.344.3 IgG2a Vh1-52 D1-1 J1 Vk14-111 Jk5
2.374.1 IgG2a Vh1-26 D1-1 J1 Vk3-7 Jk1
2.382.2 IgG2a Vh14-4 D2-1 J3 Vk3-10 Jk1
2.388.2 IgG2a Vh1-31 D2-4 J4 Vk3-10 Jk2
2.394.1 IgG2a Vh14-4 D1-1 J3 Vk3-10 Jk1
GVHD # 3 3.55.1 IgG2a Vh1-26 D1-1 J3 Vk4-74 Jk2
3.69.1 IgG2b Vh1-26 D1-1 J3 Vk4-74 Jk2
3.71.1 IgG2a Vh1-26 D2-5 J1 Vk4-74 Jk2
3.77.1 IgG2a Vh1-26 D1-1 J3 Vk4-74 Jk2
3.152.1 IgG2b Vh1-26 D1-1 J3 Vk4-74 Jk2
GVHD # 4 63.3.1 IgG2b Vh1-55 D2-4 J2 Vk4-74 Jk2
165.2.1 IgG2a Vh8-12 D2-2 J1 Vk15-103 Jk5
GVHD # 5 14.11.A IgG2b Vh1-50 D1-1 J2 Vk1-117 Jk2
381.11.A IgG2b Vh1-54 J4 Vk14-111 Jk2
685.9.A IgG2b Vh1-59 D2-5 J3 Vk17-127 Jk5
724.3.A IgG1 Vh1-26 D1-1 J3 Vk4-91 Jk4
738.8.A IgG1 Vh1-26 D1-1 J3 Vk3-7 Jk1
762.5.A IgG2a Vh5-17 D1-2 J4 Vk?
810.4.A IgG1 Vh1-52 D2-12 J2 Vk3-10 Jk1
865.12.A IgG2b Vh1-72 D3-3 J2 Vk4-74 Jk5
1011.39.A IgG2b Vh1-53 D1-1 J2 Vk17-127 Jk5
aAll the mAbs converted into germline sequences are boxed in orange.
bAll the mAbs using Vh1-26 are boxed in yellow and those using Vk4-74 in red.
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results are summarized in Tables S1–S4 in Supplementary 
Material.
Since in aging B6 mice the ANA reactivity was dominated 
by mAbs expressing a Vh1-26/Vk4-74 heavy and light chain 
combination, we tested if somatic mutations in the Vh and/or 
the Vk regions of these mAbs were required for their autore-
activity. Therefore, the Vh and Vk regions of six (derived from 
4 individual mice) mAbs of aging B6 and two mAbs of GVHD 
mice using the Vh1-26/Vk4-74 combination were reverted to 
their germline configuration. After expression and purification, 
the ANA titers of these reverted mAbs were directly compared 
to their original, mutated forms. As shown in Figures  2A,B, 
the ANA titers of all mAbs, in which the Vh region had been 
reverted into germline configuration but the Vk regions were still 
somatically mutated, behaved like the original ANAs, continuing 
to recognize the histone antigens. However, all mAbs where the 
Vh was still somatically mutated but the Vk had been reverted to 
germline configuration lost ANA reactivity. Also, as expected, all 
mAbs in which both Vh and Vkappa regions had been reverted 
to germline configuration lost ANA reactivity. Thus, the ANA 
reactivity of the Vh1-26/Vk4-74 mAbs is due to somatic muta-
tions in the Vk4-74 gene.
Due to the finding that somatic mutations within the Vk4-74 
gene determined the ANA reactivity of Vh1-26/Vk4-74 mAbs 
and in order to identify a common motif that could account for 
this autoreactivity, we analyzed the sequence of these Vk4-74 
genes in more detail. This analysis revealed that 20 of 23 Vh1-26/
Vk4-74 mAbs derived from aging B6 mice had a mutation at posi-
tion 30 (IMGT numbering) in their CDR1 region of the Vk4-74 
gene. The germline-encoded serine in these mAbs was mutated 
into a positively charged arginine residue. Introduction of such 
a serine to arginine mutation in non-autoreactive germline ver-
sions of three different mAbs resulted in a complete gain of ANA 
reactivity for all of them (Figure 2C). Thus, antinuclear reactivity 
of these mAbs can be induced by a single base pair substitution 
changing the serine at position 30 in the CDR1 of the Vk4-74 light 
chain into an arginine.
B Cells Expressing a Germline-Encoded 
Immunoglobulin Vh Gene with a 
Negatively Charged CDR2 Region 
Contribute to the ANA-Reactive B Cell 
Repertoire
We also tested if non-Vh1-26/Vk4-74 using mAbs require 
somatic mutations in their Vh and/or Vk regions for ANA reac-
tivity. Therefore, the Vh and Vk region of three mAbs of aging 
B6 mice and six mAbs of the GVHD mice were reverted to their 
germline configuration. The 1.G5.B8 mAb derived from an aging 
B6 mouse (No. 2) used a somatically mutated Vh region and a 
germline-encoded Vk region. Reversion of the Vh region of this 
mAb into germline sequences resulted in a complete abrogation 
of its ANA reactivity (Figure 3A). In contrast, upon reversion, 
the other two mAbs (7.7.3A and 6.15.1A, both from mouse 6) 
kept their ANA reactivity (Figure 3A). Thus, B cells expressing 
a germline-encoded immunoglobulin Vh can also contribute to 
the ANA-reactive B cell repertoire in aging B6 mice.
In aging B6 mice, a dominance of Vh1-26 and Vk4-74 
usage by the IgG ANA producing hybridomas was observed. In 
B6 × bm12-derived hybridomas, the same genes were also found 
to be used, but at a much lower frequency. Thus, ten (29.4%) of 
these ANAs used Vh1-26 and nine (26.5%) used Vk4-74. Six of the 
hybridomas using Vk4-74 used the Vh1-26 heavy chain; however, 
five of these were derived from one mouse (GVHD mouse 3). 
These findings show that the IgG ANA B cell repertoires of aging 
B6 mice and B6 × bm12 mice undergoing a cGVHD are partially 
overlapping. However, the IgG ANA B cell repertoire seems to be 
more diverse in the B6 × bm12 mice than in the aging B6 mice. 
Therefore, the mechanisms underlying the generation of these 
autoreactive B cells might be different in the two model systems.
Somatic Mutations in the Light Chain 
Determine the ANA Reactivity of Vh1-26/
Vk4-74 Using mAbs
Sequence analysis revealed that most mAbs with ANA reactivity 
carried somatic mutations in their Vh and Vk regions. These 
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FIGURE 2 | ANA reactivity of Vh1-26/Vk4-74 using mAbs is caused by mutations in the light chain. ANA titers of different Vh1-26/Vk4-74 mAbs derived from (A) 
aging B6 (Table 1) or (B) young B6 × bm12 mice undergoing a cGvH reaction (Table 2). The histograms depict titers of individual mAbs, either with the original 
SHM, or Vh and/or Vk in germline configuration (GL), or (C) having a single mutation in their Vk CDR1 resulting in a serine to arginine conversion. A titer of one was 
defined as binding at a concentration of 5 µg/ml mAb, followed by 1:2 serial dilution steps and recording the last dilution where binding still was possible. SHM, 
somatic hypermutation; GL, germline; n.b., no binding detectable at 5 µg/ml of mAb.
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From the six GVHD-derived mAbs, one (1.12.1A, mouse 1) 
lost ANA reactivity upon reversion of the Vk but not the Vh gene 
into germline configuration (Figure 3B). The fact that this mAb 
uses the Vk4-74 gene indicates that this Vk gene can also give rise 
to ANA reactivity when paired with a Vh gene other than Vh1-26. 
The other five mAbs kept their ANA reactivity upon reversion of 
their Vh and Vk genes to germline configuration (Figure 3B). 
Thus, B  cells expressing a germline-encoded immunoglobulin 
can also contribute to the ANA-reactive repertoire in mice 
undergoing a cGVHD.
A remarkable observation was that 5 of 7 mAbs (one from 
aging B6 mice and four from GVHD mice), which kept ANA 
reactivity upon complete reversion of their Ig genes into germline 
configuration, had a negatively charged Vh-CDR2 region as 
defined by having at least two more negatively than positively 
charged amino acids in this region (see Table 3). This observa-
tion prompted us to test if these negatively charged amino acids 
are involved in ANA reactivity. Therefore, the negatively charged 
amino acids in the CDR2 regions of these five mAbs were mutated 
into neutral glycine. As shown in Figure 3C, one mAb derived 
from an aging B6 mouse (6.15.1A) and two from a GVHD mouse 
(2.58.2 and 2.394.1), completely lost ANA reactivity upon aspar-
tic acid/glutamic acid conversion into glycine. The ANA titers 
of the other two GVHD-derived mAbs (2.344.3 and 165.2.1) 
diminished by a factor of 2 and 3, respectively (Figure 3C). Thus, 
B  cells expressing a germline-encoded immunoglobulin with 
a negatively charged Vh-CDR2 region contribute to the ANA-
reactive repertoire. At this point, it is noteworthy that 6 of 11 
(54.6%) of the non-Vh1-26 using ANA mAbs from aging B6 mice 
and 14 of 24 (58.3%) from mice undergoing cGVHD indeed carry 
a negatively charged Vh-CDR2 (Table 3).
DISCUSSION
Two Pathways to ANA-Producing B Cells
In the present study, we compared antinuclear autoantibodies 
(ANAs) from aging B6 mice, which do not show signs of disease, 
with those derived from mice undergoing a chronic GVH reac-
tion (GVHD mice) and which develop an SLE-like disease (23). 
In order to study the V-regions of ANAs, we generated B cell 
hybridomas from mice with high ANA titers in their serum. 
Almost all monoclonal ANAs bound to a mixture of histones. As 
expected from previous studies, ANA production was T cell and 
antigen dependent (1–3, 22), since virtually all V-regions of our 
monoclonal ANAs contained somatic mutations. To determine 
whether the ANA-producing B cells were derived from progeni-
tors expressing B cell receptors (BCRs) for nuclear antigens, we 
reverted the mutated V-regions into the corresponding germline 
sequences and tested the resulting antibodies for ANA reactivity. 
Based on such analyses, we found that some ANA-producing 
B cells in both aging B6 mice and GVHD mice must be derived 
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FIGURE 3 | ANA reactivity of non-Vh1-26/Vk4-74 using mAbs is mainly germline encoded. ANA titers of different non-Vh1-26/Vk4-74 mAbs derived from (A) aging 
B6 or (B) young B6 × bm12 mice undergoing a chronic graft-versus-host disease. The histograms depict titers of individual mAbs listed in Table 3 containing 
V-regions, either with the original somatic hypermutations (SHM), or Vh and/or Vk in germline configuration (GL), or (C) containing a Vh CDR2 with conversions of 
aspartic and glutamic acids to glycine. Titers and legends as defined in Figure 2.
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from progenitors expressing germline-encoded genes for BCRs 
specific for nuclear antigens, while several others were derived 
from progenitors expressing BCRs that showed no ANA reactiv-
ity. The vast majority of the latter were derived from progenitors 
using Vh1-26 in combination with Vk4-74. Antibodies with the 
germline sequences of these V-regions had no ANA reactivity. 
It has been shown previously that non-autoreactive B  cells 
can become autoreactive upon acquiring somatic mutations 
in their Vh and/or Vl regions (6, 10 , 13, 20 ). In contrast to the 
findings with Vh1-26/Vk4-74 expressing ANAs, the reversion 
of other Vh and Vk regions of several monoclonal ANAs to 
the corresponding germline sequences did not abolish ANA 
reactivity. The maintenance of ANA reactivity upon reversion 
into germline sequences was observed with 2 of 3 monoclonal 
ANAs from aging B6 mice, and with 5 of 6 monoclonal ANAs 
from GVHD mice. Thus, two pathways can be envisaged for the 
generation of ANA specific antibody forming B cells (Figure 4). 
In pathway one, they are derived from B cells undergoing somatic 
hypermutations in response to a foreign antigen (Figure 4, red 
line); in pathway two, they are derived from B cell progenitors 
expressing ANA-specific receptors that escape tolerance induc-
tion in the bone marrow, possibly by exposure to BCR crosslink-
ing by nuclear antigens (Figure 4, blue line). Indeed, we showed 
previously that anti-dsDNA reactive B  cells escaped tolerance 
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FIGURE 4 | Two distinct pathways generate ANA producing B cells. [(A) red background] B cells with a B-cell receptor (BCR) using a germline-encoded Vh1-26 in 
combination with a germline-encoded Vk4-74 gets stimulated by a non-self (NS) antigen/hapten. Due to somatic hypermutations in the Vk4-74 gene, ANA-reactive 
memory B cells are generated. In aging B6 mice, these memory cells are then activated by nuclear antigens and Th1 cells to produce ANA. In the GVHD mice, 
nuclear antigens and alloreactive T cells activate these memory cells, resulting in ANA formation. [(B) blue background] Immature B cells in the bone marrow with 
germline-encoded BCRs specific for nuclear antigens escape tolerance induction mechanisms through BCR cross-linking by a T cell independent type 2-antigen 
(TI-2) antigens or a signal from alloreactive T cells. In the periphery of aging B6 mice, these cells get stimulated by nuclear antigens and Th1 cells to produce ANAs. 
In the periphery of GVHD mice, nuclear antigens and alloreactive T cells activate these cells to ANA formation.
TABLE 3 | Vh-CDR2 regions of non-Vh1-26 ANA-reactive mAbs of graft-versus-host disease (GVHD) and aging B6 mice.a,b
Mouse number Hybridoma number Vh-region Vh-CDR2 region Mouse number Hybridoma number Vh-region Vh-CDR2 region
GVHD # 1 1.12.1A Vh8-8 I W W D D D Aging B6 # 1 7.F9.F1 Vh1-75 I L P G S G S S
1.308.1 Vh1-55 I Y P G S G S T
1.356.1 Vh1-55 I Y P G S G S T Aging B6 # 2 1.G5.B8 Vh1-39 V N P N Y G T I
1.741.1 Vh1-55 I Y P G S G S T
Aging B6 # 6 3.2.2A Vh1-74 I H P S D S D T
GVHD # 2 2.24.0 Vh1-52 I D P S D G E T Aging B6 # 6 6.15.1A Vh8-12 I Y W D D D K
2.53.8 Vh14-2 I D P E D G E T 7.7.3A Vh1-22 I N P N N G G T
2.58.2 Vh14-2 I D P E D G E S 20.15.1A Vh1-50 I D P S D T F T 
2.70.8 Vh14-4 I D P E N G D T 23.6.1A Vh1-22 I N P N N G D T
2.80.9 Vh14-4 I D P E N G D T 24.18.1A Vh1-22 I N P N N D D T
2.152.9 Vh1-52 I D P S D G E T 25.8.1A Vh3-6 I S C D G S S
2.300.2 Vh1-55 I Y P G S V S T
2.344.3 Vh1-52 I D P S D D E T Aging B6 # 7 3.25A Vh1-50 I D P S D T Y T 
2.382.2 Vh14-4 I D P E N G D T Aging B6 # 7 3.36A Vh1-80 I Y P G D G D T
2.388.2 Vh1-31 I F P Y N G V S
2.394.1 Vh14-4 I D P E N G D T
GVHD # 4 63.3.1 Vh1-55 I Y P G S G S T
165.2.1 Vh8-12 I Y W D D D K
GVHD # 5 14.11.A Vh1-50 I D P S D S Y I
381.11.A Vh1-54 I N P G S G G I
685.9.A Vh1-59 I D P S D S S S
762.5.A Vh5-17 I S R G S G I L
810.4.A Vh1-52 I D P S D S E T
865.12.A Vh1-72 I D P S S G G T
1011.39.A Vh1-53 I N P S N D G T
1011.39.A Vh1-53 I N P S N D G T
Bold font highlights negatively and positively charged amino acids.
aAll mAbs that were converted into germline sequences or in which the negatively charged amino acids in the CDR2 were converted into glycine are marked with orange boxes.
bAll the negatively charged amino acids in Vh-CDR2 region are marked in yellow and the positively charged amino acids in green.
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induction by the crosslinking of their BCRs by a T cell independ-
ent type 2-antigen (24).
Restricted Diversity of ANA Specific  
B Cells
Inspection of the V-region usage of ANA producing hybridomas 
shows that many ANAs derived from aging mice (21 of 36) 
(Table 1; Figure 4) and few from mice undergoing a cGVHD (6 of 
34) (Table 2; Figure 4) express Vh1-26 in combination with Vk4-
74. Interestingly this Vh/Vk combination is expressed in virtually 
all ANAs from aging mouse 1 (11 of 12), aging mouse 3 (6 of 6), 
and from the GVHD mouse 3 (5 of 5). Inspection of the V-regions 
strongly suggests that these ANAs are generated from single B cell 
clones with the exception of one clone of the GVHD mouse 3, 
which differs in the CDR3 compared to the other four. In other 
mice, ANAs are clearly generated from multiple B cell clones. In 
aging mouse 6, one ANA expresses the Vh1-26/Vk4-74 combina-
tion, one expresses the Vh1-26 with Vk4-61, two express the Vk4-
74 with Vh1-50 and Vh3-6, respectively, and five express different 
Vh/Vk combinations. In GVHD mice, all except one mouse (No. 
3) express ANAs derived from multiple B cell clones. Thus, in 
aging B6 mice, the ANA repertoire tends to be restricted, while 
in GVHD mice, the ANA repertoire tends to be less restricted. 
The more important question to be answered is why ANAs are 
oligoclonal in some mice and polyclonal in others. One reason for 
this restricted repertoire might be that Vh1-26 and Vk4-74 genes 
are overrepresented in the B cell repertoire of B6 mice in general. 
RNA sequence analysis of Vh1 usage by B cells from young and 
aging B6 mice showed that around 10% of these used Vh1-26 
(our unpublished results). Since about 50% of all B cells use a 
Vh1 family member, Vh1-26 is expressed by 5% of them. We did 
not attempt to verify this number in the hybrids generated, by, 
for example, cloning and sequencing the Vh regions of random 
IgM or IgG antibodies not reacting to nuclear antigens. With 
respect to Vk4-74 usage, Aoki-Ota et al. (31) analyzed the kappa 
light chain repertoire in B6 mice. This analysis revealed that B6 
B cells rarely use the Vk4-74 gene. We also have determined the 
Vk usage in developing B6 B cells and found that Vk4-74 was 
used less than 1% in single Vk-rearrangements of preBII cells and 
immature B cells of the bone marrow [unpublished observation, 
(32)]. Thus, the restricted ANA-reactive B cell repertoire does not 
simply appear to reflect a selective usage of the Vh1-26 and the 
Vk4-74 genes by the B6 B cells. Instead, and more interestingly, 
this restricted ANA repertoire may occur through selection by 
and as yet to be defined T cell dependent antigen.
Many years ago, it was shown that haptens such as NP 
(4-hydoxy-3-nitrophenyl)acetyl (33, 34), oxazolone (2-phenyl-
5-oxazolone) (35, 36), and arsonate (p-azophenyl-arsonate) 
(37, 38) could elicit an oligoclonal humoral immune response, 
at least in certain inbred strains of mice. Based on this, one 
might envisage that a hapten-like structure is responsible for the 
restricted ANA-reactive B cell repertoire in aging B6 mice. Thus, 
one could imagine that the frequency of ANA-producing B cells 
that are derived from hapten-induced memory cells in aging mice 
(red pathway in Figure 4) is higher than the frequency of B cell 
progenitors with receptors for nuclear antigens that escape toler-
ance induction in the bone marrow (blue pathway in Figure 4).
Activation of ANA-Producing B Cells
In ANA-producing mice, B  cells expressing nuclear antigen-
specific BCRs must be activated by nuclear antigens and helper 
T  cells. In GVHD mice, the alloreactive T  cells act as helper 
T cells. In their initial report on the “allogeneic effect,” Katz et al. 
reported a drastic enhancement of IgG responses as a result of 
a GVH reaction (39). Later, Osborne and Katz showed that a 
simple non-immunogenic hapten–polypeptide conjugate might 
elicit a vigorous primary IgG response as a consequence of the 
allogeneic effect (40). Likewise, Hamilton and Miller reported 
that otherwise tolerogenic hapten-conjugated syngeneic mouse 
erythrocytes would elicit a strong primary antibody response as 
a result of a GVH reaction (41). It is possible that this type of gen-
eral B cell help by alloreactive T cells contributes to the tendency 
of the ANA response in cGVHD mice to be more diverse.
In aging mice, the specificity and origin of the T helper cells 
that are required for ANA production is not known. Based on 
the IgG class of the ANAs produced in these mice, it is con-
ceivable that the helper cells involved in the ANA response are 
Th1 cells (30).
Conclusions Regarding the Structure of 
Anti-Histone Antibodies
Almost 30 years ago, Weigert and coworkers showed that arginine 
residues in CDR regions play a crucial role for the specificity of 
anti-dsDNA autoantibodies (10, 11). In the present study, we find 
an important role of arginine in the Vk-region of certain ANAs. 
Site-directed mutagenesis revealed that somatic mutations in 
the Vk4-74 light chains of the Vh1-26/Vk4-74 mAbs determine 
ANA reactivity, since conversion into their germline sequence 
completely abolished ANA reactivity. Interestingly, and highly 
significant, 20 of 23 Vh1-26/Vk4-74-expressing ANAs derived 
from aging B6 mice had a serine to arginine mutation at posi-
tion 30 in the CDR1 region of the Vk4-74 gene. In 1 of these 23 
mAbs, this change to arginine was the only mutation present in 
the entire Vk4-74 gene. The finding that one of these (17A9E6) 
mAb loses ANA-binding activity upon conversion of this arginine 
into serine strongly indicates the importance of this mutation for 
ANA reactivity. Furthermore, the introduction of single serine to 
arginine mutations in the germline configuration of three different 
mAbs conferred their antinuclear reactivity. This proves that this 
single mutation can convert an ANA-negative mAb into a positive 
one and clearly shows how easily Vh1-26/Vk4-74 using mAbs may 
become autoantibodies. The ANA-reactive B cell repertoire has 
also been analyzed in B6 mice congenic for a SLE susceptibility 
locus. Also this analysis revealed a rather frequent usage of Vk4-74 
light chains. Thus, Liang et al. (12) found that 9 of 30 ANA pro-
ducing hybridomas used Vk4-74 light chain (herein called ai4). 
Moreover, it was shown that 3 of these 9 had a serine to arginine 
mutation at position 30 in the CDR1. In a report by Guo et al. (13), 
9 of 33 ANA-producing hybridomas used a Vk4-74 light chain 
(herein also called ai4). At least 5 of these 9 had a serine to arginine 
mutation at position 30 in the CDR1, like we report herein.
However, since 5 of 6 Vh1-26/Vk4-74 using mAbs derived 
from the GVHD mice did not have this serine to arginine muta-
tion, other mutations in the Vk4-74 gene can be involved in ANA 
reactivity.
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Yet, another interesting finding reported here is that a high 
percentage of ANA-reactive mAbs not using the Vh1-26 gene, 
especially in the repertoire derived from GVHD mice, possess 
a germline-encoded negatively charged Vh CDR2 region. Thus, 
14 of the total 34 monoclonal ANAs (41.2%) derived from the 
GVHD mice and 6 of 36 (16.7%) derived from the aging B6 mice 
have such a CDR2 region. Within the total Vh gene repertoire 
of B6 mice, 11.5% possess such a negatively charged CDR2 
(42). Thus, our findings suggest that B cells with such a charged 
CDR2 might be positively selected into the ANA-reactive B cell 
repertoire, especially in GVHD mice. The finding that mutations 
of these negatively charged amino acids into glycine can result 
in a complete loss of ANA binding supports this hypothesis 
and, moreover, indicates the potential importance of this region 
in ANA reactivity. However, additional structural effects of the 
amino acid change to glycine cannot be excluded, especially since 
glycine is known to be a helix breaker.
It is noteworthy that despite high ANA serum titers, aging 
B6 mice do not show the typical lesions that are observed in 
multiple organs of SLE patients, whereas the GVHD mice do 
show this. Therefore, one could envisage that the ANA reper-
toire difference between aging B6 and GVHD mice is playing 
a role in the pathogenesis of the SLE-like disease observed in 
GVHD mice.
Overall, the findings described in the present study highlight 
various new characteristics of ANA-reactive B cell repertoires and 
argue for similar mechanisms of ANA generation in SLE patients. 
This might improve our understanding of the pathogenesis of 
this disease, thereby opening new concepts and therapies for its 
control.
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TABLES S1 AND S2 | Nucleotide sequences and their translation into amino 
acids of Vh- and Vk-regions of all hybridomas described herein, which were 
derived from aging B6 mice.
TABLES S3 AND S4 | Nucleotide sequences and their translation into amino 
acids of Vh- and Vk-regions of all hybridomas described herein, which were 
derived from young B6 × bm12 mice undergoing a GvH reaction.
TABLE S5 | Sequences of primers used for cDNA synthesis of total mRNA 
obtained from ANA-reactive hybridomas. The sequences of primers used for 
sequencing of Vh- and Vk-regions of the obtained cDNA are also shown.
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Table S5. Sequences of primers used for cDNA synthesis of total mRNA 
obtained from ANA-reactive hybridomas. The sequences of primers used for 
sequencing of Vh- and Vk-regions of the obtained cDNA are also shown 
 
Primer:  Sequence  
Igκ _C reverse  GATGGTGGGAAGATGGATACAG  
5’ L-Vκ3 Fwd  TGCTGCTGCTCTGGGTTCCAG  
5’ L-Vκ4 Fwd  ATTWTCAGCTTCCTGCTAATC  
5’ L-Vκ5 Fwd  TTTTGCTTTTCTGGATTYCAG  
5’ L-Vκ6 Fwd  TCGTGTTKCTSTGGTTGTCTG  
5’ L-Vκ6,8,9 Fwd  ATGGAATCACAGRCYCWGGT  
5’ L-Vκ14 Fwd  TCTTGTTGCTCTGGTTYCCAG  
5’ L-Vκ19 Fwd  CAGTTCCTGGGGCTCTTGTTGTTC  
5’ L-Vκ20 Fwd  CTCACTAGCTCTTCTCCTC  
5’ L-Vλ1 Fwd  TTGTGACTCAGGAATCTGCA  
Igλ _C Rev  CTCGGATCCTTCAGAGGAAGGTGGAAACA  
V
H 
Fwd  GGTSMARCTGCAGSAGTCWGG  
γ1 C Rev  CTCGGATCCTTCAGAGGAAGGTGGAAACA  
γ3 C Rev  CTTTGACAAGGCATCCCAGT  
γ2a C Rev  CCAGGCATCCTAGAGTCACC  
γ2b C Rev  CCAGGCATCCCAGAGTCACA  
Murine β-Actin Fwd  GAAGTCTAGAGCAACATAGCAC  
Murine β-Actin Rev  GTGGGAATTCGTCAGAAGGACTCCTATGTG  
pJET Rev  ATCGATTTTCCATGGCAGCT  
T7universal Fwd  TAATACGACTCACTATAGGG  
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9.2.	 Curriculum	vitae	
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